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Chikungunya virus (CHIKV) causes an acute fever with debilitating joint pain. 
Spread by the Aedes species of mosquito, recent increases in global 
temperature, and mutations in the viral glycoproteins have facilitated 
outbreaks worldwide with huge economic burden. Despite the recent 
resurgence of CHIKV, there are currently no vaccines or antiviral agents 
available.  
CHIKV, an alphavirus, possesses a positive sense, single stranded RNA 
genome that encodes four non-structural proteins (nsPs). The CHIKV nsP3 
possesses an N-terminal  macro domain, a domain found in the proteins of all 
species, and are defined by their ability to bind ADP-ribose. It is unclear what 
role the nsP3 macro domain contributes to CHIKV replication.  
Initially, a panel of cell lines was validated in terms of their physiological 
relevance and ability to support the replication of the CHIKV replicon and 
infectious virus. The phenotypes of a panel of mutants in the ADP-ribose 
binding pocket of the nsP3 macro domain were assessed in the context of a 
sub-genomic replicon and infectious virus in a range of relevant cell lines. 
Comparison of this data to the known biochemical properties of the nsP3 
macro domain from the literature, indicated that ADP-ribose binding was 
crucial to CHIKV replication. In addition, this data suggested a role for the 
nsP3 macro domain in antagonising cellular innate immune pathways. ADP-
ribose signalling has been implicated in the activation of the NFкB pathway 
therefore potential for the nsP3 macro domain to interfere with this cell 
signalling pathway was investigated.  It was demonstrated that CHIKV did not 
activate the pathway and that expression of nsP3 actively was inhibitory. 
Furthermore, macro domain mutants with reduced ADP-ribose binding were 
unable to inhibit the pathway. It is therefore proposed that the CHIKV nsP3 
macro domain is a virulence factor, able to suppress the host NFкB pathway 
to facilitate viral replication.  
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SG  Subgenomic 
SGR  Subgenomic replicon 
SH3  SRC Homology 3 Domain 
SINV  Sindbis virus 
STAT  Signal transducer and activator of transcription proteins 
SUMO  Small ubiquitin-like modifier 
SV40  Simian virus 40 
TBS  Tris buffered saline 
TDP1  Tyrosyl DNA phosphodiesterase 1 
TEMED  Tetramethylethylenediamine 
TIM-1 T cell immunoglobulin mucin domain 1 
TLR  Toll-like receptor 
TNFα  Tumour necrosis factor α 
tRNA  Transfer RNA 
UTR  Untranslated region 
VEEV  Venezuelen equine encephalitis virus 
VLP  Virus like particle 
VR  Variable region 
VZV  Varicella zoster virus 
WEEV  Western equine encephalitis virus 
wt Wildtype 
YBX1  Y-box binding protein 













1.1 Chikungunya virus 
1.1.1 Identification and classification 
Chikungunya virus (CHIKV) was first isolated and identified in Tanzania in 1952 
(Lumsden, 1955) where a large outbreak occurred that resembled Dengue fever. 
The name ‘Chikungunya’ comes from the local Kimakonde language which 
roughly translates to ‘bent upwards,’ describing the appearance from those 
suffering with the painful joint symptoms of the disease.  
CHIKV is in the Alphavirus genus of the Togaviridae family (Chen et al., 2018). 
The majority of alphaviruses, including CHIKV, are mosquito-borne, and are 
alternately transmitted between the mosquito vector and vertebrate hosts. In 
addition to CHIKV, there are eight alphaviruses that are human pathogens and 
these are further separate into “new world” and “old world” alphaviruses defined 
by their genomic sequence, disease pathology and their geographical 
distribution (Zumla, 2010). Old world alphaviruses are mostly found in Africa, 
Asia, and Australia and cause disease of high fever, arthralgia and rashes. This 
group includes CHIKV, O’nyong-nyong virus (ONNV), Semliki forest virus (SFV) 
Mayaro virus (MAYV), Ross river virus (RRV), and Sindbis virus (SINV). New 
world alphaviruses are generally found in the western hemisphere, cause 
encephalitis, and includes Venezuelan equine encephalitis virus (VEEV), eastern 
equine encephalitis virus (EEEV), and western equine encephalitis virus 
(WEEV). Not all alphaviruses are human pathogens. Although equine 
encephalitis viruses infect humans, the primary host of these viruses are equine 
species including horses and donkeys. Other alphaviruses specifically infect fish 
and seals such as rainbow trout sleeping disease virus and  southern elephant 
seal virus (Weston et al., 1999; Villoing et al., 2000; La Linn et al., 2001). Eilat 
virus is a unique alphavirus as it exclusively infects mosquitos (Nasar et al., 
2012). 
Analysis of the E1 coding regions of all the alphaviruses revealed that 
alphaviruses evolved from a common, “New World” ancestor virus (Powers et 
al., 2001). The same study also demonstrated that CHIKV falls into the “Semliki 
Forest Complex” alongside viruses including ONNV, MAYV and SFV. Due to the 





is a  biosafety level 2 (BSL2) pathogen, whereas CHIKV is BSL3, SFV is often 
used as a model virus for the study of CHIKV. Though evolutionarily less related, 
SINV is also used as a model for CHIKV as it is also a BSL2 pathogen 
(Sourisseau et al., 2007). 
1.1.2 Epidemiology and transmission 
CHIKV is spread by the Aedes (Ae.) species of mosquito, primarily by Ae. 
aegypti, although the virus has been detected in many other species of the Aedes 
mosquitos as well as some Anopheles and Culex species (Diagne et al., 2014). 
Humans become infected with CHIKV via mosquitos which bite when taking a 
blood meal. CHIKV can also be transmitted vertically from infected pregnant 
mothers to the unborn child (Gérardin et al., 2008).  
It is thought that CHIKV originated in African forests since the only non-human 
hosts to have been identified are wild primates in these areas (Brault et al., 
2000). These areas have been suggested to maintain a sylvatic cycle between 
primates and mosquito vectors which eventually spilled over into nearby human 
populations (Peyrefitte et al., 2007). It is thought that, from this initial zoonotic 
event, the virus spread further in Africa and to Asia. Since the discovery of CHIKV 
in Tanzania in 1952, the virus has been isolated in many African and Asian 
countries and has repeatedly re-emerged, causing many outbreaks in these 
countries, a phenomenon that is difficult to predict (Brault et al., 2000). There are 
now three distinct, both genetically and geographically, strains of CHIKV; the 
West African, the east/central/south African (ECSA) and the Asian genotypes 
(see Figure 1.1). 
In recent years, CHIKV has re-emerged on a global scale, emerging in many 
countries where the virus had not previously been isolated. This global re-
emergence is thought to have initiated through the large Kenyan and Indian 
Ocean outbreaks of 2004-6. Part of this re-emergence was the large outbreak 
on La Reunion island in 2005/6, where 33% of the population were infected and 
213 deaths were recorded that were attributed to CHIKV infection (Josseran et 
al., 2006). It is thought that CHIKV was introduced to the island from Kenya, 
transported by shipping of goods and the migration of people through the Indian 





factors thought to contribute to this explosive outbreak including the fact that 
CHIKV had never before been detected in La Reunion, with the local population 
naïve to the virus (Borgherini et al., 2007). It is well documented that CHIKV is 
capable of rapid transmission in populations with little or no pre-existing immunity 
(Johansson, 2015). Also, Ae. albopictus, the primary mosquito species attributed 
to this outbreak, was already fully established on the island. Finally, a mutation 
in the E1 glycoprotein E1-A226V, first identified in this particular epidemic, 
allowed adaptation to the Ae. albopictus mosquito. The E1 mutation that 
developed from the East Central South African strain (see Figure 1.1), was 
termed the Indian Ocean lineage (IOL) and was found to facilitate higher midgut 
infectivity and greater dissemination to the salivary glands of the mosquito, 









Figure 1.1 CHIKV phylogeny based on the complete coding region of 
clinical isolates. The east/central/southern African (ECSA) strain 
containing the E1-A226V mutation is represented as the Indian Ocean 
lineage (IOL) in light green. (Adapted from Wahid et al., 2017). 
 
The E1-A226V mutation has allowed CHIKV to thrive in areas where the 
previous, predominant vector; Ae. aegypti is absent, but where Ae. albopictus is 
established. There are many factors that contribute to the successful colonisation 





the Ae. aegypti prefers much warmer and wetter climates, whereas the Ae. 
albopictus can tolerate much milder climates (Ducheyne et al., 2018). There are 
many regions of the world where the Ae. albopictus has colonised but the Ae. 
aegypti has not, meaning that the E1-A226V mutation enables CHIKV to spread 
further than previously possible with the Ae. aegypti vector.  
The Ae. aegypti mosquito is not common in Europe, however, over 30 European 
countries have established populations of the Ae. albopictus and are therefore 
susceptible to CHIKV outbreaks, as shown in Figure 1.2 (Wahid et al., 2017).  
The first autochthonous CHIKV infection (transmission within the same country) 
in Europe was reported in Italy, 2007 and has been directly attributed to the E1-
A226V mutation and the Ae. albopictus vector (Severini et al., 2018). In France, 
multiple autochthonous infections have occurred in 2010, 2013 and 2014 which 
a small outbreak occurring in 2014. This outbreak originated by a traveller, 
returning from Cameroon, who introduced the virus to the local Ae. albopictus 
population resulting in the infection of 12 individuals. It is thought that the 
outbreak was limited due to the quick response of the French public health 
authorities, including the use of insecticide and the dissemination of information 
but also partly due to the onset of Autumn at the time, with cooler temperatures 







Figure 1.2 Distribution of the Ae. aegypti and Ae. albopictus  in Europe. 
Correct as of Jan 2018. Red indicates countries with established 
populations of the mosquito (although not necessarily universally 
distributed within that country), yellow is where the mosquito has 
been detected but not established and green is where none have been 
detected. Adapted from the European Centre for Disease Prevention 
and Control (ECDC), map created using mapchart.net.  
 
In contrast to Europe, the cases of CHIKV in the Americas are mostly due to the 
Asian strains of the virus. The first case of CHIKV in the Americas was on the 
island of Saint Martin in December 2013, with 50 cases confirmed in the same 
month (Leparc-Goffart et al., 2014). By January 2014, many surrounding islands 
also reported autochthonous cases of CHIKV. In the Americas, there were 
existing, overlapping populations of both the Ae. aegypti and Ae. albopictus 
mosquito before CHIKV arrived into the region (Díaz et al., 2015; Chin et al., 
2018; Honório et al., 2018). Since 2013, autochthonous cases of CHIKV have 
been reported in 45 countries within the Americas. Genotypic analysis of CHIKV 
isolated from this outbreak have shown that the outbreak in the Americas was 
due to viruses that form a single clade within the Asian genotype of CHIKV, rather 
than the more recently-developed IOL clade (Lambert and Lanciotti, 2016). Early 
isolates from the initial St Martin outbreak were closely related to isolates from 
the Philippines taken at a similar time. Although the precise event that introduced 
CHIKV to the island is unknown, it is likely due to international travel that 





(Johansson, 2015). A summary of the global spread of CHIKV is show in Figure 
1.3. 
 
Figure 1.3 The global spread of CHIKV, with significant outbreaks denoted 
by the year. CHIKV is thought to have originated in central/eastern 
Africa (Brault et al., 2000, with the ECSA strain depicted in dark green) 
and spread to west Africa and Asia which independently evolved to 
form distinct genotypes (shown in orange and purple respectively). 
The first major outbreak of recent years was in La Reunion and 
surrounding islands in 2005, which was the first detected instance of 
the E1-A226V mutation which has since been termed the Indian Ocean 
lineage (Tsetsarkin et al., 2007, depicted in light green). The outbreaks 
in the Americas began in 2013 on the Caribbean island of Saint Martin, 
and were found to be from the Asian genotype (Johansson, 2015). This 
has since spread to all the American continents. Adapted from the 
Centre for Disease Control (CDC), correct as of May 2018. Map created 
using mapchart.net. 
 
1.1.3 Pathology of Chikungunya fever 
As shown in Figure 1.4, CHIKV is introduced into the body via a mosquito bite. 
The virus enters the skin and replicates to high levels in the local dermal 
fibroblasts. From the bite site, the virus is transported via the lymphatic and 
circulatory systems to disseminate throughout the body. It has been shown that 
the saliva from the mosquito, delivered alongside the virus, can enhance 
infection by inducing neutrophil-mediated inflammation which recruits myeloid 
cells (Pingen et al., 2016). These myeloid cells become infected with CHIKV and 
transport the virus to the lymph nodes, where it is then disseminated systemically 
(Kam et al., 2009). The virus favourably replicates in fibroblast, epithelial, 





brain (Thon-Hon et al., 2012). After an incubation period of 2-4 days post-bite, 
symptoms occur such as high fever, myalgia, skin rash and arthralgia that can 
be debilitating (Tang, 2012). In this symptomatic period, viremia occurs with titres 
as high as 108 PFU/mL of blood (Simmons et al., 2016), allowing mosquitos to 
acquire the virus from infected humans. It has been reported that titres of 107 
PFU/mL of blood is sufficient for a mosquito to become infected through a blood 
meal (Hugo et al., 2016).  
 
 
Figure 1.4 Infection and spread of CHIKV throughout the human body. The 
virus is introduced via mosquito bite where it infects and replicates in 
dermal fibroblasts and spreads through the circulatory and lymphatic 
systems to the lymphoid tissue, muscles, joints, liver and brain to 
replicate. Figure from Schwartz and Albert, 2010. 
 
Although Chikungunya fever is rarely fatal, the joint pain resulting from infection 
can be incapacitating, thought to be mainly due to the direct infection of cells in 
musculoskeletal tissues (Haist et al., 2017; Zaid et al., 2018). After the acute 





however, a sub-set of patients develop long term symptoms such as joint pain 
and swelling that can persist for months to years (Chang et al., 2018; McHugh, 
2018). Patients with long-term symptoms often report them occurring in a 
fluctuating manner. There were suggestions of these long-term symptoms being 
the result of CHIKV-induced autoimmunity, although there was no strong 
evidence to support this (Suhrbier et al., 2012). More recently, chronic CHIKV-
related symptoms have been attributed to viral persistence in joint tissues 
(Hawman et al., 2013) and that a high viral load at the time of the acute infection 
is an indicator of persistence developing (Chow et al., 2011).  
 
1.1.3.1 Complications from CHIKV infection 
In some cases of CHIKV infection, severe complications can develop. CHIKV 
can replicate in neuronal cells and, in rare cases, this can cause a range of 
neurological complications, the most common of which are encephalopathy and 
encephalitis. Encephalopathy is defined as “a clinical state of altered mental 
status, manifesting as confusion, disorientation, behavioural changes or other 
cognitive impairment” whereas encephalitis describes the pathological 
presentation of inflammation within the brain (Venkatesan et al., 2013). In 
CHIKV-associated encephalitis, symptoms present between 0-13 days following 
onset of classical Chikungunya-fever symptoms. The pathology of CHIKV 
associated encephalitis varies between patients, with no district patterns on 
imaging by MRI, unlike other CNS pathogens such as cytomegalovirus (Boppana 
et al., 1997). Encephalopathy is a particular problem with neonates and young 
children infected with CHIKV (Charlier et al., 2017). Encephalitis is one of the 
most common presentation of atypical CHIKV infection and is a major cause of 
intensive care hospitalisation for CHIKV patients (Economopoulou et al., 2009). 
Another neurological complication caused by CHIKV is myelopathy (damage to 
the spinal cord) and myelitis (inflammation to the spinal cord).  Patients with 
myelopathy present 0-3 weeks after classical CHIKV symptoms occur (Chandak 
et al., 2009). The incident rate of spinal cord inflammation with CHIKV infection 





deaths have been reported for CHIKV patients with myelopathy alone  (Mehta et 
al., 2018).  
There have been reports that link Guillain-Barre syndrome (GBS) to CHIKV, with 
incidents of GBS increasing following outbreaks of CHIKV (Willison et al., 2016). 
Individual case studies of CHIKV patients with GBS symptoms show that most 
made a full recovery within 3 months of infection (Mehta et al., 2018). 
Neurological complications of CHIKV are a particular issue for perinatal acquired 
infection with up to 50% of infected neonates developing encephalopathy, 
although this does vary by outbreak and causative genotype (Gérardin et al., 
2008). A significant number of children who acquire CHIKV perinatally develop 
issues later in life including reduced neurocognitive function, coordination and 
language issues with some cases of cerebral palsy and microcephaly (Gérardin 
et al., 2014).  
Another common complication of CHIKV infection is related to the cardiovascular 
system. In some outbreaks, up to 50% of patients infected with CHIKV report 
cardiovascular symptoms associated with the infection including myocarditis, 
heart failure and arrhythmia (Rajapakse, Rodrigo and Rajapakse, 2010). It has 
been shown that CHIKV is capable of infecting myocytes and this can result in 
damage of cardiac muscle fibres (Alvarez et al., 2017). It has been noted 
however that these complications occur more regularly, although not exclusively, 
in patients with existing cardiac conditions (Economopoulou et al., 2009). 
Much rarer complications include hepatitis, which can be fatal (Torres et al., 
2015), as well as ocular inflammation, respiratory complications, pneumonia, 
renal failure and pancreatitis (Economopoulou et al., 2009; Alvarez et al., 2017). 
 
1.1.4 Treatments and prevention strategies for CHIKV 
Despite the pressing need for effective treatment and prevention of CHIKV there 
are currently no anti-viral agents or vaccines available (Abdelnabi et al., Delang, 
2016).  Current treatment of CHIKV infection involves treating the symptoms 
rather than the virus with the predominant treatment of rest and hydration, 





medication to treat any specific complications that may occur (Cunha and Trinta, 
2017). 
1.1.4.1 Anti-viral agents for CHIKV 
Although there are currently no licenced anti-viral agents available for the 
treatment of CHIKV infection, many agents have shown anti-viral effects in vitro 
and in vivo.  
Some already licenced therapeutics such as ribavirin, which has been previously 
approved for use against Hepatitis C virus (HCV) and severe cases of respiratory 
syncytial virus (RSV), has also shown to have anti-CHIKV effects in vitro, which 
were enhanced when used in combination with IFN-α (Briolant et al., 2004). 
Favipiravir (also referred to as T-705), was recently approved for use against 
Influenza in Japan, has broad-spectrum anti-viral activity. It has been shown to 
inhibit replication of both laboratory and clinical strains of CHIKV in cell culture 
and also reduced the mortality rate and limited neurological disease in 
experimentally infected mice (Delang et al., 2014). It has shown to be effective 
against many RNA viruses in vitro and analysis of resistant mutants has implied 
its mechanism of action is against a highly conserved lysine residue (residue 291 
in the case of CHIKV) in the RNA-dependent RNA-polymerase (RdRp).  
Other treatments in development include monoclonal antibodies which has been 
demonstrated to protect mice lacking the IFN α/β receptor (IFNAR-/-) mice from 
CHIKV induced mortality, both when given prophylactically or post-infection (Pal 
et al., 2013). Another treatment strategy is to modulate cellular processes to 
combat CHIKV infection. This includes modulating the host immune response for 
example, treatment with IFN-α (Bordi et al., 2011),  polyinosinic acid:polycytidylic 
acid (poly(I:C)), (Li et al., 2012) and RIG-I antagonists (Olagnier et al., 2014) 
have all shown to reduce CHIKV replication in vitro.  
Despite the recent advances in development of anti-viral agents for CHIKV in the 
pre-clinical stage, none have been approved for use in the clinic as of yet. Some 
therapeutics that demonstrated anti-viral activity in vitro were shown to not confer 
this activity in vivo. For example, chloroquine, originally used as an anti-malarial, 
was shown to have anti-viral activity against several viruses, including 





culture, possibly by disrupting the CHIKV entry process (Khan et al., 2010). 
However, when used clinically on patients with acute CHIKV infection, 
chloroquine showed no significant efficacy (Chopra, Saluja and Venugopalan, 
2014). This demonstrates that despite progress at the pre-clinical stage, there is 
still a lot more research and development required to produce an effective CHIKV 
anti-viral agent.   
1.1.4.2 Vaccine development 
Although there are currently no approved or licenced vaccines for use against 
CHIKV, there are many promising vaccine candidates in development that utilise 
a number of different strategies. Reverse genetics and biochemical studies of 
CHIKV have been utilised to better attenuate vaccines in order to increase safety, 
particularly to limit the possibility for reversion or to induce adverse reactions 
(Powers, 2018). It is therefore important to better understand the cellular and 
biochemical properties of the CHIKV proteins to rationally develop effective 
vaccines.   
One of the first CHIKV vaccines to reach clinical trials was a virus-like particle 
(VLP) vaccine. These are non-infectious virus particles that lack genetic material 
so cannot replicate. These may be comprised of the structural proteins of a virus, 
or use a different, often more stable, virus ‘scaffold’ to which antigenic proteins 
can be presented to the immune system (Tagliamonte et al., 2017). A particularly 
promising vaccine utilised a CMV expression vector, expressing the structural 
polyprotein of CHIKV in HEK293T cells, generating empty capsids of CHIKV. 
When tested in vivo, the vaccine conferred a strong neutralising antibody 
response in monkeys that protected them from infection, (Akahata et al., 2010). 
When taken to human phase 1 trials, no adverse side effects were observed and 
all participants produced cross-genotype neutralizing antibodies, although the 
antibody titres were significantly reduced by the final point of the study (Chang 
et al., 2014; Goo et al., 2016).  
Despite live attenuated vaccines requiring large scale production of virus in cell 
culture, recent developments of reverse genetics systems have allowed for 
genetic attenuation, increasing the safety profiles of vaccines and high 





attenuated vaccine for CHIKV used reverse engineering to replace the 
subgenomic promotor with an IRES which restricted the host range so that, if the 
vaccine ever produced disease in individuals, it would not be able to replicate in 
mosquitos. This particular vaccine was able to produce a neutralizing antibody 
response and protect vaccinated mice when challenged.  
Many of the CHIKV vaccines in development have adopted chimeric 
approaches. One of the most promising CHIKV chimeric vaccines is using 
alternate alphavirus systems. It has been shown previously that using alternate 
non-structural and structural open reading frames (ORFs) from different 
alphavirus can produce viruses that can replicate but are highly attenuated (Kim 
et al., 2011). However, the resulting replicative phenotype can vary wildly with 
different combinations, not all of which being attenuated (Frolov, Frolova and 
Schlesinger, 1997). One particular alphavirus chimera, to protect from VEEV 
infection was formed using an attenuated strain of VEEV and SINV. This 
contained the SINV non-structural ORF and the VEEV structural ORF. This virus 
was further attenuated by mutating the sub-genomic promotor from the VEEV 
sequence to resemble the SINV sequence whilst still preserving the VEEV 5' 
RNA secondary structure in the subgenomic RNA. This vaccine produced strong 
immunogenic responses and inoculated mice survived and showed no 
symptoms when challenged with VEEV (Paessler et al., 2003).  
Subunit vaccines, such as those that contain the CHIKV structural proteins (Metz 
et al., 2011) and DNA vaccines, which contain an attenuated CHIKV genome 
(Hallengard et al., 2014) have both shown some effectivity against CHIKV, but 
as of yet, no vaccine is licenced for use against CHIKV.  
1.1.4.3 Vector control 
A different approach to reducing CHIKV and other arbovirus infections is to target 
the vector rather than the host. CHIKV cannot be transmitted horizontally 
between humans, mosquito vectors are essential for the spread of CHIKV, 
therefore effective control of the vector could reduce disease spread. A particular 
challenge for the control of alphavirus vectors; the Aedes mosquito, is that they 
have adapted to thrive in urban environments and bite during the day whereas 





at night (Ferguson, 2018). Meaning that the simple measure of using mosquito 
nets to effectively reduce malaria infections is not an option for many arboviral 
infections (Fullman et al., 2013). Many different measures have been attempted 
to control the Aedes alphavirus vector with varying levels of success. 
Tackling environmental factors such as educating the local population about 
mosquitos and reducing potential breeding grounds has been shown to be 
effective although it requires willing community involvement that is sustained. 
This technique often reduces the risk of arboviral infections, but not significantly 
or for long periods of time (Andersson et al., 2015). 
Use of insecticides is the most prevalent approach to vector control, either by 
targeted deployment to destroy mosquito larvae, or by mass spraying. However 
this approach can be very costly and the success of application is highly 
dependent on the timing of the response which is often hampered by poor co-
ordination (Esu et al., 2010; Horstick et al., 2010). Another recent issue with this 
approach is that many mosquitos have developed resistance to many insecticidal 
agents. There are multiple mechanisms of resistance including mutations to 
mosquito enzymes that process the insecticide. These include mutations to 
either the target protein of the insecticide, or to proteins that are able to process 
and excrete insecticides. Modification of behaviour allowing the mosquitos to 
actively avoid insecticide altogether has also been observed (as reviewed in 
Moyes et al., 2017; Auteri et al., 2018).    
Some novel, biological approaches have been used to control Aedes mosquito 
populations and limit arboviral infections. Wolbachia bacteria have been 
previously characterised to inhibit multiple pathogens from replicating in infected 
mosquitos, including CHIKV and Dengue virus (Moreira et al., 2009). Wolbachia 
are endosymbiotic intracellular bacteria, able to infect a wide range of insect 
species and is transmitted vertically. Although Wolbachia is not normally present 
in Aedes aegypti mosquitos (Zug and Hammerstein, 2012). The World Mosquito 
Program (formally ‘Eliminate Dengue’) aims to reduce arboviruses by releasing 
Wolbachia-infected mosquitoes into the wild, spreading Wolbachia to mosquito 
populations which produces a population that is less-able to transmit viruses to 





establish Wolbachia in wild, naïve mosquito populations which can be sustained 
(Jiggins, 2017).  Data modelling has predicted that this technique will reduce 
arboviral infections however, in practice, this has yet to be determined (O’Neill et 
al., 2018).  
Another novel method of vector control is the use of genetically modified 
mosquitos to modify the wild population. One approach is to distort the sex-
distribution of mosquitos, since only female mosquitoes bite humans, distorting 
the population to become predominantly male will reduce population number and 
restrict spread of disease. This can be achieved by introducing female-specific 
lethal genes, such as expression of X-chromosome endonucleases in sperm 
cells, so that male mosquitoes only produce sperm cells carrying 
Y-chromosomes so that all resulting offspring are male (Galizi et al., 2014). Other 
methods such as use of transposons, engineering hyper-immune mosquitos, 
knock-out/knock-in systems, or introducing inducible lethal genes have all been 
demonstrated in laboratory mosquitos although it is unclear whether these 
systems could be established and maintained in wild populations (Gabrieli, 






1.2 Molecular Biology of CHIKV 
1.2.1 Genome organisation 
CHIKV is a positive sense, single stranded RNA virus (+ssRNA). The 11.8 Kb 
genome comprises of two ORFs, the non-structural ORF at the 5' end and the 
structural ORF at the 3', separated by a junction region. The genome, as shown 
in Figure 1.5, has a 5' m7G cap and a poly(A) tail, resembling a cellular mRNA, 
as well as 5' and 3' untranslated regions (UTR) that are highly structured 
(Vasiljeva et al., 2000; Solignat et al., 2009).  
 
 
Figure 1.5 The genome organisation of CHIKV. The coding regions for the 
non-structural and structural proteins are shown in green and blue 
respectively. Black areas indicate untranslated regions of the 
genome. (Original figure).  
 
The first ORF encodes for the four non-structural proteins (nsPs). The nsPs 
function to replicate viral RNA. RNA capping is performed by nsP1, nsP2 is a 
protease/helicase and nsP4 is the RdRp. The role of nsP3 is unclear but is 
required for RNA replication. Of the structural ORF, five proteins are expressed, 
three of which are components of the mature CHIKV virion: C, which forms the 
virus core, and E1 and E2 which form the viral glycoproteins. E3 acts as a 
chaperone protein to ensure correct glycoprotein folding and 6k is a proposed 
viroporin required for virus assembly.  
Alphavirus genomes contain many RNA structures, both in coding and non-
coding regions. In SINV, many of these structural elements have been shown to 
be important for virus production and/or replication. Some of these structures 
have been shown to be specific to either mammalian or mosquito cells whereas 
others have been shown critical for both species (Kutchko et al., 2018). In 
CHIKV, there are many predicted secondary RNA structures across the genome, 





2002). There is a high level of secondary structure in the 5' UTR and nsP1 coding 
regions. Multiple stem loops in this area have been shown to be crucial to viral 
replication in mammalian and mosquito cells – with some stem loops being 
mammalian or mosquito specific (Dr Andrew Tuplin, University of Leeds, 
personal communication). Interestingly, some of the secondary structures found 
in the 3' UTR of the CHIKV genome are genotype-specific, with unique structures 
found in the 3' UTR of the Asian genotype. These unique regions are thought to 
be due to adaptation to the mosquito vector (Chen et al., 2013).  
1.2.2 CHIKV virion organisation 
All alphaviruses are spherical, enveloped viruses with a diameter of 70 nm 
(700 Å), as shown by Figure 1.6. At the centre of the virion is an icosahedral 
nucleocapsid core, comprising of 240 copies of C protein containing genomic 
RNA, closely surrounded by the membrane-derived envelope (Strauss and 
Strauss, 1994). Inserted in the envelope are the glycoprotein spikes formed of 
the E1, E2 and E3 proteins. The E1 and E2 proteins form a heterodimer where 
E1 is responsible for membrane fusion of the viral envelope with endosomal 
membranes whereas E2 binds cellular receptors as well as protecting the E1 
fusion loop at a neutral pH (Yap et al., 2017). E3 is responsible for the correct 
folding of the E2 precursor and the formation of the E1/E2 heterodimer. Unlike 
other alphaviruses, (R. Zhang et al., 2011), E3 is not thought to be present on 







Figure 1.6 A cross section of CHIKV virion produced by cryo-electron 
microscopy reconstruction with envelope proteins shown in 
yellow/red, membrane in green, capsid in light blue and RNA in dark 
blue. Adapted from Yap et al., 2017. 
 
1.2.3 CHIKV life cycle 
An overview of the CHIKV lifecycle is summarised in Figure 1.7. Few studies on 
alphavirus replication and lifecycle have been performed with CHIKV, instead 
much of the current literature have studied viruses such as SINV and SFV, 
presumably due to the lower containment requirement of these viruses. Due to 
the high level of sequence homology and protein structures, it is assumed that 
many of the processes in the alphavirus lifecycle are broadly similar across the 
alphaviruses. Hence, throughout this section, the virus used in each study has 






Figure 1.7 Overview of the CHIKV lifecycle. CHIKV enters cells through 
endocytosis and fuses with mature endosomes to release the 
genomic RNA into cells. (1) The non-structural proteins are directly 
translated from the genomic RNA which form replication complexes. 
(2) Replication complexes generate minus sense genomic RNA as a 
template to form genomic RNA for packaging (3) and for synthesis of 
the subgenomic RNA for translation of the structural proteins (4). The 
structural proteins are translated into a polyprotein which is 
subsequently cleaved in various areas of the infected cell. The 
structural proteins and the genomic RNA then co-ordinate at sites of 
assembly, thought to be at the plasma membrane, where they 
assemble to form virus particles and release from the cell.  Original 
figure interpreted from references in section 1.2.3. 
 
1.2.3.1 Cell entry 
The first stage in CHIKV entry is the binding of a cellular receptor. It has been 
known for some time that the E2 glycoprotein is responsible for receptor binding, 
however, the cellular receptor for CHIKV is currently unclear (Smith et al., 1995). 
CHIKV has a relatively wide cell tropism as it infects many cell types of the human 
body (Couderc et al., 2008), as well as mosquito cells. This suggests that the 





protein or, CHIKV utilises multiple receptors for cell entry. No single protein has 
been defined as the cell-entry receptor for CHIKV to date. Many cell surface 
proteins have been proposed to be the receptor or receptor binding factors for 
CHIKV entry in mammalian cells including (but not limited to): prohibitin 
(Wintachai et al., 2012), T cell immunoglobulin mucin domain 1 (TIM-1), (Moller-
Tank et al., 2013), glycosaminoglycans (GAGs) (Silva et al., 2014), and Mxra8 
(Zhang et al., 2018). In mosquito cells, ATP synthase beta subunit (ATPSβ) has 
been identified as a potential binding receptor. It was demonstrated via 
immunoprecipitation that ATPSβ binds CHIKV particles and co-localisation 
between CHIKV and the receptor was observed via immunofluorescence 
(Fongsaran et al., 2014). It is likely that CHIKV uses multiple receptors for entry 
as few of these proposed receptor proteins are ubiquitously expressed and it has 
been shown for most of these proposed proteins, that CHIKV can still establish 
infection, albeit reduced, in the absence of these individual receptors.  
Although there has been much conflicting data, the general consensus is that 
Alphaviruses enter host cells predominantly through clathrin-mediated 
endocytosis (CME), however there is also evidence for entry via clathrin-
independent endocytosis (Bernard et al., 2010; Hoornweg et al., 2016). It has 
also been demonstrated that, under certain conditions, SINV particles can fuse 
directly with the plasma membrane (Vancini et al., 2013). CME is a complex 
process involving many proteins. Many of the CME associated proteins have 
been shown to be essential for CHIKV cell entry including Esp15, Rab5, and 
dynamin (Sourisseau et al., 2007; Bernard et al., 2010), interestingly, all of these 
proteins play roles in both clathrin-mediated and clathrin-independent 
endocytosis. It is likely that CHIKV primarily utilises CME for entry into cells but 
is also able to exploit multiple entry mechanisms where required in order to 
achieve successful entry (Yat-Sing Leung et al., 2011). In mosquito cells, CHIKV 
has only been shown to enter via CME although few studies have investigated 
this phenomenon in insect cells (Ching Hua Lee et al., 2013).  
In mammalian cells, it has been demonstrated that CHIKV predominantly fuses 
with early endosomes. Through both live-cell microscopy and the use of various 
inhibitors of endocytosis, it has been shown that CHIKV infection requires Eps15 





present in early endosomes, but does not require Rab7, which is responsible for 
the maturation of endosomes to lysosomes (Bernard et al., 2010; Hoornweg et 
al., 2016). In contrast, despite CHIKV entering mosquito cells in a similar manner 
and is again reliant on Eps15 and Rab5, successful entry also requires Rab7, 
indicating that CHIKV fuses with late endosomes in mosquito cells, possibly due 
to variations in endosomal pH compared to mammalian cells (Ching Hua Lee et 
al., 2013; Nuckols et al., 2014). The E1 glycoprotein alone is responsible for 
fusion with the endosomal membrane. Work with SFV and SINV show that this 
process requires a conformational change of the E1/E2 heterodimer, induced by 
exposure a low pH, in order to expose the fusion loop of E1 (Bron et al., 1993; 
Justman et al., 1993; van Duijl-Richter et al., 2015; Zeng et al., 2015). Fusion of 
alphaviruses to endosomal membranes also requires cholesterol which is 
thought to facilitate hydrophobic interactions between E1 and the target 
membrane (White and Helenius, 1980; Smit et al., 1999; Ahn et al., 2002).  
Once the virus envelope has fused with the endosomal membrane, the 
nucelocapsid is delivered into the cytoplasm. The nucleocapsids of SINV and 
SFV have shown to be destabilised due to an interaction of the 60S ribosomal 
RNA with the C protein (Ulmanen et al., 1976; Wengler et al., 1992). Once the 
nucleocapsid uncoats, the viral genomic RNA is released and becomes available 
for translation and the initiation of replication.   
1.2.3.2 Genome replication 
Once the genomic RNA is in the cytoplasm of the infected cell, the non-structural 
protein ORF is directly translated from the genome. The CHIKV non-structural 
proteins form replicases that are membrane associated. It is thought that nsP1 
is responsible for the anchoring and the stability of the viral replicase as it has 
been shown to interact with membranes and is the only non-structural protein 
capable of binding all other non-structural proteins (Spuul et al., 2007; Sreejith 
et al., 2012). For SINV and SFV, replication sites have been reported to be in 
membrane invaginations, often referred to as spherules or  cytopathic vacuoles 
(CPVs). Initially, it was thought that the CPVs were formed by modification of 
endosomal and lysosomal membranes at early stages of infection, as they are 





demonstrated that the spherules are formed on the cytoplasmic side of the 
plasma membrane (shown in Figure 1.8), a process that does not require the 
presence of the non-structural proteins. The spherules are then internalised 
through endocytosis and develop into CPVs as previously described (Spuul et 
al., 2010). Spuul et al. also demonstrate the dynamic nature of the CPVs which 




Figure 1.8 Electron microscopy of BHK cells transfected with SFV genomic 
RNA at 3 hpt. Spherules can be seen at the plasma membrane of the 
transfected cells. Scale bar for main image 0.3 µm, in the inset 60 nm. 
Figure from Peränen and Kääriäinen, 1991.  
 
Due a conserved, leaky opal stop codon 6 residues from the end of nsP3, 
translation of the non-structural ORF results in either p123 or p1234 polyprotein 
(Chen et al., 2013). This regulates the amount of nsP4 (the RNA-dependent-
RNA-polymerase) that is produced in infection and the post-translation cleavage 
of nsP3/4 (Jones et al., 2017). Some strains (e.g. Caribbean strains) have an 
arginine in place of the stop codon so only produce the p1234 polyprotein. The 
non-structural polyprotein is proteolytically cleaved by the nsP2 protein initially 
into p123 and nsP4 (Rausalu et al., 2016). In SINV replication, it has been shown 
through the disruption of cleavage sites, that the p123 polyprotein alongside the 
nsP4 polymerase are predominantly required for minus-strand RNA production 
whereas the individual nsPs are required for positive-strand synthesis (Lemm et 





can be temporally segregated in two stages. As summarised in Figure 1.9, the 
first stage is the production of full length, minus-strand RNA. Then, upon 
polyprotein cleavage by nsP2, this switches to positive-strand production of the 
full length genomic RNA for further translation and  packaging, and the 26S sub-
genomic RNA, a small, positive-sense capped RNA that encodes for the 
structural proteins (Albulescu et al., 2014).  
 
 
Figure 1.9 CHIKV RNA replication. Upon entry to the cell, the non-structural 
ORF is translated and produces polyprotein p123 and p1234, 
subsequently cleaved into p123 and nsP4. These proteins induce 
negative sense RNA production. Upon further polyprotein processing 
by the nsP2 protease to form the individual nsP1, nsP2, nsP3 and 
nsP4 proteins, positive sense RNA production is initiated, producing 
full genomic RNA for packaging or further transition, and the 26S 
subgenomic RNA for translation of the structural proteins. Original 
figure interpreted from Lemm et al., 1994. 
 
All four nsPs are required for RNA replication and have distinct roles. The nsP1 
protein, as well as being the membrane-anchor of the replicase complex, also 





that allow nsP1 to cap newly synthesised positive sense RNA (Ahola and 
Kääriäinen, 1995). The nsP2 protein has multiple functions. As discussed 
previously, it has protease activity and is responsible for polyprotein processing 
into individual proteins (Russo et al., 2006). Another function of nsP2 is a 
helicase/NTPase, to unwind RNA secondary structure in order to facilitate 
replication (Rikkonen, 1996). Although known to be essential for RNA replication, 
it is unclear what specific role the nsP3 protein plays in this process. The 
alphavirus nsP3 contain a macro domain at the N terminus, an alphavirus unique 
domain (AUD) and a hyper-variable domain (HVD) at the C terminus. The 
functions of these domains in terms of viral replication are poorly understood 
although mutations in the AUD and HVD of nsP3 have been shown to be 
defective in synthesis of minus strand and subgenomic RNA (Rupp et al., 2015). 
The nsP4 is the RdRp and its sole function is RNA synthesis. At the N-terminus 
of nsP4 is a disordered region which has been shown to interact with nsP1. 
Various mutations to this disordered region produced defects in either positive, 
or negative strand synthesis. This suggests that  this region, and possibly its 
interaction with nsP1 is required for the switch from negative to positive strand 
synthesis (Shirako and Strauss, 1998; Rupp et al., 2011).   
1.2.3.3 Translation of structural proteins 
Once RNA replication has occurred, the structural proteins can be translated 
from the newly synthesised 26s subgenomic RNA into the structural polyprotein. 
The polyprotein is then subsequently cleaved. The core protein (C) contains a 
serine protease allowing cleavage in cis to remove C from the N terminus of the 
polyprotein (Choi et al., 1991). The cleavage of pE2 (the precursor to E3 and 
E2), 6k, and E1 occurs in the ER (Singh et al., 2018). E1 then forms a 
heterodimer with the E2 portion of pE2 and is further cleaved by host cell furin to 
form E3 and the E1/E2 heterodimer (Firth et al., 2008). The processing of the 








Figure 1.10 The processing of the structural polyprotein. The subgenomic 
26s RNA is translated to form a single polyprotein. Core protein then 
auto-catalytically cleaves itself from the polyprotein. Processing in 
the ER allows correct cleavage and folding of the pE2, 6k and E1 
proteins. E1 then forms a heterodimer with pE2 for stability, prior to 
E3 being cleaved by host cell proteases. Original figure interpreted 
from Choi et al., 1991; Firth et al., 2008; Singh et al., 2018. 
 
1.2.3.4 Assembly and release 
Assembly of alphaviruses begins in the cytoplasm with the formation of the 
nucleocapsids with viral genomic RNA being encapsidated by C protein. In SINV, 
it has been shown that this process is facilitated and stabilised by a amphipathic 
coiled coil α-helix at the N-terminus of C that is highly conserved across the 
different alphaviruses, including CHIKV (Perera et al., 2001). Once formed, it is 
thought that the nucleocapsid freely diffuses in the cytoplasm and binds to the 
E2 of the glycoprotein heterodimer in order to target the nucleocapsid to the cell 
membrane for assembly (Suomalainen et al., 1992; Solignat et al., 2009).  The 
nucelocapsid is then thought to bud from the plasma membrane which contains 
E1/E2 heterodimers. Assembly requires the putative viroporin 6k, which although 





suggested to be involved in manipulation of the plasma membrane for efficient 
budding and release of the virus (Yao et al., 1996; Sanz and Carrasco, 2001). 
 
1.2.4 Immune response to CHIKV infection 
Cells infected with CHIKV mount a profound inflammatory immune response, a 
time scale of which is shown in Figure 1.11. Much of this response is protective 
against CHIKV infection but some responses also contribute to the spread of the 
virus and the disease pathology. 
 
Figure 1.11 Time scale of cellular response to CHIKV infection. As viral load 
increases after initial infection, a substantial IFN response is formed 
that correlates with the acute disease symptoms. A protective 
antibody and protective T cell response is formed between 3-5 days 
post infection. Some infected individuals, after recovery of the acute 
infection, have long term, recurring symptoms. Image adapted from 
Schwartz and Albert, 2010. 
 
1.2.4.1 IFN response 
It has been well documented that CHIKV infected cells mount a profound type I 
interferon (IFN) response within 2-5 days of infection (reviewed by Schwartz and 
Albert, 2010). As shown in Figure 1.12, the type I IFN response is induced by 
virus-infected cells which release IFN-α and/or -β to alert surrounding naïve cells 
through the interferon-α/β receptor (IFNAR) to initiate an anti-viral state. The IFN 





infected IFNAR-/- mice develop a more severe disease with increased viral titres 
and neurological complications (Thérèse Couderc et al., 2008).   
 
Figure 1.12 Type I IFN response. IFNα/β is produced by virus infected cells. 
This is released to the surrounding cells which is detected through 
the cell surface interferon-α/β receptor (IFNAR) to induce an IFN 
response in naïve cells, forming an anti-viral state prior to infection. 
IFNs also enhance the adaptive immune response through 
upregulation of antigen presentation and chemokine production to 
form a robust effector T cell response. The T cells further interact with 
B cells to form antibodies to the virus. Figure from Ivashkiv and 
Donlin, 2014. 
 
CHIKV has been demonstrated to trigger the IFN pathway through sensing of 
the viral RNA. CHIKV RNA can be recognised in infected cells by both retinoic 
acid-inducible gene I (RIG-I) and toll like receptor 3 (TLR3). It has been shown 
that sensing through TLR3 is essential for the formation of a neutralising immune 
response to CHIKV infection (Her et al., 2015).  Upon the detection of CHIKV 
RNA, RIG-I is able to signal through mitochondrial anti-viral signalling protein 
(MAVS, also commonly referred to IFN promoter stimulator 1/IPS-1) to trigger 
the IFN pathway (Olagnier et al., 2014). Cells with functional MAVS were more 





has shown that interferon regulatory factor 3 (IRF3) is critical for the IFN 
response in CHIKV infected cells. IRF3 is activated via MAVS signalling and 
induces the transcription of many IFN stimulated genes (ISGs) (White et al., 
2011), as is summarised in Figure 1.13. 
 
Figure 1.13 The IFN response to CHIKV infection. CHIKV RNA is detected 
in the cytoplasm by RIG-I (retinoic acid-inducible gene I ) which 
signals through MAVS (mitochondrial anti-viral signalling protein) and 
many adaptor proteins to activate IRF3 (interferon regulatory factor 3) 
through phosphorylation. IRF3 then translocates to the nucleus to 
induce the transcription of IFN-β and many IFN stimulated genes 
(ISGs). Original figure, interpreted from White et al., 2011; Olagnier et 
al., 2014. 
 
Many ISGs exhibit anti-viral effects against CHIKV. ISG15 has been shown to be 
critical for survival of CHIKV infection, as neonatal mice lacking ISG15 all died 
within 8 days of infection (Werneke et al., 2011). Many other ISGs such as IFN 
regulatory factor 1 (IRF-1) and zinc anti-viral protein (ZAP) have been shown to 
be potently anti-viral against CHIKV (Bick et al., 2003; Schoggins et al., 2011).  
Interestingly, the ISG adenosine deaminase (ADAR) was found to be an 
enhancer of CHIKV infection (Schoggins et al., 2011).  
Although the IFN response is protective of cells infected with CHIKV, it does also 





generic disease symptoms such as fatigue and myalgia (Sleijfer et al., 2005). In 
addition, CHIKV has been shown to induce the expression of cytokines CXCL9 
and CXCL10,  via the IFN response, which have been shown to contribute to 
joint inflammation in CHIKV infection. Both these cytokines are  also implicated 
in the progression of rheumatoid arthritis (Kelvin et al., 2011).  
1.2.4.2 NFкB response 
Despite CHIKV infection inducing a robust IFN response, it has been 
demonstrated that it does not trigger the NFкB pathway (Selvamani, et al., 2014). 
An overview of the NFкB pathway is shown in Figure 1.14. The lack of activation 
of the pathway by CHIKV is particularly interesting as there are multiple points of 
cross-talk between the IFN and NFкB pathways with both pathways capable of 
activating the other (Wang et al., 2010; Iwanaszko and Kimmel, 2011; Rubio et 







Figure 1.14 Overview of the NFкB pathway. The pathway can be triggered 
by multiple stimuli, both external such as TNF-α, or internal, for 
example dsRNA from infecting viruses. These stimuli activate the 
pathway through different mechanisms though, regardless of method 
of activation, the pathway converges on an active IKK complex that 
removes IкB (inhibitor of NFкB) from NFкB/p105. This activates the 
NFкB complex and allows translocation to the nucleus where it acts 
as a transcription factor for a range of inflammatory and antiviral 
genes.  This results in an antiviral state of the cell and the secretion 
of molecules (e.g. IFN) to signal to surrounding cells.  
 
1.2.4.3 Autophagy 
In human cells, it has been shown that CHIKV induces autophagy which 
enhances the replication of the virus. In CHIKV infected cells, light chain 3 (LC3, 
a marker of autophagy) is redistributed to form punctate structures in the 
cytoplasm of CHIKV-infected HeLa and HEK293 cells, indicating the formation 
of autophagosomes. Activating autophagy in HeLa cells with rapamycin 





is inhibited in HEK293 cells, CHIKV replication is reduced, with fewer E1 positive 
cells and less viral RNA production (Krejbich-Trotot et al., 2011). In mouse cells, 
CHIKV has also been shown to induce the formation of autophagosomes. 
However, in contrast to the human cells, these appear to have a protective effect 
from infection, as CHIKV caused higher rates of cell death in the absence of 
autophagy machinery (Joubert et al., 2012). It was proposed that autophagy 
delays the onset of CHIKV-induced apoptosis, and therefore in the absence of 
autophagy , apoptosis occurs earlier in the virus lifecycle, therefore limiting 
production of infectious virus.  
1.2.4.4 Apoptosis  
Many viruses induce apoptosis in infected cells and this was widely considered 
to be a defence mechanism to reduce virus replication and further spread within 
the infected organism (Vaux and Häcker, 1995). Apoptosis rapidly occurs in 
CHIKV infected cells (Dhanwani et al., 2012; Nayak et al., 2017). Through recent 
studies, it is now considered that CHIKV and other alphaviruses induce 
apoptosis as a means to increase viral spread to neighbouring cells (Long and 
Heise, 2015). It has been shown that the apoptotic blebs left by dead 
CHIKV-infected cells can be engulfed by neighbouring cells and macrophages, 
the latter of which are normally refractory to CHIKV infection (Krejbich-Trotot et 
al., 2011). The cellular regulation of apoptosis in response to infection can 
determine whether an alphaviral infection is acute (which normally occurs when 
apoptosis is rapid) or becomes persistent, the latter being commonly observed 






1.2.5 Non-structural protein 3 
The alphavirus nsP3 is known to be essential for viral RNA replication, yet, it is 
still unclear what specific functions nsP3 contributes to the virus lifecycle.  
1.2.5.1 Structural features of nsP3 
The alphavirus nsP3 has three distinct domains; the macro domain at the N-
terminus, the alphavirus unique domain (AUD) in the centre, and the hyper 
variable domain (HVD) at the C-terminus, as shown in Figure 1.15. 
 
Figure 1.15 Schematic of the CHIKV nsP3, highlighting the three domains 
of the protein: the macro domain, the alphavirus unique domain (AUD) 
and the hypervariable domain (HVD). (Original figure).  
 
1.2.5.2 Macro domain  
At the N-terminus of nsP3 there is a macro domain. Macro domain are found in 
the proteins of all species and are defined by their ability to bind ADP-ribose. The 
macro domain of CHIKV has been demonstrated to bind mono- and poly-ADP-
ribose and RNA and possesses ADPR-hydrolase activity (Rupp et al., 2015). As 
this is the focus of this project, the macro domain is discussed in more detail in 
section 1.3.2.3. 
1.2.5.3 Alphavirus unique domain 
The alphavirus unique domain (AUD) is, as the name implies, a domain only 
found in alphaviruses where it is highly conserved. The full protein structure of 
the AUD is currently unknown but structural analysis of the nsP2/3 interface 
revealed a zinc coordination site at the start of the AUD (Shin et al., 2012). The 
function of the AUD is yet to be determined and there are currently very few 
publications that focus on this domain. Various mutagenic studies of the SINV 
and SFV AUDs have demonstrated it is required for minus strand-RNA synthesis, 
subgenomic RNA synthesis, and neurovirulence (Dé et al., 2003; Tuittila and 





in both RNA replication and virus assembly (Yanni Gao, University of Leeds, 
personal communication). Still the precise function of the AUD remains unclear.  
1.2.5.4 Hypervariable domain 
The hyper variable domain (HVD) also often referred to as the hyper variable 
region (HVR) or just variable region (VR), is an intrinsically disordered, 
unstructured domain that is highly phosphorylated. It is highly variable in both 
sequence and length between the alphavirus nsP3s. The HVD of various 
alphaviruses have been shown to have many interactions with various cellular 
proteins and processes, including the well characterised nsP3 interaction with 
G3BP (Foy et al., 2013). Near the C-terminus of the HVD, there are two 
polyproline motifs (PxxP) that are known to bind SH3 domains. Many cellular 
proteins contain SH3 domains that are involved in a wide range of signalling 
pathways (Kaneko, Li and Li, 2008). The polyproline motifs of SFV, CHIKV and 
SINV have all been shown to bind amphiphysins 1 and 2 (Neuvonen et al., 2011). 
Abrogation of this interaction by mutation or deletion of the PxxP motifs resulted 
in impaired RNA replication in both SFV and SINV. It is thought that since 
amphiphysins are able to induce curvature of membranes this interaction with 
nsP3 may contribute to spherule formation (Götte et al., 2018). It is also proposed 
that the HVD is a hub of interactions with cellular proteins and these interactions 
are crucial to replication and the cellular distribution of nsP3 (Foy et al., 2013). 
Deletion of the hypervariable domain results in a significant shift in cellular 
distribution. Unlike with deletions of the macro domain which resembles the 
cytoplasmic puncta of full length nsP3, deletion of the HVD resulted in distinctive 
filamentous-like structures as shown in Figure 1.16, postulated to be due to the 







Figure 1.16 Deletions of nsP3 domains affect cellular distribution. EGFP-
tagged forms of full nsP3 (top) and AUD-HVD (middle) show similar 
distribution however, the AUD alone (bottom) exhibits a drastic 
change in cellular distribution. Figure adapted from Fros et al., 2012.  
 
Seven codons N-terminal to the end of nsP3 is a ‘leaky’ stop codon.  As 
discussed previously in section 1.2.3.2, this affects regulation of minus or 
positive strand synthesis, however it also has effects on nsP3 production and 
stability. The nsP3 stop codon, found in all CHIKV strains except the Caribbean 
strain (which instead encodes for an arginine at this site), results in two forms of 
nsP3; a 443 aa if terminated at the stop codon or 449 aa if read through to 
produce the full p1234 polyprotein (as shown in Figure 1.17). The additional 
amino acids in full length SFV nsP3 has been shown to act as a ‘destability 
sequence’ as their presence greatly reduces the stability of nsP3 in cells (Varjak, 
et al,. 2010). Although the precise functions of the short and full versions are still 
unclear, Varjak et al. demonstrated that both versions are required for efficient 
replication and suggested that the extra amino acids may alter nsP3 localisation, 






Figure 1.17 RNA sequence (top) and protein translation (bottom) of the 
CHIKV nsP3 C-terminus. The leaky opal stop codon is shown in red. 
(Original figure). 
 
1.2.5.5 Known interactions of nsP3 
Although the structure and localisation of the non-structural proteins in replicase 
sites is currently unclear, it is known that nsP3 directly interacts with nsP1 which 
is required for functional replicases. The nsP1 then forms additional interactions 
with nsP2 and nsP4 (Sreejith et al., 2012).  
It has been demonstrated that nsP3 is able to bind RNA, a well-characterised 
property of the macro domain, but the AUD has also been shown to capable of 
RNA binding (Malet et al., 2009, Yanni Gao, University of Leeds, personal 
communication) although it is yet unclear whether RNA binding is specific e.g. to 
viral RNA. It has been shown that the macro domain of nsP3 is capable of 
suppressing the RNA interference (RNAi) anti-viral pathway, although it is 
unclear what specific interaction is causing this effect (Mathur et al., 2016). 
One of the best characterised interactions of nsP3 is that with G3BP. G3BP is a 
marker of stress granules, which are pools of untranslated mRNAs and 
associated proteins that form in response to many cellular stresses such as viral 
infection (Protter and Parker, 2016).  The interaction between G3BP and nsP3 
is dependent on the SH3 domain binding motif in the HVD and is thought to 
actively inhibit stress granule assembly in CHIKV-infected cells (Fros et al., 
2012). It has been shown that G3BP is crucial for the RNA replication of the “old 
world” alphaviruses, of which CHIKV is a member of (Kim et al., 2016). In 
mosquito cells, a similar interaction with rasputin (an insect homologue of G3BP), 
has been shown to play a very similar role in alphavirus replication to that of 





Another interaction of nsP3 mediated by its SH3 domain binding motif is with 
amphiphysins. The nsP3 of SFV, SINV and CHIKV have all been shown to 
interact with amphiphysin 1 and amphiphysin 2. When these interactions were 
abolished by mutation of the SH3-binding motifs of nsP3, RNA replication was 
reduced (Neuvonen et al., 2011). Amphiphysins are involved in many cellular 
pathways. Amphiphysin 1 is known to play a key role in clathrin mediated 
endocytosis, particularly in neuronal synapses and phagocytosis, and binds 
dynamin 1, an interaction facilitated by the SH3-binding domain of amphiphysin 
1  (Yamada et al., 2007). Amphiphysin 2 (also referred to as Bin1 in the literature) 
is an ubiquitously expressed protein, found in both the nucleus and cytoplasm of 
mammalian cells. It has a wide range of cellular functions including membrane 
trafficking and remodelling, regulation of the actin cytoskeleton, DNA repair, cell 
cycle regulation and apoptosis (Prokic et al., 2014). It has been proposed that 
the alphavirus nsP3 utilises the membrane-regulation abilities of amphiphysins 
to rearrange host cell membranes to support viral replication (Neuvonen et al., 
2011).  
The SINV nsP3 has been demonstrated to interact with Y-box-binding protein 
(YBX1), (Gorchakov et al., 2008). YBX1 has many cellular roles including cell 
cycle progression, DNA repair, transcription, translation and is upregulated upon 
cellular stress (Prabhu et al., 2015). YBX1 is also able to bind RNA and DNA,  
chaperone mRNAs and is a component of mRNPs (Eliseeva et al., 2011). The 
function of the nsP3-YBX1 interaction and its effects on viral replication is 
unclear. YBX1 interacts with other viral proteins with contradictory outcomes. 
YBX1 is known to inhibit Dengue virus virion production and can suppress the 
translation of viral RNA (Paranjape and Harris, 2007). Conversely, in HCV, YBX1 
association with viral proteins NS3 and NS4A is required for efficient RNA 
replication (Chatel-Chaix et al., 2011). More research is required to determine 
the  role of YBX1 in the alphavirus lifecycle.  
The hyper-phosphorylated HVD of nsP3 of interacts with Akt, which activates the 
PI3K-Akt-mTOR pathway. This activation has been shown to be necessary for 
the internalisation of replicases at the plasma membrane for SFV but not for 
CHIKV, which activates the pathway to a much lesser degree (Spuul et al., 2010; 





Other interactions of nsP3 with cellular proteins includes the heat shock protein 
70 (Hsp70) although the purpose of this interaction is currently unknown 
(Gorchakov et al., 2008).  The nsP3 of VEEV has been shown to interact with 
DEAD box domain proteins DDX1 and 3, which are thought to act as additional 
helicases to assist viral RNA replication (Amaya et al., 2016). The VEEV nsP3 
has also been shown to interact with IκB kinase-β (IKKβ) to activate the NFкB 
pathway. Inhibition of this interaction reduced production of infectious virus and 





1.3 Macro domains 
At the N-terminus of the CHIKV nsP3 is a macro domain. A macro domain is a 
conserved protein fold that are found either singularly or, more commonly, as a 
component of larger proteins (Leung et al., 2018). They are defined by their 
ability to bind ADP-ribose (ADPR), which exists either as a monomer: mono-
ADP-ribose (MAR), or as a polymer: poly-ADP-ribose (PAR), as shown in Figure 
1.18. Macro domains are capable of binding either free ADPR or that which is 
attached to proteins, as ADP-ribosylation is a common post-translational 
modification (Karras et al., 2005; Dani et al., 2009).  
 
Figure 1.18 Chemical structures of the monomeric (A) and polymeric (B) 
forms of ADP-ribose. Original figure drawn using ChemDraw software. 
 
Some macro domains have also been shown to have enzymatic activity such as 
ADP-ribose 1″-phosphate phosphatase activity, which catalyses the reaction 
shown in Figure 1.19, an activity required for tRNA splicing (Kumaran et al., 





domains possess hydrolase activity where they can remove ADPR from modified 
proteins (Gupte et al., 2017).  
 
 
Figure 1.19 Reaction scheme showing the hydrolysis of ADP-ribose 1″-
phosphate to form ADP-ribose, and inorganic phosphate, catalysed 
by enzymes that possess ADP-ribose 1″-phosphate phosphatase 
activity, such as the CHIKV macro domain. Original figure drawn using 
ChemDraw software. 
 
The first macro domains discovered were in coronaviruses (Lee et al., 1991). At 
the time, these highly conserved domains were termed “x-domains” to denote 
their unknown function. Since this initial discovery, similar domains were found 
in the proteins of mammals, birds, bacteria and viruses (Pehrson and Fuji, 1998). 
They were renamed ‘macro domains’ when high levels of homology were found 
with a histone protein called macroH2A, which is one of the most widely studied 
macro domains (Malet et al., 2009; Pasque et al., 2012). MacroH2A, is a histone 
protein in humans which has been shown to have roles in transcriptional 
repression, chromatin reorganisation, DNA replication and repair (Chakravarthy 
et al., 2005; Buschbeck and Di Croce, 2010). Macro H2A functions to organise 
the nucleus and stabilise chromatin (Douet et al., 2017). Further sequence 
alignments of the mammalian macroH2A with other proteins revealed similar 
domains in bacteria Alicaligenes eutrophus and E. coli as well as the RNA 
viruses Rubella and Sindbis (Pehrson and Fuji, 1998). In the same study, it was 
demonstrated that there was a high level of conservation of the amino acid 
sequence of the protein domain across species.  
1.3.1 ADP-ribosylation in cell signalling 
ADP-ribosylation is a common post-translational modification of many cellular 
proteins, discovered over 50 years ago (Chambon et al., 1963). Relatively little 





could be modified with either mono- or poly- ADPR. This modification is 
performed by a family of enzymes named poly-ADPR-ribose polymerases 
(PARPs) that are able to catalyse the transfer of ADPR onto proteins from 
nicotinamide adenine dinucleotide (NAD+), (Leung, 2017). There are 17 known 
human PARPs which are implicated in a range of cellular functions as described 
in Table 1.1. Ironically most PARPs only exhibit mono-ADP-ribosylation activity, 
therefore a new nomenclature was proposed, terming ‘PARPs’ as ‘ARTDs’ 
(ADP-ribosyltransferase diphtheria toxin-like proteins) alongside the 
renumbering the PARPs due to function (Hottiger et al., 2010). Despite this 
remaining addresses the accuracy of naming these proteins, it does cause 
confusion in the literature where many previous studies have referred to proteins 
as “PARPs” and others as “ARTDs” and, as shown in Table 1.1, the numbering 












Reported biological functions 
PARP1 ARTD1 PAR DNA maintenance and repair, cell cycle, 
transcription 
PARP2 ARTD2 PAR DNA maintenance and repair, cell cycle and 
transcription 
PARP3 ARTD3 MAR DNA repair and cell cycle regulation 
PARP4 vPARP, ARTD4 MAR Cancer biology  
PARP5a TNK1, ARTD5 PAR Anti-viral, inflammation, RNA processing 
PARP5b TNK2, ARTD6 PAR Inflammation 
PARP6 ARTD17 MAR Cell proliferation 
PARP7 TiPARP, 
ARTD14 
MAR Anti-viral, RNA processing 
PARP8 ARTD16 MAR Unknown 
PARP9 ARTD9, BAL1 None 
(inactive) 
Cell migration 
PARP10 ARTD10 MAR Cell proliferation, RNA processing and 
inflammation 
PARP11 ARTD11 MAR Unknown  






PARP14 ARTD8, BAL2 MAR Inflammation, transcription, RNA processing 
PARP15 ARTD7, BAL3 MAR RNA processing 
PARP16 ARTD15 MAR Unfolded protein response 
Table 1.1 Human PARPs, their alternative names, enzymatic activity and 
known cellular functions. Adapted from Vyas et al. 2013, Vyas et al. 






In much of the literature of ADP-ribosylation and signalling, ARTDs are termed 
the “writers,” ADP-ribose binding domains being the “readers” and ADPR-
hydrolases being “erasers” demonstrated by Figure 1.20 (Gupte et al., 2017). All 
macro domains are considered “readers” but mainly also fall into the “eraser” 
category as some merely bind ADPR whilst others can both bind and hydrolase 
the moiety. This includes the human protein macroD2 which is able to both bind 
and hydrolyse ARPR (Chen et al., 2011).  
 
 
Figure 1.20 Overview of proteins involved in ADP-ribosylation. Writers, 
such as ARTDs, add ADPR to proteins. Readers such as macro 
domains and PBZ domains are able to bind ADPR. Erasers, such as 
PAR glycohydrolase (PARG), are able to remove ADPR from proteins 
by hydrolysis. Original figure adapted from Gupte, Liu and Kraus, 
2017. 
 
ADP-ribosylation of proteins has been shown to be a tool for cell signalling in 
many pathways including DNA repair, transcription, RNA processing and 
trafficking and innate immunity.  
One of the best-studies ARTDs and ADP-ribose signalling pathways is PARP1, 
which is a true poly-ADP-ribose polymerase (Vyas et al., 2014). PARP1 has been 
well characterised as a DNA repair protein. When DNA damage occurs by either 
single or double stranded breaks, PARP1 is activated and becomes heavily auto-
ribosylated, forming extensive branches of PAR upon itself and nearby chromatin 
(Chaudhuri and Nussenzweig, 2017). This assists in the recruitment assembly 
of protein complexes in order to repair the damaged DNA. Proteins such as DNA 





and Ren, 2012). Some of these proteins are ADP-ribosylated for recruitment 
whilst others contain ADPR-binding domains e.g. macroH2A which bind 
PARylated PARP1 through their macro domains (Timinszky et al., 2009). When 
the DNA damage is minimal, PARP1 is able to quickly recruit the necessary 
proteins for successful repair. However, when there is excessive DNA damage, 
PARP1 performs extensive PARylation which drastically reduces NAD+ levels of 
the cell (Yu et al., 2002). This induces the translocation of apoptosis inducing 
factor (AIF) from the mitochondria to the nucleus, where it contributes to the 
degradation of chromatin (Candé et al., 2002). Alongside AIF, mitochondria also 
release cytochrome C, which activates caspases and results in apoptosis 
(Chiarugi and Moskowitz, 2002). Caspases then cleave PARP1, presumably to 
cease pointless production of PAR by this stage in the process (Cohausz and 
Althaus, 2009). Cleaved PARP1 is considered a hallmark of apoptosis.  
Many processes regulated by ribosylation involve interplay with other forms of 
signalling. It has been shown that poly-ADP-ribosylation can act as a signal for 
ubiquitination of proteins for eventual degradation by the proteasome. E3 ligase 
can bind PAR through its WWE domain, then ubiquitinate the ribosylated protein 
to target it for degradation (Zhang et al., 2011). ADPR signalling has also been 
shown to interact with SUMOylation. In the DNA damage response, proteins are 
recruited to sites of DNA breakages by extensive PARylation of the damaged 
site by PARPs. Certain proteins such as tyrosyl-DNA phosphodiesterase 1 
(TDP1), a crucial enzyme for DNA repair, have been shown to be both 
PARylated, for recruitment to the damage site, and SUMOylated for stability (Das 
et al., 2014).  
1.3.1.1 ADP-ribosylation in anti-viral immunity 
Many ARTD proteins are IFN stimulated genes (ISGs). This includes ARTD10, 
ARTD12L (the long isoform of ARTD12), ARTD13 (aka ZAP) and ARTD14 (Guo 
et al., 2004; Atasheva et al., 2014). 
ARTD12 has been shown to locate to stress granules to inhibit mRNA translation, 
which has been shown to be reliant on the catalytic activity and autoribosylation 
of the protein (Atasheva et al., 2014; Welsby et al., 2014).  For alphaviruses, the 





virus infection, ARTD12 has also been shown to exhibit strong anti-viral activity 
by targeting the viral proteins NS1 and NS3 for degradation (Atasheva et al., 
2014; Li et al., 2018).  
ARTD13, also referred to as Zinc-finger anti-viral protein (ZAP) is an anti-viral 
protein that has been widely studied. Curiously, this ARTD is catalytically inactive 
but has potent anti-viral effects. It is has an inhibitory effect on a range of viruses 
including retroviruses such as murine leukaemia virus, and alphaviruses such as 
SINV, the inhibition of which relied on the zinc finger motifs of ZAP (Guo et al., 
2004). Guo et al. demonstrated that ZAP inhibition varied dependent on the virus 
targeted. For retroviruses such as murine leukaemia virus (MLV), ZAP can bind 
viral mRNA and target it for degradation. It has also been shown that ZAP can 
prevent retrotransposition (Goodier et al., 2015). Whereas for SINV, ZAP 
inhibited the translation of viral RNA. More recently, it has been shown that ZAP 
is able to selectively bind to RNA that has a higher GC content than host genomic 
RNA (Takata et al., 2017). In vertebrate genomes, there is evidence for 
suppression of GC content as it is much lower than would be expected from a 
random distribution of nucleotides. In this publication, it was shown that ZAP 
selectively binds to GC-rich RNA. When the genome of HIV-1 was mutated to 
contain a higher GC content this resulted in a defective virus. However, when 
this GC-rich HIV-1 was used to infect ZAP-/- cells, replication of the virus was 
restored to wt levels. Together, this data indicates that ZAP is able to selectively 
bind GC-rich RNA and acts to remove this non-self RNA from cells.  
ARTD10 has been shown to be a regulator of the inflammatory NFкB pathway. 
Upregulation of ARTD10 decreased NFкB activity, this was later shown to be 
due to an interaction with a key NFкB protein; NEMO (Verheugd et al., 2013). 
ADP-ribosylation of NEMO by ARTD10 prevents the formation of the IKK 
complex, a kinase complex central to the pathway. The lack of an active IKK 
renders NFкB inactive in the cytoplasm, as it remains bound by IκBα, preventing 
it from translocating to the nucleus, so that it cannot enact its effects as a 
transcription factor for anti-viral and inflammatory genes.  
ARTD12 has also been linked to activation of the NFкB pathway. Although the 





catalytic domain, but not the zinc finger domain of the protein and possibly 
requires and interaction with the autophagy protein p62/SQSTM1 (Welsby et al., 
2014).  
1.3.2 Viral macro domains  
Macro domains are found in the proteins of several positive sense, single 
stranded RNA viruses. The first viral macro domains, termed x domains at the 
time of discovery, were identified in 1991 in coronaviruses (CoVs), specifically; 
mouse hepatitis virus (MHV) and infectious bronchitis virus (IBV) (Lee et al., 
1991). Since this discovery, macro domains have also been found in other 
coronaviruses such as severe acute respiratory syndrome (SARS) (Malet et al., 
2006), as well as hepatitis E virus (HEV) (Anang et al., 2016), and alphaviruses 
(Götte, Liu and McInerney, 2018). Rubella virus, which is closely related to the 
alphaviruses, also possesses a macro domain (Neuvonen and Ahola, 2009) 
although to date, no studies have focussed on the Rubella macro domain.  
The fact that macro domains are found in multiple positive sense, single-
stranded RNA viruses with some degree of conservation at the amino acid level 
indicates there may be an evolutionarily conserved function of the domain across 
these viruses (Gorbalenya, Koonin and Lai, 1991).  
1.3.2.1 Coronavirus macro domains 
Macro domains were first discovered in the coronaviruses IBV and MHV. It has 
been since determined that all coronaviruses possess macro domains and they 
are important virulence factors (Eriksson et al., 2008; Fehr et al., 2016). The 
structure of the SARS-CoV macro domain was determined in 2006 and was 
demonstrated to readily bind ADP-ribose but have very poor ADPR 1”–
phosphatase activity, providing evidence that this enzymatic activity is possibly 
not the primary function of viral macro domains (Egloff et al., 2006). In terms of 
cellular function, there is mounting evidence that the CoV macro domain is 
involved in counteracting host defences. Fehr et al (2016) demonstrated that the 
SARS macro domain can suppress innate immunity but was not sufficient to 
block these pathways when triggered by various stimuli. Other have shown that 
various mutations in the SARS-CoV macro domain render the virus more 





Most of studies of CoV macro domains focus on that of SARS however, studies 
have shown differences in the structure and binding capabilities between the 
SARS-CoV and the MERS-CoV macro domain (Cho et al., 2016). This highlights 
the importance of studying individual viral macro domains as high conservation 
between macro domains of viruses within the same family does not ensure the 
same biochemical properties or cellular functions. 
1.3.2.2 Hepatitis E virus macro domain  
HEV is a small positive sense RNA virus in the Hepeviridae family (Doceul et al., 
2016). The HEV macro domain has shown to be essential for viral replication as 
certain deletions within macro domain completely abrogate virus replication (van 
Tong et al., 2016). The HEV macro domain has been shown to interact with the 
viral methyltransferase and ORF3, a small viral phosphoprotein (Anang et al., 
2016). More recently, it has been shown that the HEV macro domain can interact 
with, and hydrolyse, MAR and PAR from ribosylated substrates in vitro. Further 
mutagenic studies showed that residues key to ADPR-binding and enzymatic 
activity are essential for HEV replication (Li et al., 2016). Another study 
demonstrated that the HEV macro domain is able to inhibit the poly(I:C) mediated 
phosphorylation of IFN regulatory factor 3 (IRF3) (Nan et al., 2014). The macro 
domain has also been associated with HEV persistence, attributed to its ability 
to modulate the host immune response (Lhomme et al., 2014).  
1.3.2.3 Alphavirus macro domains 
In alphaviruses, the macro domain is found at the N-terminus of nsP3 (Leung et 
al., 2018). Studies focussing on the SINV macro domain have shown that 
mutations that do not disrupt PAR-binding (N10A and N24A) can affect viral 
replication, although many of these mutations were shown to rapidly revert 
and/or produce compensatory mutations when in both cell culture and mice. 
These mutations were shown to disrupt interactions with nsP3 and other viral 
replicase proteins and reduced RNA replication, overall reducing virulence in 
mice (Park and Griffin, 2009).  Other studies have shown that some insertion 
mutations in the macro domain affected plaque size and were defective in RNA 





There have been multiple studies investigating the macro domain of CHIKV. The 
three-dimensional structure of the domain was determined by X-ray 
crystallography in 2009 (Malet et al., 2009),.  As shown in Figure 1.21, this study 
revealed the structure of both the native (apo) CHIKV macro domain but also the 
domain in complex with ADP-ribose and RNA.  In the same publication, it was 
demonstrated that the CHIKV macro domain is capable of binding ADPR with a 
lower affinity than the VEEV macro domain, with both alphaviruses exhibiting far 
weaker affinity than the SARS-CoV macro domain. Conversely, the CHIKV 
macro domain, alongside VEEV, SFV and SINV, all  bound PAR with far greater 
affinity than the SARS-CoV macro domain. The ADPR 1”-phosphatase activity 
was also detected in all alphavirus macro domains to varying levels except that 
of SFV, which was below the detection limit.  
 
Figure 1.21 The 3-dimensional structure of the CHIKV nsP3 macro domain. 
(A) The native domain, (B) the domain in complex with mono-ADP-
ribose, (C) the domain in complex with RNA. PDB numbers 3GPG, 
3GPO and 3GPQ respectively (Malet et al., 2009). 
 
Surprisingly, the macro domain with the highest sequence and structural 
similarity to the CHIKV macro domain was that of E. coli, not coronaviruses. This 
may allude to the alphavirus macro domain having a different cellular function 
than the coronavirus equivalent and, interestingly, may also imply that there were 
two separate evolutionary events where +ssRNA viruses acquired macro 
domains (Malet et al., 2009; Neuvonen and Ahola, 2009).  
In common with the HEV macro domain, it was demonstrated that the CHIKV 





macro domain was demonstrated to be able to efficiently remove MAR from 
ribosylated proteins in vitro, with evidence that this process also occurs in vivo 
(Eckei et al., 2017). The same study demonstrated that hydrolysis of PAR from 
modified proteins was inefficient, which is curious as Malet et al. (2009) 
demonstrated that the CHIKV macro domain had a high affinity for PAR binding.  
A separate study published very similar findings. It was demonstrated that the 
CHIKV macro domain could hydrolyse MAR from aspartate and glutamate 
residues, but not lysine (McPherson et al., 2017). In the same publication, it was 
demonstrated through mutagenic studies, that binding and hydrolysis of MAR 
was essential for replication of the virus in cell culture and mutations to the 
domain reduced virulence in infected mice.  
A more recent publication by the same group showed that upon CHIKV infection, 
there is an increase in general ADP-ribosylation within infected neurones and 
that MARylation activity of cellular ARTDs is required for optimal CHIKV infection 
(Abraham et al., 2018). In agreement with previous results it was shown that 
when both hydrolase and ADPR-binding of the CHIKV macro domain were lost 
through mutation, the replication of the virus was significantly reduced from early 
stages of infection. However when binding capabilities are maintained but 
hydrolase activity reduced, early stages of infection proceeded as normal such 
as the translation of non-structural proteins and the formation of replicase 
complexes, however, translational shut-off occurs earlier than is observed for wt 
CHIKV, resulting in a delay in virus replication for these mutants.  
All this information together forms a rather confusing picture. The CHIKV nsP3 
macro domain is more similar to E. coli than coronaviruses, indicating that there 
may be little crossover between its function in alphaviruses and coronaviruses. 
It has also been shown to bind MAR and PAR with high affinity, yet possesses 
the ability to efficiently hydrolase MAR, but not PAR from ribosylated proteins. It 
has been shown that the CHIKV nsP3 macro domain requires binding and 
hydrolysis of MAR in order to establish replication, but when lacking hydrolase 
activity alone, early stages of replication resemble wt, only reducing due to the 





as to what specific functions the CHIKV nsP3 macro domain provides in virus 






Previous studies have mostly focused on in vitro biochemical properties of the 
macro domain with few assessing its cellular function in detail. Therefore, the 
overall aim of this project was to determine the function of the CHIKV nsP3 macro 
domain in the context of the replication cycle of the virus. To achieve this, initially, 
replicon and infectious virus clones had to be optimised in a range of suitable 
and appropriate cell lines in order to study the molecular biology of CHIKV under 
optimal conditions. Following this, mutagenic studies were performed on the 
nsP3 macro domain to form a range of replicative phenotypes and investigate 
the cause(s) of these phenotypes. From this data, further study into the precise 
cellular function of the domain were conducted, leading to the investigation of 












2.1 Molecular Biology 
2.1.1 Polymerase Chain Reaction (PCR) 
PCRs were assembled at room temperature using as shown in Table 2.1 and 
were cycled as defined in Table 2.2. Details of plasmid maps and primers used 
for PCR and cloning are detailed in chapter 8.  
Component Per tube  
Template DNA 100 ng 
100 µM forward primer 0.5 µL 
100 µM reverse primer 0.5 µL 
Vent polymerase (NEB) 1 µL 
ThermoPol buffer (NEB) 5 µL 
100 mM dNTPs (BioLine) 0.4 µL 
DMSO (ThermoFisher) 1 µL 
ddH2O Up to 50 µL 
Table 2.1 Assembly of PCRs 
Temperature  Time (min) Number of cycles 
95 °C  2:00 X 1 
95 °C  00:30 
X 30 Annealing (see appendix?) 00:30 
72 °C  1:00 per 1 kb 
72 °C  2:00 X 1 
4 °C  Infinite hold X 1 
Table 2.2 PCR cycle program generic template 
2.1.2 Mutagenesis 
Site-directed mutagenesis was performed using the NEB Q5 site directed 
mutagenesis kit, using primers in Table 7.2. Reactions were prepared as shown 





product was Kinase/ligase/DpnI (KLD) treated, assembling the reaction using: 1 
µL PCR product, 5 µL KLD buffer, 1 µL KLD enzyme mix and 3 µL nuclease free 
ddH2O. The reaction was incubated for 10 min at rt and 5 µL of the reaction was 
transforming into 50 µL competent cells (see 2.1.7).  
Component Per tube (µL) 
Q5 master mix 12.5  
10 µM forward primer 1.25 
10 µM reverse primer 1.25 
Template DNA (25 ng/µL) 1.0 
Nuclease-free ddH2O 9.0 
Table 2.3 Assembly of Q5 mutagenesis reactions 
Temperature Time Number of cycles  
98 °C 0:30 X 1 
98 °C 0:10 
X 25 
Annealing temperature 
(see appendix for specific 
temperatures) 
0:30 
72 °C 0:30 per 1 kb 
72 °C 2:00 X 1 
4 °C Hold X 1 
Table 2.4 PCR cycle program for Q5 mutagenesis reactions 
2.1.3 Restriction endonuclease digestions 
All restriction digests were performed using NEB enzymes. Reactions were 
performed with the appropriate buffer and recommended temperature. For 
linearisation of the CHIKV replicon and virus DNA constructs for in vitro RNA 
transcription, 5 µg of DNA was digested for 5-16 h using NotI-HF. For general 
cloning, a minimum of 1 µg DNA was digested with 10 units of enzyme at a total 





intestinal phophatase (CIP, NEB) treated: 10 units of CIP was added directly to 
the digestion mix and incubated at 37 °C for a further hour. Resulting DNA was 
then extracted by phenol-chloroform extraction and ethanol precipitation (see 
sections 2.1.4 and 2.1.5).  
2.1.4 Phenol-chloroform extraction DNA extraction  
The total volume of DNA to be extracted was adjusted to 200 µL with ddH2O. 
One volume phenol:chloroform:isoamyl (25:24:1) alcohol added, vortexed for 1 
min and centrifuged at 16,000 xg for 5 min. The resulting upper phase was 
removed, transferred to a fresh tube and 1 volume of chloroform added, vortexed 
1 min and centrifuged at 16,000 xg for 5 min. The upper phase was again 
removed and transferred to a new tube for ethanol precipitation (see 2.1.5) 
2.1.5 Ethanol precipitation of DNA 
Where possible, the total volume of the DNA sample for precipitation was 
adjusted to 200 µL, if the sample was in excess of 200 µL, the following volumes 
were adjusted accordingly. Three volumes of absolute ethanol and 0.1 volume 
of 3M sodium acetate added, briefly vortexed and incubated at -20 °C for a 
minimum of 3 h, preferably overnight. Samples were centrifuged at 20,000 xg at 
4 °C for 30 min. Supernatant was discarded and replaced with 200 µL 70 % 
ethanol. Samples were centrifuged at 20,000 xg at 4 °C for 10 min. Ethanol was 
removed and samples left to air dry for 30 min before resuspending the DNA 
pellet in ddH2O for most constructs (e.g. for cloning) or with RNase-free water 
for in vitro RNA synthesis.  
2.1.6 Transformation of DNA into competent cells and culture 
DNA was transformed into 5-alpha competent E. coli (NEB) that were prepared 
using the Mix and Go kit (Zymo), following manufacturer’s protocol, to produce 
Z-competent cells. For intact DNA constructs, 20 µL of cells were mixed with 
5 µL plasmid DNA and incubated on ice for 5 min. The total volume was made 
up to 200 µL with LB and plated out onto LB agar containing ampicillin (100 
µg/mL), incubating at 37 °C overnight. For ligated or mutagenesis DNA products, 





added, with samples being incubated at 37 °C in a shaking incubator for 1-2 h 





2.1.7 DNA preparation  
2.1.7.1 DNA constructs 
2.1.7.1.1 Replicon constructs 
All replicons used in this project were generated, and kindly provided by Andres 
Merits. All replicons were derived from the ECSA genotype RL2006OPY1 isolate 
virus and modified with various tags. The dual luciferase (dLuc) replicon contains 
a Renilla luciferase (RLuc) inserted into the VR of the nsP3 coding region via an 
engineered SpeI site, and contains a firefly luciferase (Fluc) in the subgenomic 
region of the genome, replacing the structural ORF (see appendix Figure 7.1).  
An mCherry-tagged nsP3 replicon was generated using the same SpeI site as 
detailed for the dLuc replicon. The nsP3-mCherry replicon contains a 
subgenomic Gaussia luciferase and is referred to as nsP3-mCherry/SG-GLuc 
throughout.An untagged nsP3 replicon is also used in this project, referred to as 
wt-nsP3/SG-Fluc, which contains a Fluc in the subgenomic region of the 
replicon.   
2.1.7.1.2 Virus constructs 
Similarly to the replicon constructs, the virus construct used throughout this 
project, termed “ICRES,” was derived from a patient isolate from the ECSA 
genotype RL2006OPY1 virus (see appendix Figure 7.3). 
2.1.7.1.3 Expression constructs 
For protein expression, constructs were formed using pcDNA3.1+ (see 
appendix Figure 7.1). 
2.1.7.2 Small scale DNA preparation 
To purify DNA on a small scale, a single colony containing the desired construct 
was used to inoculate a 5 mL LB culture containing 100 µg/mL ampicillin and 
grown overnight at 37 °C, shaking at 180 rpm. Plasmid DNA was then prepared 
by alkaline lysis using the Monarch Plasmid Miniprep kit (NEB) using the 







2.1.7.3 Large scale DNA preparation 
For large DNA preparation, 1 mL from a 5 mL overnight culture (as described in 
2.1.7.2) was used to inoculate a 50 mL LB culture containing 100 µg/mL 
ampicillin and incubated over night at 37 °C with shaking. DNA was prepared by 
alkaline lysis using the GeneJET Plasmid Midiprep kit (ThermoFisher Scientific) 
using the manufacturer’s recommended protocol.  
2.1.8 DNA agarose gel electrophoresis 
Agarose gels at 1% were used for DNA gel electrophoresis (1% agarose in TAE 
buffer with SYBR safe 1:10000). DNA was prepared using purple gel loading dye 
(6x, NEB). Hyperladder 1kb (Bioline) was used for size markers. Gels were 
electrophoresed at 100 volts for 40 min.   
2.1.9 Gel extraction of DNA 
DNA bands were visualised via blue light (470 nm) with an orange filter, and 
relevant bands were excised from the gel. The DNA was extracted from the gel 
slices using the Monarch gel extraction kit (NEB) using the manufacturer’s 
recommended protocol.  
2.1.10 Ligation of DNA 
Ligations were performed at a 5:1 molar ratio of insert to vector,  with 50 ng of 
vector. DNA was mixed, incubated on ice for 5 min, then 50 °C for 5 min before 
adding 400 units of T4 ligase, ligation buffer and ddH2O to 20 µL total volume. 
Ligation reactions were incubated at room temperature for 1 h then transformed 





2.1.11 Verification and sequencing of DNA constructs 
Generated DNA constructs were assessed for size and quality by an appropriate 
restriction digest and gel electrophoresis prior to DNA sequencing. All DNA 
sequencing was performed by Genewiz (formally Beckman Coulter Genomics) 
using primers shown in Table 7.5.  
2.1.12 In vitro transcription of capped RNA 
The mMessage mMachine kit (Ambion) was used to synthesise capped RNA 
transcripts using 1 µg of linearised template DNA, using the manufacturer’s 
recommended protocol. Resulting RNA was assessed for size and quality by 
MOPS gel electrophoresis. For long term storage, RNA was aliquoted and stored 
at -80 °C.  
2.1.13 RNA gel electrophoresis  
RNA size and quality was determined by MOPS (3-(N-
morpholino)propanesulfonic acid) gel electrophoresis. Samples were prepared 
using RNA loading dye (2x, NEB) and loaded on a 1% MOPS gel (1% agarose, 
1X MOPS (40 mM 3-(N-morpholino)-propanesulfonic acid pH 7.0, 10 mM sodium 
acetate, 1 mM EDTA, 4.7% formaldehyde and 1:10,000 SYBR safe dye) at 80 V 






2.2 Cell Culture 
2.2.1 Mammalian cell lines and maintenance 
Mammalian cell lines were maintained in media shown in Table 2.5 
Cell line Origin Media 
Huh7 Human, hepatocellular carcinoma (HCC) 
Dulbecco’s modified eagle 
medium (DMEM) + 10% foetal 
calf serum (FCS) + non-
essential amino acids (NEAA) 
HepG2 Human, HCC DMEM + 10% FCS + NEAA 
C2C12 Mouse, myoblast DMEM + 20% FCS 
RD Human, rhabdomyosarcoma DMEM + 10% FCS 
SVG-A Human, astroglia DMEM + 10% FCS + NEAA 
Dermal fibroblasts Human, dermal fibroblasts DMEM + 10% FCS + NEAA 
BHK-21  Hamster, kidney fibroblast DMEM + 10% FCS 
HeLa Human, cervical adenocarcinoma DMEM + 10% FCS 
Vero African green monkey, kidney epithelia DMEM + 10% FCS 
A549 Human, lung carcinoma  DMEM + 10% FCS 
Table 2.5 Mammalian cell lines used, their origin and culture media 
All mammalian cell lines were maintained in their full media in T175 flasks at 
37 °C with 5% CO2. Cells were passaged by washing in PBS, 2 mL trypsin added 
and incubated at 37 °C until cells detached from the flask, resuspended in 
complete media and the required amount transferred to a new T175 flask and 
the total volume made up to 20 mL with media.  
2.2.2 Mosquito cell lines and maintenance 






Cell line Origin Media 
Aag2 Aedes aegypti  Leibovitz's L-15 media,  10% FCS and 10% Tryptose 
phosphate broth 








Leibovitz's L-15 media,  10% FCS and 10% Tryptose 
phosphate broth 
Table 2.6 Mosquito cell lines used, their origin and culture media 
All mosquito cell lines were maintained in full media in T175 flasks at 28 °C (no 
additional CO2). Cells were passaged by washing in PBS, scraping the cells into 
10 mL media, the required amount was then transferred to a new T175 flask and 
the total volume made up to 20 mL with media. 
2.2.3 Transfection of cells 
Transfection mixes were generated by mixing the desired amount of 
lipofectamine (Invitrogen) in Optimem (50 µL/well, Gibco) and, separately, the 
required amount of RNA/DNA in Optimem (50 µL/well), incubating each for 5 min 
at rt then mixing together and incubating for a further 20 min. Cells were washed 
and media changed to Optimem prior to adding 100 µL of the transfection mix to 
each well and mixed by gentle swirling. Cells were incubated for 4 h in the 
transfection mixture prior to washing with PBS and media replaced with complete 
media.  
For RNA transfection, number of cells, amount of lipofectamine and RNA was 
dictated by plate size (see table 2.2.3). 
For DNA transfections, cell number and amount of lipofectamine used was the 
same as RNA shown in Table 2.7, though the amount of DNA used varied by 





DNA constructs transfected into cells were pcDNA3.1+ expression constructs 
(see appendix figure 7.1), expressing various tagged forms of nsP3. For 
assessing activation of the NFkB pathway, two plasmids were used in 
combination; the NFkB-Fluc plamsid, that encodes a firefly luciferase under the 
control of a NFKB-sensitive promotor, and the pRL-TK plasmid, which encodes 
a Renilla luciferase under the control of a thymidine kinase promoter, therefore 
acting as a transfection control.  
Plate size Number of cells plated Lipofectamine (per well) RNA (per well) 
24-well 1x105 1 µL 250 ng 
12-well 2x105 2 µL 500 ng 
6-well 4x105 3 µL 1 µg 
Table 2.7 Numbers for lipofectamine transfection of cells 
2.2.4 Luciferase assay 
Transfected cells were lysed in 1x passive lysis buffer (PLB, Promega, 100 
µL/well in 24 well plates) and frozen at -20 °C until dual luciferase assays were 
performed using the Promega dual luciferase reporter assay system. Cell lysates 
were defrosted and aliquoted at 30 µL per well in a white, flat-bottomed 96 well 
plate. Manually, 40 µL of LarII (FLuc detection reagent) was pipetted per well 
then luciferase signal read. Then, 40 µL of Stop and Glo (RLuc detection reagent, 
which also quenches the firefly reaction) was added to the wells and luciferase 
signal read again for Renilla. Luciferase activity was detected using the 
FLUOStar optima microplate reader (BMG Labtech). 
2.2.5 Electroporation for virus propagation 
Electroporations for virus propagation were performed in BHK cells. Cells were 
trypsinised, resuspended in complete media, centrifuged at 1000 xg for 3 min, 
resuspended in pre-cooled DePC (Diethyl pyrocarbonate) PBS, centrifuged 
again and resuspended in 5 mL DePC PBS. Cells were counted and 
resuspended to achieve a concentration of 3x106 cells/mL. In a pre-cooled 
electroporation cuvette, 1 µg of virus RNA was added to the bottom, 400 µL 





single pulse at 250 volts for 25 ms. Two electroporations were pooled in 10 mL 
of complete media in a T75 flask and transferred to the BSL3 facility. Media was 
removed at 24 h post electroporation, aliquoted and frozen at -80 °C and titred 
by plaque assay.  
2.2.6 Plaque assay 
Plaque assays were performed on BHK cells. Number of cells/media used was 
dependent on plate size as shown by Table 2.8. 
Plate size Number of cells Volume of virus Volume of MC 
6-well 4x105 200 µL 2 mL 
12-well 1.5x105 150 µL 1 mL 
Table 2.8 Numbers for plaque assays 
Cells were plated 16 h prior to plaque assay. Virus to be titred was serially diluted 
in serum-free media (number of dilutions was dependent on expected titres). 
Dilutions of virus was then placed on pre-plated cells (150 µL for 12 well plates 
and 180 µL for 6 well plates), rocked for 5 min at rt then incubated at 37 °C for 
1 h. Virus was then removed and cells overlaid with 1.6 % methyl cellulose (MC) 
mixed 1:1 with complete media. Cells were incubated at 37 °C for 48-72 h, then 
fixed in 10 % formaldehyde for 30 min and stained using 0.5% crystal violet for 
1 h. Stain was then removed and plates washed in water until plaques become 
visible. Virus titres were calculated using the equation shown in equation 2.1. 
 
𝑃𝐹𝑈𝑚𝐿 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (10−𝑥)× 𝑣𝑜𝑙𝑢𝑚𝑒𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑎𝑑𝑑𝑒𝑑 (𝑚𝐿)
 
Equation 2.1 Calculation of virus titres (plaque forming units/mL) from 
plaque assay 
 
2.2.7 Infection of cells with CHIKV 
Virus stocks were diluted in serum-free media to the desired MOI. Cells were 
washed in PBS, virus added, plates were rocked for 5 min then incubated at 





and cells were washed thoroughly in PBS twice before replacing complete 
media. Cells were then incubated at 28/37 °C for the required amount of time.  
2.2.8 Infectious centre assay (ICA)  
BHK cells were plated in 6 well plates, 4x105 cells/well, 16 h prior to the assay, 
and a minimum of two T175 flasks prepared to achieve confluency overnight. 
Confluent BHK cells were then electroporated with virus RNA (see section 2.2.5), 
two separate electroporations per RNA were pooled and total volume made to 
1.2 mL with serum-free media. Suspensions of electroporated cells were serially 
diluted from 10-1 to 10-6 in complete media. Pre-plated BHK cells were washed 
in PBS and 1 mL of cell dilution added to each well. Plates were gently rocked 
by hand briefly, transferred to BSL3 and  incubated at 37 °C for 1 h, cell 
suspension removed from wells and replaced with 2 mL of 1.6% MC mixed in 
complete media (1:1). Plates were incubated for 72 h prior to fixation and stain 
as described in 2.2.6. Resulting plaques were used to calculate PFU/µg of input 
RNA via the equation shown in Equation 2.2. 
𝑃𝐹𝑈





Equation 2.2 Calculation of virus production per µg of input RNA (PFU/µg 
RNA) from an infectious centre assay 
 
2.2.9 Trizol Extractions  
RNA was extracted from infected cells using TRIzol (Life Technologies). Media 
was removed, cells were washed in PBS then 500 µL/well of TRIzol added (for 
12 well plates, or used at 1 mL/10 cm2 for other dishes), plates were rocked to 
ensure coverage and mixed by pipetting in the well before transferring to 
microcentrifuge tubes. The TRIzol samples were incubated for 5 min at rt and 
then stored at -80  C before continuing. Once thawed, 100 µL chloroform was 
added, samples were vortexed briefly and incubated at rt for 3 min. Tubes were 
then centrifuged at 12,000 xg for 15 min at 4 °C. The resulting upper layer was 
transferred to a new tube, 250 µL isopropanol added, mixed by inversion and 





resulting in a visible RNA pellet. Supernatant was removed (without disturbing 
the pellet) and 500 µL of ice cold 75% ethanol added. Samples were centrifuged 
at 7500 xg for 5 min at 4 °C, ethanol removed and sample briefly air dried at rt 
before resuspending in 20-50 µL nuclease-free water. Resulting RNA was 
electrophoresed on a MOPs gel to ensure successful extraction where ribosomal 






All qRT-PCR was performed using the ‘one step MESA GREEN qRT-PCR 
MasterMix for SYBR assay’ (EuroGenTec). Following manufacturer’s protocol 
with reaction mix being assembled as described in Table 2.9, with primers used 
described in Table 7.3. 
Component  Per Tube (µL) 
2x buffer 12.5 
Foward Primer (10 µm) 2.0 
Reverse primer (10 µm) 2.0 
Enzyme mix and RNase inhibitor 0.125 
RNA (50 ng/µL) or standards 2.0 
RNase-free ddH2O 6.375 
Table 2.9 Reaction assembly for qRT-PCR using MESA green qRT-PCR 
mastermix kit 
For each qRT-PCR, a set of DNA standards of known concentrations as well as 
a no template control were assembled alongside extracted RNA samples. 
Reactions were cycled using the Stratagene Mx3005P (Agilent technologies) as 
shown in Table 2.10. 
Temperature  
 
Time (min) Cycles  
48 °C 30:00 X1 
95 °C 5:00 X1 
95 °C 0:15 X40 
56 °C 1:00 
95 °C 1:00 X1 
55 °C 0:30 
95 °C 0:30 





2.2.11 Reverse transcription and sequencing of extracted virus RNA 
In order to sequence TRIzol extracted RNA, reverse transcription was performed 
using the SuperScript II Reverse Transcriptase kit (Life technologies) using 
manufacturer’s recommended protocol and random hexamer primers (Themo 
Scientific). Resulting cDNA was then used as input for PCR to amplify the nsP3 
region (see section 2.1.1) using primers described in Table 7.4, and the resulting 





2.3 SDS-PAGE and Western blotting 
2.3.1 Bradford assay 
Protein samples were quantified by Bradford assay. Protein samples and bovine 
serum albumin (BSA) standards were plated on flat bottom, clear 96 well plate 
(5 µL/well), 250 µL of Bradford reagent (8.5% H3PO4, 5% methanol, 0.005% 
Coomassie Brilliant Blue G-250) added, incubated at rt in the dark for 10 min, 
absorbance read on a plate reader at 570 nm and protein concentrations 
calculated from the standard curve formed by the BSA protein standards.  
2.3.2 SDS-PAGE 
Protein samples were quantified by Bradford assay and prepared with Laemmli 
loading dye (250 mM Tris-HCl, 40% (v/v) glycerol, 8% SDS, 0.2% bromophenol 
blue, 20% ? β-mercaptoethanol). SDS-polyacrylamide gels were prepared with 
either 7.5%, 10% or 15% acrylamide with 375 mM Tris-HCl/Cl, pH 8.8; 0.1% 
SDS, 0.1% APS, 0.01% TEMED; with stacking gel: 5% Acrylamide, 125 mM Tris-
HCl, pH 6.8; 0.1% SDS, 0.1% APS, 0.01% TEMED. Gels were assembled in a 
gel tank, filled with Tris-glycine buffer (0.25 M glycine, 25 mM Tris-HCl and 0.1% 
SDS), and electrophoresed at 180 v until required protein resolution was 
achieved. 
2.3.3 Western blot 
SDS-PAGE gels were transferred onto Immobilon PVDF membranes (Sigma) 
using a semi dry trans-blotter at 15 A for 1 h in transfer buffer (25 nM Tris base, 
192 mM glycine, 20% methanol, 0.1% SDS). Membranes were blocked in 
LICOR-TBS blocking buffer for a minimum of 20 min, rocking at rt. Primary 
antibodies (see Table 2.11) were diluted in TBS and added to membranes 
overnight, rocking at 4 °C. Membranes were washed in TBS 5 times, then 
appropriate LICOR secondary antibody was applied (diluted 1:10,000 in TBS) for 
1 h rocking at rt in the dark. Blots were washed a further 5 times in TBS, then 
rinsed in water and left to dry in the dark. Membranes were imaged using the 






Antibody Species Origin Working dilution 
Anti-nsP3 (full) Rabbit Andres Merits 1:1000 
Anti-β actin Mouse Sigma A1978 1:10,000 
Anti-p65 Mouse Santa Cruz SC-8008 1:200 
Anti-phospho-p105 Rabbit  NEB 4806 1:1000 
Anti-flag Mouse Sigma F3165 1:500 






Cells for immunofluorescence (IF) were plated out into 12-well plates onto glass 
coverslips. Cells were fixed using 4% para-formaldehyde (PFA) for 10 min and 
washed with PBS three times. Cells expressing fluorescent proteins that did not 
require antibody staining were washed and mounted in Prolong Diamond with 
DAPI (Life Technologies). For cells requiring antibody staining, after fixation, 
cells were permeabilised with 0.5% Triton-x for 10 min, washed with PBS and 
blocked in 2% BSA for 1 h. Three more PBS washes were performed and cells 
were subjected to primary antibody (see Table 2.12) , diluted in PBS, for 1 h at 
rt. Coverslips were again washed and then incubated with appropriate secondary 
antibody, (diluted 1:1000) in PBS for another h. Coverslips were washed in PBS 
three times, dipped in ddH2O then mounted onto slides using Prolong Gold with 
DAPI (Life Technologies) and left to dry overnight.  
 
Antibody Species Origin Working dilution 
Anti-nsP3 (full) Rabbit Andres Merits 1:1000 
ARTD10/PARP10 Rat Santa Cruz 5H11 1:50 
p65 Mouse Santa Cruz SC-8008 1:50 







Chapter 3 Establishing a panel of suitable and relevant cell 




















CHIKV was discovered in 1952, but little research has been conducted on the 
virus until recently, within the last 10 years. In publications on the molecular 
biology of CHIKV, the cell lines most commonly used are BHK (baby hamster 
kidney cells), Vero (African green monkey cells), HeLa (human cervical 
carcinoma) and HEK293T (human embryonic kidney, expressing SV40 T 
antigen) cells. These cells are often used in virological research and are 
regarded as the ‘workhorse’ cell lines for the production of many viruses, 
however, none of these are particularly physiologically relevant to CHIKV 
infection in vivo.  
CHIKV is introduced to the human host via mosquito bite. From the bite site, 
CHIKV infects and replicates in the dermal fibroblasts. The virus then spreads 
throughout the lymphatic and circulatory systems throughout the body to the 
‘target organs;’ the liver, muscles, joints and the brain (Thérèse Couderc et al., 
2008).  
There have been multiple studies on CHIKV infection of the myeloid and 
lymphoid cells as little is known on how CHIKV disseminates through the 
lymphatic and cardiovascular systems (Sourisseau et al., 2007). There have also 
been some studies on cell tropism, particularly in neuronal cell types due to the 
severe symptoms CHIKV can induce if the brain becomes infected (Dhanwani et 
al., 2012). However, there is currently no consensus on ‘model’ cell lines for 
molecular CHIKV research. 
Choice of cell line can be critical for experiments. Many cell lines, because of  
transformation or their origins, may have different expression profiles than their 
tissue of origin which may have a profound effect on experiments. Many 
malignant cell lines have mutations typical of cancers. For instance, cells from 
the malignant mammary cell line, MCF-7 do not express caspase-3 (Kagawa et 
al., 2001) and A549 cells have a mutated Ras gene that affects cell motility 
(Okudela et al., 2004). HeLa cells are the most widely used cell line in many 
areas of research but are severely mutated, contain various numbers of 
chromosomes per cell (aneuploidy) and possess a range of chromosome 





many as 2000 proteins are over-expressed in HeLa cells when compared to 
human tissue (Landry et al., 2013). HeLa cells also contain integrated human 
papilloma virus DNA and express the viral oncogenic proteins E6 and E7 
(DeFilippis et al., 2003) which make them a poor model for most areas of cellular 
and molecular study. Despite this, HeLa cells have proved useful for many 
purposes including the production of the first polio vaccine (Turner, 2012) and 
for early-stage drug testing for cancer (Shi et al., 2015; Y. Zhang et al., 2018).  
Some cell lines, despite not being malignant, can possess expression profiles 
which can make them irrelevant for certain areas of study. For instance Vero 
cells, a non-malignant cell line commonly used for virus studies, cannot produce 
endogenous IFN in response to infection (Desmyter et al., 1968). These cell lines 
are therefore not suitable for the study of pathways that involve these proteins 
that are absent or mutated. However, defective cell lines such as these can also 
prove useful in experiments looking at these particular pathways.  
Primary cell lines are often regarded as more representative of cellular 
processes in vivo, however, the use of primary cells has many issues. Firstly, 
they are slow growing with a limited life-span, meaning that it may take weeks to 
months to grow sufficient cells for a single experiment that then must be done in 
a timely manner. This often makes experimental replicates difficult as the cells 
may not survive long enough for all required repeats and different primary cells 
must be used. Secondly, most individual primary cells come directly from the 
donor and are therefore not well characterised in terms of their expression profile, 
and cells from different donors introduce the issue of heterogeneity. Thirdly, 
many cell types quickly de-differentiate in cell culture so become less 
representative of their progenitor cell type after a few days in culture, this is a 
particular issue with primary hepatocytes (Hengstler et al., 2005). However, it is 
possible to immortalise primary cells in vitro in order to produce physiologically 
relevant cells that are easier to work with, as shown here with the dermal 
fibroblast cells.  
Established cell lines are more commonly used in laboratory work as they are 
immortal, quick-growing and many are well characterised from previous studies. 





successfully replicate data produced by others. This makes them relatively 






The aim of this part of the project was to screen a wide range of cells and cell 
lines. With particular attention to those that are physiologically relevant to CHIKV 
infection in vivo, but also cells commonly used in the literature as a comparison, 
in order to determine a set of appropriate cell lines that are useful for CHIKV 
research.  Mosquito cell lines were also evaluated as CHIKV is an arbovirus and 
it is important to study the virus lifecycle in the mosquito vector as well as the 
human host.  
An ideal cell line for CHIKV research would be one that is physiologically relevant 
(i.e. derived from a tissue that CHIKV would infect in an in vivo infection) and can 
be easily propagated in culture (exhibit a reasonable growth rate, no requirement 
for complex or unusual growth media, maintain viability during passage and 
trypsinisation). In practical terms, in order to study CHIKV, cells would also need 
to be capable of being transfected with replicon RNA, support replication of the 
replicon, be able to be successfully infected with CHIKV and support viral 
replication. Since this project is focussed on nsP3, cells were also evaluated for 






3.2 Results  
3.2.1 Mammalian cell lines 
Humans are the main host for CHIKV. The virus is introduced to the body via a 
mosquito bite, where the virus replicates in the dermal fibroblast cells before 
spreading through the lymphatic and cardiovascular systems to the “target” 
organs; the liver, muscles, joints/connective tissues and the brain.  
There is some evidence that CHIKV is able to infect and replicate in non-human 
primates but this is not essential for the infectious cycle between mosquitos and 
humans (Haese et al., 2016).  
In contrast to its cell tropism in vivo, in cell culture, CHIKV has been shown to be 
capable of replication in a vast range of cell types with a few exceptions. For 
example, A549 cells, a lung epithelial cell line have been shown not to support 
virus replication despite CHIKV being able to bind to the cell surface (Sourisseau 
et al., 2007). 
As of yet, there is little consensus in the literature as to which cell lines are 
appropriate for their use in CHIKV research. Here, multiple cell lines were 
evaluated for their use in CHIKV research, from this four ‘model’ mammalian cell 
lines were selected for their use with CHIKV, particularly for investigating nsP3.  
3.2.1.1 Replicon 
Initially, ten cell lines were selected for transfection with CHIKV replicon RNA to 
determine whether each cell line could support CHIKV RNA replication. The ten 
cell lines (shown in Table 2.5) represent lines that are representative of that 
‘target organs’ that  CHIKV favourably replicates in vivo (e.g. Huh7, dermal 
fibroblasts) but also cell lines commonly used in virus work including CHIKV (e.g. 
BHK, Vero). For initial experiments, the dual luciferase (dLuc) CHIKV replicon 
was used, a schematic of which is shown in Figure 3.1 A. This replicon expresses 
all four non-structural proteins, with nsP3 containing a Renilla luciferase in the 
variable region as an indirect indicator of translation of the non-structural ORF. 
In the subgenomic region, a firefly luciferase (Fluc) gene replaces the structural 
ORF previously described by McFarlane et al., 2014. When Fluc signal is 





sub-genomic RNA (26S RNA) from this region in order for the structural proteins 
to be expressed. All ten cell lines were transfected with the dLuc replicon, using 
lipofectamine2000, cell lysates taken over a 48 h time period and luciferase 







Figure 3.1 Transfection of mammalian cell lines with the dual luciferase 
CHIKV replicon.   (A) Schematic of the dual luciferase CHIKV replicon. 
Mammalian cell lines transfected with the CHIKV replicon. Liver 
(Huh7, HepG2), muscle (C2C12, RD), brain (SVG-A), fibroblasts 
(Dermal fibs, BHKs), as well as Vero, HeLa and A549 cells were 
transfected with dLuc CHIKV replicon RNA. Cell lysates were taken at 
indicated time points over a 48 h period and luciferase assayed (n=3). 
The Renilla luciferase is present in the VR of nsP3, indicating levels of 
nsP3 present in the cell (B). The Firefly luciferase is in the sub-
genomic region of the replicon, indicating that RNA replication has 





The increase in Renilla luciferase values between 0 and 6 hpt indicates that the 
replicon RNA was translationally-competent in all 10 cell lines. The replication of 
the replicon RNA, however, was quite diverse between the cell lines in both 
signal levels and pattern of RNA replication. Half of the lines exhibited peak 
replication at 24 hpt. The exceptions to this were RD, Vero, Huh7, A549 and 
HepG2 cells. Both A549 and HepG2 cells produced quite low signal throughout 
the time course with the highest at 6 hpt. RD cells produced higher levels of 
replication at 48 hpt. Vero cells were the only line to produce the highest Fluc 
signal at 12 hpt. Of the physiologically relevant cell lines, C2C12, RD, dermal 
fibroblasts and SVG-A cells performed well. Both liver-derived cell lines 
supported low levels of CHIKV RNA replication with HepG2 cells performing far 
worse than the Huh7 cells.  
To ensure these results were due to the ability of the cells to replicate the 
replicon, rather than their transfection efficiency, all 10 cell lines were transfected 
with pRL-TK plasmid DNA, which constitutively expresses Renilla luciferase 
under control of a thymidine kinase promoter, with lipofectamine2000 for 24 h 






Figure 3.2 Transfection efficiencies of screened cell lines.   Cells were 
transfected with 100 ng pRL-TK using lipofectamine2000, harvested 
at 24 hpt and luciferase signal assayed.  
 
Although there were some marked differences in transfection efficiencies, this 
did not directly relate to replicon translation/replication. For instance, the dermal 
fibroblasts had the lowest transfection efficiency, which was expected due to 
their primary-like origins, but with the dLuc replicon, exhibited high replication 
levels. RD and BHK cells had some of the highest transfection efficiencies as 
well as very high replication levels, this may suggest that the luciferase produced 
in the dLuc CHIKV replicon experiment (Figure 3.1) may be partly due to high 
transfection efficiency.  
As this project is based around understanding the role of nsP3, the ten cell lines 
were assessed for their use in western blotting for the detection of this particular 






Figure 3.3 Western blot for nsP3 in mammalian cell lines transfected with 
CHIKV replicon.   Cells were transfected with wt (untagged) nsP3/SG-
Fluc replicon, lysed at 24 hpt and blotted for nsP3. 
 
On the western blot, nsP3 was clearly detectable in lysates from Huh7, C2C12, 
SVG-A, RD and BHK cells. Faint bands were observed in the lysates of HepG2, 
A549, HeLa and Vero cells. In contrast to the luciferase data, nsP3 was 
practically undetectable in dermal fibroblasts.  
Next, all cell lines were transfected with a CHIKV replicon that contained a 
mCherry-tagged nsP3 in order to visualise the intracellular distribution of nsP3 
via confocal microscopy (Figure 3.4 A and B). Three different organisations of 
nsP3 were observed: puncta, rings and rods. Although not all cells contained all 
these organisations. All lines contained puncta of nsP3. Only C2C12 and Huh7 
cells produced ring organisations – though these were a small sub set of the 
nsP3-expressing cell populations. All cell lines contained rods except RD and 
HeLa cells. There was no apparent link between replication levels and type of 
nsP3 organisation in cells. At present, it is unclear what determines these 
different structures of nsP3 and what significance they represent in terms of 
CHIKV replication.  
From the collective data, four physiologically relevant cell lines were selected as 
‘model’ cell lines for their use in CHIKV research. C2C12 (myoblast) cells were 
overall, the physiologically relevant cell line that produced the highest levels of 
RNA replication, and high levels of nsP3, both on a western blot and via IF. 
Dermal fibroblasts also performed well, producing high levels of RNA replication 
and good expression of nsP3-mCherry but unfortunately, produced very low 
nsP3 signal on western blot, this could potentially be due to their significantly 





produced moderate levels of replication, and detectable nsP3 via western blot 
and IF. The liver cell lines Huh7 and HepG2 cells both were among the worst 
replicators of CHIKV RNA but overall, Huh7 cells had higher replication levels, 
higher nsP3 expression as shown by western blot and IF. Huh7 cells are also 
more practical to culture than HepG2 cells, which grow in large aggregates 
instead of monolayers. Huh7 cells were therefore chosen as the liver model cell 






Figure 3.4 IF of nsP3-mCherry in mammalian cell lines. (A) All 10 
mammalian cell lines were transfected with CHIKV replicon RNA 
containing an mCherry tagged-nsP3. Cells were fixed, DAPI stained 
and imaged using the LSM700 confocal microscope. Three 
cytoplasmic organisations of nsP3 were observed; puncta, rods and 
rings. An “X” indicates that the type of organisation was not observed 
for that particular cell line. (B) Large representative examples of the 





3.2.1.2 Infectious virus 
Before work could be initiated using infectious virus with the selected cell lines, 
optimisation of the production and titration of infectious CHIKV was required.  
3.2.1.2.1 Production of virus stocks and titration by plaque assay 
CHIKV has been routinely propagated and titrated using BHK cells (Gardner et 
al., 2012; Lani et al., 2015).  It was therefore decided to use these cells for 
production of virus stocks. Using these cells, high titres of virus could be 
produced allowing for a wide range of MOIs to be utilised in experiments. Using 
this method, virus could be detected as early as 6 hpe, though at very low titres 
(data not shown). It was established through observations in the laboratory and 
personal communications from others (Prof Andres Merits) that, for production 
of virus stocks, virus should be collected at 24 hpe rather than 48 h. By 48 h, 
high levels of cell death has occurred due to CHIKV replication so for an 
additional day of incubation, there is little gain in virus titres but more cell debris 
is produced. Therefore all virus stocks were produced by electroporation of 
CHIKV RNA into BHK cells, and supernatant collected and titred at 24 hpe. 
Supernatant was briefly centrifuged to pellet cell debris, resulting virus-
containing supernatant was removed, mixed, aliquoted and stored at -80 °C.  
Throughout this project, virus titration was performed using plaque assay with 
BHK cells. Other have shown that CHIKV can be titred on Vero cells (Her et al., 
2015), however, since no issues were experienced using BHK cells for plaque 
assays in this project, there was no need for further optimisation using Vero cells. 
Initially, titration of CHIKV was performed in 6 well plates as shown in the 







Figure 3.5 Example plaque assay of wt CHIKV. Plaque assay was performed 
by standard protocol, using dilutions of 10-3 to 10-8 to calculate wt 
CHIKV titres.  
In an effort to increase productivity and reduce waste and reagents, plaque 
assays using 12 well plates were optimised (as described in methods section –
2.2.6). To ensure that results obtained using 12-well plaque assays did not differ 
from those using 6-well, a direct comparison of the two methods was performed 
using wt CHIKV. As shown by Figure 3.6, there was no significant difference 






Figure 3.6 Direct comparison of CHIKV titres obtained using either 12 well 
or 6 well plate plaque assays. CHIKV was serially diluted in serum free 
media, of which 200 µL (for 6-well) or 150 µL (12 well) from the same 
dilution series were placed onto pre-plated, sub-confluent BHK cells. 
Normal plaque assay protocol was adhered to as described previously 
(n=2 for each condition, data analysed by paired T test). 
 
As there were no significant differences between the results obtained using 
either 12 well or 6 well plaque assays, hereafter all plaque assays were 
performed in 12 well plates. 
3.2.1.2.2 Mammalian cell lines for use with infectious CHIKV  
To confirm the findings of the replicon-based assays using the selected cell lines, 
similar experiments were conducted using infectious virus. The virus construct 
used was derived from the East Central and South African (ECSA) strain that all 
the replicons used in this project were derived from (all kindly provided by Andres 
Merits). A virus stock was produced by electroporation of BHK cells with CHIKV 
genomic RNA and subsequently titrated on BHK-21 cells by plaque assay.  
The four selected mammalian cell lines were infected at an MOI of 1 and 5 for 
24 h. Virus production was quantified by plaque assay of the cell supernatant, 
and intracellular genomic RNA was quantified by qRT-PCR (Figure 3.7 A and B). 
Western blots for nsP3 was performed on these samples to confirm expression 






Figure 3.7 CHIKV infection of mammalian model cell lines.  (A) Huh7, 
C2C12, SVG-A, and dermal fibroblasts (D Fibs) cells were infected, in 
triplicate, at MOIs of both 1 and 5. Cell supernatant was collected at 
24 hpi and virus titred by plaque assay (n=3). (B) Corresponding qRT-
PCR quantification of genomic CHIKV RNA in infected cells. 
Intracellular RNA was extracted using TRIzol reagent and RNA 
quantified using CHIKV nsP3-specific primers (n=3). (C) Western blots 






Resulting virus titres of infected mammalian cells broadly reflect the replicon 
replication levels, with C2C12 producing the highest titres and Huh7 cells the 
lowest. However, all cell lines produced workable levels of virus over a 24 h 
period, with little difference between the different two MOIs. The RNA 
quantification broadly reflects the virus titres for each cell line.  SVG-A cells 
appear to contain more intracellular genomic RNA copies relative to the virus 
titre, and C2C12 cells appear to have slightly less genomic copies compared to 
their high virus production. With virus infection, the nsP3 expression levels in 
C2C12, and for dermal fibroblasts in particular, were much higher than with the 
replicon (Figure 3.3), indicating the suitability of these cells for virus replication. 
This also highlighting the difference between using replicon and infectious virus, 
and indicates that caution is needed when interpreting data from replicon 
experiments when using them as a model for infection virus.  
Similarly to the replicon experiments, cells were infected with CHIKV for 24 h 
then fixed, stained for nsP3 and DAPI and imaged by confocal microscopy 
(Figure 3.8). Unlike in the replicon cells, only two cytoplasmic forms of nsP3 were 
observed; puncta and rods. No ring like structures were found. Similarly to 
replicon, the vast majority of cells contained exclusively either rods or puncta, 
very few cells contained both forms of nsP3. The two cell lines that produced the 
highest titres; C2C12 and dermal fibroblasts, appeared to contain more rods per 







Figure 3.8 Confocal images of nsP3 in wt CHIKV infected mammalian cells.  
Mammalian cell lines (Huh7, C2C12, SVG-A and Dermal fibroblasts) 
were infected with an CHIKV , fixed at 24 hpi, stained for nsP3 and 
DAPI, then imaged using the LSM700 confocal microscope. Two 
different cytoplasmic structures of nsP3 were observed; puncta and 
rods.  
 
3.2.1.3 Differentiated cells 
Both Huh7 (liver) and C2C12 (myoblast) cells can be differentiated to cells that 
more resemble in vivo liver and muscle tissue respectively. To assess whether 
these differentiated states would support higher levels of replication, both cell 





3.2.1.3.1 Differentiation of Huh7 Cells  
Adding 2% DMSO to the culture medium of Huh7 cells arrests their growth, 
keeping cells in G0 phase of the cell cycle. It also upregulates liver-specific genes 
such as albumin and cytochrome p450 (Choi et al. 2009). This model is 
considered more representative of liver tissue in vivo and is often used in early 
stage pharmaceutical testing. Huh7 cells have also been demonstrated to 
differentiate using human serum, which led to increased titres of hepatitis C virus 
(Steenbergen et al., 2013). 
To assess whether the differentiation status of Huh7 cells affected CHIKV 
replication, cells were differentiated by the addition of 2% DMSO to complete 
media for 7 days (replacing the media when necessary), then transfecting the 
differentiated cells with the dLuc CHIKV replicon over a 48 h time period, 
alongside non-differentiated Huh7 cells. For the Huh7 cells, there is a clear 
morphological difference between undifferentiated and differentiated cells.  
Differentiated hepatocytes form large rafts of confluent epithelial-like cells that 
have higher levels of albumin and CYP3A4 (a cytochrome p450 enzyme), as 
shown by Figure 3.9 A and B respectively indicating that these differentiated cells 






Figure 3.9 Differentiation of Huh7 cells and transfection with the CHIKV 
replicon. Huh7 cells were differentiated via addition of DMSO to 
complete media. (A) Bright field image demonstrating the morphology 
of differentiated cells compared to Huh7 cells maintained in complete 
culture medium. (B) Western blot for albumin and Cytochrome P450 
3A4 (CYP3A4), is more highly expressed in differentiated cells 
compared to undifferentiated cells. (C) Both Huh7 cells and 
differentiated hepatocytes were transfected with CHIKV dLuc replicon 
RNA, cells were lysed at indicated time points and luciferase assayed. 
Data analysed by parametric T-test. (D) Western blot of nsP3 in 
transfected differentiated and undifferentiated cells, 24 hpt. (E) 
Confocal images of Huh7 and differentiated cells transfected with 





When transfected with the dLuc-CHIKV-SGR, the differentiated cells have 
greatly reduced translation and replication throughout the time course, when 
compared to undifferentiated Huh7 cells (Figure 3.9 C and D). The cytoplasmic 
distribution of nsP3 differs between the undifferentiated and differentiated cells 
(Figure 3.9 E). In the majority of undifferentiated Huh7 cells, nsP3 is arranged in 
small puncta found throughout the cytoplasm, whereas in the differentiated cells, 
nsP3 tends to form fewer, larger puncta that are mostly perinuclear. Though, 
again, it unclear what these differences in nsP3 distribution represent in terms of 
CHIKV replication.  
3.2.1.3.2 Differentiation of C2C12 Cells  
For C2C12 cells, reducing the serum in the media to 2% FBS (rather than 20%) 
induces the myoblasts to form myotubes, forming a similar organisation to 
muscle tissue in vivo (Lawson and Purslow, 2000; Burattini et al., 2004). This 
serum depletion has been shown to induce the expression of insulin-like growth 







Figure 3.10 Differentiation of C2C12 cells and transfection with the CHIKV 
replicon. C2C12 cells were differentiated via serum starvation. (A) 
Bright field image showing the different morphology of differentiated 
cells compared to C2C12 cells maintained in complete culture medium 
(undifferentiated cells). (B) Western blot for skeletal myosin, a marker 
of skeletal muscle tissue, is highly expressed in differentiated cells 
(D) compared to undifferentiated (U). (C) Both differentiated and 
undifferentiated C2C12 cells were transfected with dLuc replicon 
RNA. Cells were lysed at indicated time points and luciferase assayed. 
Data analysed by parametric T-test. (D) Western blot of nsP3 in 
undifferentiated (U) and differentiated (D) transfected cells at 24 hpt. 
(E) Confocal images of C2C12 and differentiated cells transfected with 





Differentiated C2C12 cells form very distinct, multinucleated myotubes, 
demonstrated in the bright field images in Figure 3.10 A, with upregulated 
skeletal myosin, a marker of muscle tissue (Figure 3.10 B) both indicate that 
these differentiated cells are more representative of muscle tissue in vivo 
compared to C2C12 cells. In the differentiated myotubes, the CHIKV replicon 
exhibits significantly higher levels of RNA replication (Fluc), approximately 7 fold 
higher than undifferentiated cells by the 48 h time point, despite little detectable 
difference in nsP3 by western blot (Figure 3.10 C and D respectively). The 
cellular localisation of nsP3 also varies between transfected differentiated and 
undifferentiated cells (Figure 3.10 E). In undifferentiated C2C12 cells, nsP3 
forms distinct puncta or rod-like organisations throughout the cytoplasm. In 
contrast, nsP3 in differentiated cells appears less organised with less distinction 
between the clusters of nsP3 which have no clear shape or organisation. 
However, the IF data is inherently unclear as differentiated C2C12 form large 
multi-nucleated cells which lack their own structure which can make it difficult to 
determine cellular components such as the nucleus or the cytoplasmic 
membrane. 
3.2.2 Mosquito cell lines  
As CHIKV is an arbovirus, it is important not only to study the virus in the human 
host but also in the mosquito vector. CHIKV is transmitted by the Aedes species 
of mosquito – primarily the Aedes aegypti but more recently, the Aedes 
albopictus. The virus is acquired by mosquitoes through a blood meal from a 
viremic host. CHIKV initially replicates in the cells of mid-gut before 
disseminating to all organs of the insect, including the salivary glands where it 
then goes on to infect upon future blood meals upon naïve human hosts (Vega-
Rua et al., 2014).  
A popular strategy of controlling the spread of arboviruses is to target the vectors 
(Alphey, 2014). If achieved, this would mitigate the need for vaccines or antivirals 
as, since CHIKV cannot be transmitted from human to human, successful control 
of the vector would prevent human disease. Therefore it is crucial to understand 





Here we were able to evaluate four mosquito cell lines for their use with CHIKV, 
and specifically nsP3. A20 and Aag2 cells are derived from Aedes aegypti and 
U4.4 and C6/36 cells are derived from Aedes albopictus. All four lines are derived 
from embryonic cells of the stated species. C6/36 cells have been commonly 
used in viral research for many years as they are permissible to a wide range of 
arboviruses. However, these cells have recently been shown to have an 
ineffective RNAi system, a key anti-viral pathway of insects, resulting from a 
single nucleotide deletion in the coding region of Dicer2 producing a frame shift 
and a premature stop codon, rendering the resulting protein non-functional 
(Brackney et al., 2010; Miller et al., 2018). Dicer2 is active in U4.4 cells however, 
and its activity has been shown to restrict viral replication of Bunyamwera virus 
(Szemiel et al., 2012). Aag2 cells been shown to be persistently infected with cell 
fusing agent virus (CFAV), an insect specific flavivirus (Zhang et al., 2017), this 
infection was detected in the original cell line and is known to be able to transmit 
vertically, so it is assumed that CFAV was present in the larval cells used to form 
the cell line and therefore is present in all resulting Aag2 lineages (Stollar and 
Thomas, 1975).  
3.2.2.1 Replicon 
Much like with the mammalian cell lines, initially the four mosquito cell lines were 
transfected with the dual luciferase CHIKV replicon to assess their ability to 








Figure 3.11 Transfection of mosquito cell lines with CHIKV dLuc replicon 
RNA.  Aag2, A20 (both Aedes aegypti), U4.4 and C6/36 (both Aedes 
albopictus) cells were transfected with CHIKV dLuc replicon RNA. 
Cells were lysed over a 48 h period and luciferase assayed. Rluc is 
present in the VR of nsP3 and indicates translation of the non-
structural proteins. Fluc is present in the subgenomic region of the 
replicon, indicating that RNA replication has occurred.  
 
Renilla luciferase was detected in three of the four cell lines, indicating that the 
replicon was translationally- competent in all cells except in Aag2 cells, which 
exhibited luciferase signal below the detectable level (<5x102 RLU) throughout 
the time course. Despite their different origins, A20 and U4.4 cells exhibited 
similar levels of translation and RNA replication of the replicon over the time 
course, though U4.4 cells had peak firefly luciferase signal at 24 h whereas A20 
cells peaked at 48 hpt. C6/36 cells had much higher translation and replication, 





Western blots for nsP3 with mosquito cell lysates proved to be problematic due 
to high levels of cross reactivity with the antibodies to many mosquito proteins 
(Figure 3.12). Initially, all four mosquito cell lines were transfected with an 
untagged-nsP3 replicon, but the nsP3 antibody was cross reactive with proteins 
of many sizes, but particularly with one ~58 kDa, the same size as nsP3, – which 
is present in roughly equal intensities in both the transfected and mock samples. 
Many alterations to the method were tried e.g. different blocking buffers, 
different/longer wash steps, but the contaminating 58 kDa band was always 
present. The blot shown in Figure 3.12 A is representative of the various attempts 
of blotting using nsP3 for mosquito cell lysates. The nsP3 antibody used here is 
a polyclonal antibody, produced in-house so it was not surprising that it was 
highly cross reactive. In order to rectify this, a flag-tagged nsP3 replicon was 
utilised so that a commercial, monoclonal flag-tag antibody could be used to 
detect nsP3. Though this did produce blots with far fewer non-specific bands, it 
still cross reacted with a protein around 58 kDa, so nsP3 was undetectable using 
this method.  
 
Figure 3.12 Western blots for various proteins in mosquito cells.  A. 
Mosquito cell lines were transfected using the CHIKV Fluc SGR (with 
untagged nsP3), cells were lysed at 24 hpt and western blot performed 
for nsP3 (58 kDa) and actin (42 kDa). B. U4.4 and C6/36 cells were 
transfected with nsP3-Flag replicon and cells were lysed at 24 hpt. 
Western blots were performed using both anti -nsP3 and -Flag 






The mosquito cell lines were then transfected with the nsP3-mCherry replicon 
for 24 h then fixed, DAPI stained and imaged by confocal microscopy (Figure 
3.13). 
 
Figure 3.13 Confocal images of mosquito cell lines transfected with nsP3-
mCherry replicon.  A20, Aag2, U4.4 and C6/36 cells were transfected 
with nsP3-mCherry/SG-Gluc-SGR RNA.  
 
In the transfected U4.4 and C6.36 cells, nsP3 formed distinct puncta in the 
cytoplasm. However, both A20 and Aag2 cells exhibited very different 
organisations of nsP3. In Aag2 cells, nsP3 was very diffuse in the cytoplasm with 





blebbing nuclei with diffuse nsP3, indicating that the replicon, or perhaps the 
transfection reagent, was toxic to the cells.  
From the collective replicon data, the use of A20 and Aag2 cells was abandoned 
due to the inability of the Aag2 cells to support replication of the replicon and the 
difficulty experienced imaging nsP3 in both Aag2 and A20 cells. 
3.2.2.2 Infectious Virus 
To confirm the results from the replicon work and assess the ability of the 
mosquito cells to produce virus, the U4.4 and C6/36 cells were infected with the 
ECSA virus at MOIs of both 1 and 5 for 24 h, the supernatant was collected and 
titred by plaque assay (performed on BHK cells, Figure 3.14).  
The titres produced by both cell lines was reflective of the replicon experiments 
with C6/36 cells producing more virus than U4.4 for both MOIs. However both 
cell lines exhibited similar levels of intracellular genomic CHIKV RNA as 







Figure 3.14 CHIKV infections of model mosquito cell lines.  U4.4 and C6/36 
cells were infected at an MOI of 1 or 5 for 24 h. (A) Supernatant was 
collected and titred by plaque assay (n=3). (B) Intracellular RNA was 
extracted from the infected cells using TRIzol and CHIKV genomic 
RNA was quantified by qRT-PCR using primers specific for nsP3 
(n=3). 
 
Since the nsP3 antibody proved to be unreliable on western blots with mosquito 
cells, to image nsP3 in infected cells we opted to use virus expressing ZsGreen 
tagged nsP3. Cells were infected for 24 h, fixed, DAPI stained and imaged via 






Figure 3.15 Confocal images of mosquito cell lines infected with nsP3-
ZsGreen virus.  Cells were infected for 24 h, fixed, DAPI stained and 
imaged using the LSM700 confocal microscope. 
 
Infected mosquito cells had similar nsP3 expression to the cells transfected with 
the replicon. Both mosquito cell lines exhibited cytoplasmic puncta of nsP3 with 
a slightly less distinct appearance than the puncta observed in mammalian cells. 
For both cell lines, nsP3 positive cells contained many puncta with a range of 






3.3.1 Mammalian cells  
At the start of this project, it was unclear which cell lines should be utilised in 
order to study the molecular virology of CHIKV. In the literature, a range of cells 
have been used,, such as Vero, BHK and HeLa cells, though none of these are 
physiologically relevant to CHIKV infection in vivo. Therefore, a range of cell 
lines, both physiologically relevant ones and ones previously used in the 
literature were evaluated for their ability to replicate the CHIKV replicon and 
assayed for their expression of nsP3 via IF and western blot.  
From the replicon data, multiple cell lines fulfilled the role of being physiologically 
relevant whilst also supporting replication of the CHIKV replicon. Both muscle 
cell lines (C2C12 and RD) exhibited high levels of replicon replication and nsP3 
expression. C2C12 cells were selected over RD as they exhibited higher replicon 
replication, can be differentiated to a state closely resembling muscle tissue and 
are widely used in the field of muscle biology as a model for muscle development 
and differentiation (Burattini et al., 2004). RD cells, derived from a 
rhabdomyosarcoma  are considered the model cell line for the study of the 
disease (Hinson et al., 2013) as well as for the study of enteroviruses (Perez-
Ruiz, 2003).  For the liver cell lines, Huh7 and HepG2 cells were assessed. 
Though neither of these cell lines produced particular high luciferase signal when 
compared to the full panel, Huh7 cells were selected as the model liver cell line 
as they had the higher replicon replication of the two liver cell lines and had 
detectable nsP3 via western blot and IF. Huh7 cells can also be differentiated to 
better mimic liver tissue in vivo. Both dermal fibroblasts and SVG-A (astroglia) 
cells were selected as model cell lines as they were the only cells of their 
respective tissue type tested. Both cell lines did support replicon replication and 
expressed nsP3 well. These four cell lines were then further assessed using 
infectious virus, and all four produced high titre virus with good expression of 
nsP3 as shown by western blot and IF. C2C12 and dermal fibroblasts both 
produced the highest titres and nsP3 expression levels. Huh7 and SVG-A cells 
performing similarly, both producing moderate virus titres. This reflects the 





The ability to differentiate both C2C12 and Huh7 cells may be useful in future 
CHIKV experiments. Differentiation of these cells are commonly used; 
differentiated hepatocytes are commonly used in early-stage pharmaceutical 
testing (Guo et al., 2011), and differentiated C2C12 cells are used to study 
muscle development (Erbay and Chen, 2001). Other studies have shown that 
differentiated Huh7 cells were more permissive to infection and produced higher 
titres of hepatitis C virus, which is thought to be due to the more cells mimicking 
liver tissue more closely than undifferentiated Huh7 cells (Sainz and Chisari, 
2006). To see whether this was the same of CHIKV, both cell lines were 
differentiated for seven days prior to transfection with the dual luciferase CHIKV 
replicon. Both cell lines demonstrated they were more representative of their 
corresponding in vivo tissue both by cell morphology and the upregulation of 
certain markers that are highly abundant in the in vivo tissue (albumin and 
CYP3A4 for liver, and skeletal myosin for muscle tissue). Differentiated C2C12 
cells supported higher levels of replicon replication than undifferentiated cells 
which was as expected. Surprisingly, however, differentiated Huh7 cells 
produced a lower luciferase signal than the undifferentiated cells. Though there 
was little detectable difference in nsP3 expression by western blot, the IF shows 
that there were far fewer puncta of nsP3 per cell though these tended to be 
larger. This was surprising as we hypothesised that a more physiological-like 
model of the liver, an organ that CHIKV preferentially replicates in, would support 
higher levels of CHIKV replication. However, it may be that since the cells are in 
growth arrest, this may slow down the replication cycle of CHIKV. Though there 
has been little research into CHIKV replication and the cell cycle, studies have 
shown that CHIKV is able to replicate in serum-starved non-dividing cells 
(Sourisseau et al., 2007) and, in early infection, CHIKV downregulates cell cycle 
proteins such as CDK1 (Thio et al., 2013). It may also be that despite 
differentiated cells being more representative of liver tissue, it may still be lacking 
certain factors that CHIKV requires to efficiently replicate. It is possible since 
differentiated Huh7 cells produce ‘rafts’ of cells with tight cell-cell junctions, it may 
be limiting the transfection process, reducing the amount of RNA that enters the 
cells. Alternatively, it may just be that the slower replication of the replicon in 





infectious virus could be used to infect the differentiated cells which would be 
more representative of in vivo infection and would remove the issue of 
transfection efficiency.  
Other cell lines that have been previously used for CHIKV research in the 
literature had surprising results. In the replicon luciferase assay, both Vero and 
HeLa cells supported replication to only moderate levels, with dramatically 
reduced signal at 48 hpt. The IF data for both these cell lines showed blebbing 
nuclei in nsP3-positive cells indicating that the replicon is very toxic to these cells, 
which would explain why both cell lines had low luciferase signal at later time 
points. There would appear to be no apparent advantage to using these cell lines 
in CHIKV research, particularly in comparison to the others tested here. In 
contrast, BHK cells, which have been used extensively in virological research, 
including for CHIKV, produced the highest luciferase signals throughout the 
luciferase assay and expressed nsP3 to high levels as shown by IF and western 
blot. It was therefore sensible to use these cells for virus production and plaque 
assay as others have previously (Gardner et al., 2012; Lani et al., 2015). Though 
many other groups have used Vero E6 cells for virus propagation and titre 
(Gokhale et al., 2015; Her et al., 2015), BHK cells were used initially in this 
project and had no issue with these cells for these purposes so felt no need to 
try alternative methods.  
The data obtained for A549 cells is in agreement with the literature where studies 
have shown that CHIKV is able to bind and enter A549 cells but is unable to 
effectively replicate in these cells (Solignat et al., 2009).  The mechanism of 
inhibition and the stage in the virus lifecycle at which inhibition occurs is currently 
unknown, but the replicon and IF data shows that the replicon can be 
successfully translated in A549 cells to produce non-structural proteins, and a 
limited amount of RNA replication can occur, as indicated by signal at the 6 and 
12 hpt time points, but this signal reduces at 24 and 48 h. The reduction in signal 
at later time points could suggest that the inhibition is due to an innate immune 
response, as A549 cells are known to elicit a comprehensive innate immune 
response upon viral infect (Hartman et al., 2007; Devhare et al., 2013), though 





It is worth noting that in this project although it would have been ideal to trial a 
much wider range of physiologically relevant cell lines, there were limitations to 
the cell lines that were available. The limitations of the cell lines used are also 
noteworthy. For instance, C2C12 cells are mouse derived and mice are not 
natural hosts of CHIKV. Though mice can be successfully infected in the lab 
environment and are frequently used as models for the disease (Teo et al., 
2013). SVG-A cells are astroglia-derived cells. Experimentally, infected mice 
have demonstrated glial infection which results in an illness similar to that shown 
in CHIKV infected humans with neurological-complications (Das et al., 2015). 
However, there is evidence that the neuronal cells are also infected and 
unfortunately we were unable to obtain a neurone-derived cell line for this project. 
Immortalised liver cell lines are widely known to be problematic as most do not 
express similar proteomic profiles when compared to hepatocytes in vivo. 
However, immortalised liver cell lines are much easier to culture and more widely 
available than primary liver cells (Choi et al., 2009). Primary liver cells are 
particularly problematic as they rapidly de-differentiate in culture, therefore Huh7 
cells are commonly used in hepatitis research despite their drawbacks. The 
dermal fibroblasts used here were a primary cell line from a healthy donor that 
were transformed in-house. They are physiologically ideal due to their origin 
however, since they are not a well-used established cell line, it is unclear what 
their expression profile is like and whether the process of transformation had any 
unintended consequences such as disrupting a gene or promotor region.  
3.3.2 Mosquito cells 
As CHIKV is an arbovirus, transmitted by the Aedes species of mosquito, it is 
important to study the virus in mosquito cells as well as mammalian cells. Four 
mosquito cell lines were available to us; A20, Aag2 (both are derived from the 
Aedes aegypti), and U4.4 and C6/36 cells (both Aedes albopictus). Again, all 
cells were transfected with the CHIKV replicon to assess their ability to replicate 
CHIKV RNA. All cell lines were able to translate and replicate the replicon except 
Aag2 cells where signal was below detectable levels throughout the time course. 
This may be due to their persistent infection with CFAV – potentially activating 





transfection (Zhang et al., 2017). From this data, Aag2 cells were dismissed as 
a usable cell line for CHIKV research.  
U4.4 and A20 cells exhibited very similar levels of replication from the luciferase 
assay but behaved very differently when looking at nsP3 via IF. U4.4 cells 
exhibited defined puncta of nsP3 whereas the only nsP3 positive A20 cells had 
very diffuse nsP3 with no intact nuclei. This implies that either the replicon or 
transfection process is toxic to these cells. Due to this, A20 cells were also 
discarded for the study of CHIKV.  
C6/36 cells have been extensively used in virological research, probably due to 
their inactive RNAi system allowing them to produce high titres of virus (Brackney 
et al., 2010; Miller et al., 2018). In the replicon experiment, the C6/36 cells 
produced the highest signal, which reflects the literature. These cells also 
produced defined puncta of nsP3, as shown by IF, making them a useful cell line 
for CHIKV research.  
U4.4 and C6/36 cells were further evaluated with infectious virus. Both produced 
high titres of virus, again with C6/36 cells producing approximately 2-log higher 
titres than U4.4 cells. However, both cell lines appear to have similar levels of 
genomic RNA as shown by the qRT-PCR. This implies that RNA replication may 





3.3.3 Chapter summary 
Here, a range of physiologically relevant cell lines have been demonstrated for 
their usefulness in the study of CHIKV, and particularly for nsP3. These provide 
a range of appropriate cell lines to choose from when undertaking experiments, 
using both replicon and infectious virus, to investigate the function of the CHIKV 
nsP3 macro domain. These experiments are described in the following chapters 
where initially mutations were generated in the RNA/ADPR binding pocket of the 
nsP3 macro domain, in both replicon and infectious virus. The phenotypes of 
these mutants were assessed in several cell types to have a more 
comprehensive understanding of the function of the macro domain in different 
mammalian tissue types as well as mosquito cells. This data has been published 
in an open-access journal, available for other researches to access and use for 











Now that appropriate cell lines had been optimised for use with the CHIKV 
replicon and infectious system, attention could be turned to the specific focus of 
this project: determining the function of the CHIKV nsP3 macro domain.  
The three-dimensional structure of the CHIKV macro domain in complex with 
either ADP-ribose or RNA had been previously solved (Malet et al., 2009, see 
Figure 4.1). This study highlighted the binding pocket, similar to that of other 
macro domains, which is only partially shared by ADP-ribose and RNA 
nucleotides.  
 
Figure 4.1 The CHIKV nsP3 macro domain in complex with ADP-ribose (A) 
and RNA (two adenosine bases) (B) adapted from PBD 3GPO and 
3GPQ respectively (Malet et al. 2009).  
 
The biochemical function and capabilities of the CHIKV macro domain have been 
assessed previously. The CHIKV macro domain has been shown to be capable 
of binding poly-ADP-ribose (PAR) and mono-ADP-ribose (MAR). Mutagenic 
analysis of the CHIKV macro domain has revealed that the aspartic acid residue 
at position 10 is crucial for ADPR binding, as substitution  for alanine obliterates 





It has also been demonstrated that the CHIKV nsP3 macro domain possesses 
ADP-ribose 1”-phosphate phosphatase activity, to similar levels as the VEEV 
nsP3 macro domain, although the macro domain of SFV does not possess this 
activity as it was below the limit of detection (Egloff et al., 2006; Malet et al., 
2009). Egloff et al. suggest that ADP-ribose 1” phosphatase activity may have 
little relevance in vivo as macro domains (both cellular and viral) are not closely 
related to any other known phosphatases. Furthermore, viruses such as SFV 
replicate with a macro domain that does not exhibit this activity, suggesting that 
ADP-ribose 1”-phosphate phosphatase activity is a dispensable function that 
contributes little to virus replication.  
More recently, the CHIKV macro domain has been shown to possess hydrolase 
activity where MAR is removed from aspartate and glutamate residues in vitro 
(McPherson et al., 2017). In the same publication, McPherson et al. generated a 
panel of macro domain mutants and assessed their ability to bind and hydrolyse 
MAR in vitro and their ability to produce virus in cell culture and mice. From these 
experiments, it was concluded that binding and hydrolysis of MAR is essential 
for CHIKV replication in cell culture and for virulence in mice.  
Further investigation from the same research group revealed that CHIKV 
infection increases the general level of ADP-ribosylation in cells and that the 
ability of cells to MARylate proteins was required for optimal CHIKV replication 
(Abraham et al., 2018). In addition, this publication demonstrated that defects in 
both the hydrolase and ADPR-binding capabilities of the CHIKV macro domain 
resulted in diminished virus replication but when only the hydrolase function was 
reduced, initial stages of replication occur much like wt, such as expression of 
the nsPs and the formation of replicases. However, with the hydrolase-defective 
macro domain, protein synthesis was more rapidly shut off, replication 
complexes become inefficient and virus production was delayed.  
Despite these recent advances in the biochemical properties of the domain, the 







In this chapter, the aim was to define the function of the CHIKV nsP3 macro 
domain in the virus lifecycle. To achieve this, a range of mutations were 
generated in the binding pocket of the CHIKV macro domain, based on the data 
available in the literature, and these mutants were assessed for their ability to 






4.2.1 Generation of macro domain mutants 
To determine the function of the macro domain, firstly a panel of substitutions 
were made individually in the ADPR binding pocket. To determine which 
residues to mutate, sequence alignments were performed on the nsP3 macro 
domain of CHIKV compared to other alphaviruses, and of the CHIKV macro 
domain compared to other viral macro domains such Rubella virus, SARS and 






Figure 4.2 Macro domain sequence alignments. (A) Amino acid sequence 
alignment of alphavirus macro domains. (B) Amino acid sequence 
alignment of CHIKV macro domain compared to other non-alphavirus 
viral macro domains. (C) Amino acid sequence alignment of CHIKV 
macro domain from the three major strains, with differences 
highlighted in blue. Produced using Clustal Omega (McWilliam et al., 
2013). (* = absolute alignment, : = residues with strongly similar 






As shown by Figure 4.2, in the alphavirus sequence alignment, there were 57 
absolutely conserved residues. When comparing CHIKV to other viruses, there 
were 17 absolutely conserved residues.  Figure 4.2 C demonstrates the high 
level of conservation at the amino acid level of the macro domain between the 
three major CHIKV strains. These conserved residues were then compared to 
the three-dimensional structure of the CHIKV macro domain. Conserved 
residues that were also exposed in the ADPR/RNA binding pocket were selected 




Figure 4.3 Selection of residues for mutagenesis. The three-dimensional 
structures of the CHIKV macro domain bound to ADP-ribose (left) and 
RNA (right) with indicated residues for mutagenesis shown in pink. 
Adapted from Malet et al., 2009, PBD 3GPO and 3GPQ respectively. 
 
Residues G32 and G112 were completely conserved across all viral macro 
domains and were highly conserved in mammalian, yeast and bacterial macro 
domains (Li et al., 2013). Although not completely conserved throughout viruses, 
the D10 and T111 residues are highly conserved in the macro domains across 





although not particularly highly conserved, were selected for mutagenesis due to 
their proximity to the ADP-ribose molecule within the CHIKV macro domain 
binding pocket as shown by the three-dimensional structure in Figure 4.3.  
Alanine scanning was performed on the residues selected for mutagenesis. 
These mutations were engineered into the infectious CHIKV clone. Mutagenesis 
was performed using Q5 site directed mutagenesis on the CHIKV virus construct. 
Specific nucleotide changes are noted in appendix Figure 7.4.  
 
4.2.2 Phenotypic analysis of CHIKV macro domain mutants in 
mammalian cell lines 
4.2.2.1 BHK cells 
As BHK cells were frequently used to generate wt CHIKV at high titres, they were 
initially used here to assess the replicative phenotypes of the macro domain 
mutants in the infectious CHIKV clone. Capped CHIKV RNA was produced for 
wt, each macro domain mutant. Alongside these, an nsP4 active site GDD>GAA 
polymerase mutant was generated to act as a negative control, as this mutation 
has been shown to completely inactivate polymerase activity. An infectious 
centre assay (ICA) and corresponding time course and titres were performed 
together. ICAs have been used in virological research in multiple contexts, such 
as assessing the number of infected cells in a patient sample (Dutta and Myrup, 
1983). Here, it is used to assess the ability of an RNA genome to form an 
infectious virus whilst preventing any reversion to wt from overwhelming the 
population due to the presence of the overlay, using the method previously 
described by Gorchakov et al., 2004. 
BHK cells were electroporated with wt or mutant CHIKV RNA, and either serially 
diluted and plated onto a monolayer of prepared BHK cells for the ICA. These 
were then overlaid with MC and incubated for 72 h prior to staining and 
quantification. From the same electroporated BHK cells, 1 mL of each 
suspension was plated into 12 well plates, harvested at 24 and 48h and titred by 
standard plaque assay.  
As shown by Figure 4.4 A, three mutants, G32A, T111A and Y114A were able 





produced very few plaques and D10A and G112A produced no plaques at all. 
When comparing this to the 24 and 48 hpe titres as shown in Figure 4.4 B, the 
three mutants that produced ~wt levels for the ICA also produced similar to wt 
levels over the time course. For both D10A and V113A titres increased between 
at 48 hpe, indicating possible reversion to wt.  In contrast, much like the GAA 
polymerase negative control, G112A did not produce any infectious virus as 
measured by either ICA or plaques assay at 24 or 48 hpe. 
To detect nsP3 in cells electroporated with mutant virus RNA, lysates were 
probed by western blot. As indicated by Figure 4.4 C, nsP3 was easily detectable 
for wt, G32A, T111A and Y114A at 24 hpe, attributable to their high titres. Despite 
some virus production by V113A, nsP3 was not detectable in these cells by this 
method. No nsP3 was detected for D10A nor G112A due to extremely low virus 
production, by these mutants. Despite the high titres at 48 hpe, levels of  nsP3 
as detected by western blot were much lower at this time point. In addition, it was 
not possible to extract RNA from these cells for further experiments such as qRT-
PCR and RT for sequencing. This was most likely due to high levels of 
cytotoxicity and cell death in CHIKV infected BHK cells. Therefore, other cell lines 






Figure 4.4 Phenotype of CHIKV nsP3 macro domain mutants in BHK cells. 
(A) ICA of the macro domain mutants. RNA was produced for wt, each 
macro domain mutant and nsP4-GAA. An ICA was performed for each 
RNA.  (Data analysed by One-way ANOVA with Bonferroni correction 
compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
**** = P ≤ 0.0001). (B) Electroporated cells from A were plated 
separately and supernatant collected at 24 and 48 hpe. Virus was titred 
via plaque assay. Data analysed as described in part A. (C) Western 
blot for nsP3 and actin loading control in electroporated BHK cells at 





4.2.2.2 Huh7 cells 
Due to the issues experienced with BHK cells, Huh7 cells were selected to 
analyse the replicative phenotypes of the macro domain mutants, as it had been 
shown in Chapter 3 that they are suitable and relevant to CHIKV research. We 
have observed in the laboratory that Huh7 cells were less sensitive to the 
cytotoxic effects of CHIKV infection when compared to other cell lines such as 
BHK cells. They were therefore proposed as a more suitable cell line for 
experiments such as RNA and protein extraction or immunofluorescence.  
Prior to experiments using the infectious virus, the dLuc CHIKV replicon (as 
described previous in 3.2.1.1) was utilised to assess the levels of RNA replication 
of the macro domain mutants in Huh7 cells. As shown in Figure 4.5, all macro 
domain mutants were able to replicate CHIKV RNA, as all produced signal above 
that of the nsP4-GAA mutant. Both V113A and Y114A exhibited a significant 
increase in RNA replication compared to wt. Though none of the other mutants 
exhibited a statically significant difference to wt replication, D10A, G32A, G112A, 






Figure 4.5 All macro domain mutants are capable of RNA replication in 
Huh7 cells. Huh7 cells were transfected with the dual luciferase 
replicon and lysed over at 2 and 24 hpt. Data shown is the 24 h Fluc 
signal, normalised to the 2 h Rluc signal for each individual mutant. 
The dotted line indicates signal from the GAA polymerase mutant. 
(Data analysed by One-way ANOVA with Bonferroni correction 
compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
**** = P ≤ 0.0001 ).   
 
Despite attempts to optimise the process, it was not possible to perform 
quantitative ICAs using electroporated Huh7 cells, nor did these cells respond 
well to electroporation with CHIKV RNA. Therefore, cells were transfected with 
CHIKV wt or mutant RNA, plated into 12 well plates and resulting virus was 
harvested and titred by plaque assay at 24 and 48 hpt. As shown by Figure 4.6, 
Huh7 cells did not support virus replication of most mutants. Only one mutant, 
Y114A, was capable of producing detectable virus at both 24 and 48 h time 
points. At 48 h, infectious virus was also detected for T111A. However, as shown 
by Figure 4.6 B, western blot analysis revealed that nsP3 was only robustly 
expressed in cells containing wt RNA at 24 and 48 hpe.  
To complement the western blot analysis, IF for nsP3 was performed for Huh7 
cells transfected with wt or mutant CHIKV RNA. Cells were transfected with wt 
or mutant CHIKV RNA, fixed at 12 and 24 hpt, and stained for nsP3, and DAPI 
stained to highlight nuclei. These time points were selected as previous work 





was detectable by IF. No 48 h time point was taken as, for most cell lines, by 
48 h there is a high level of cell death making imaging of cells problematic. As 
shown by Figure 4.7, at 12 hpt, wt-electroporated cells contain many defined 
puncta of nsP3, with many localised to the perinuclear region of the cells. In 
contrast, all of the mutants either contained no puncta or few puncta per cell. 
These few puncta may be indicative of input translation or the attempt to form 
replication complexes that are defective. Interestingly, with cells that contained 
few, small puncta, few were localised to the perinuclear region indicating a 
possible transport/trafficking issue for nsP3 macro domain mutants. At 24 hpt, wt 
appears very similar to that shown for 12 h with cells containing more nsP3 
puncta. Again, most cells electroporated with mutant RNA contained one or two 
puncta of nsP3. Cells transfected with T111A RNA exhibited multiple puncta, 
although fewer and far less intense than wt. Many of these puncta were 
perinuclear and may indicate low levels of replication which is in agreement with 
the virus titre data shown in Figure 4.6. Similarly in agreement to the previous 
data, Y1114A at 48 hpt exhibited many bright puncta, with some in the 







Figure 4.6 Phenotype of CHIKV nsP3 macro domain mutants in Huh7 cells. 
(A) Huh7 cells were transfected with wt or mutant CHIKV RNA. Cells 
were plated out into 12 well plates and supernatant harvested and 
titred by plaque assay on BHK cells at 24 and 48 hpt. Mock cells were 
electroporated without RNA present. (Data analysed by One-way 
ANOVA with Bonferroni correction compared to wt, **** = P ≤ 0.0001 ).   
(B) Western blot for nsP3 and actin loading control in corresponding 







Figure 4.7 Cytoplasmic distribution of mutant nsP3 Huh7 cells. IF was 
performed for nsP3 in Huh7 cells electroporated with macro domain 
mutant RNA, fixed at 12 and 24 hpt. Images taken using an LSM700 
confocal microscope. 
 
Corresponding transfected cells were used to extract whole cell RNA by TRIzol 
extraction at 24 hpt. Unfortunately, it was not possible to extract RNA from cells 
at 48 h due to cytotoxicity, this was particularly true for cells transfected with wt 
CHIKV.  Extracted RNA was then used to quantify viral RNA in transfected cells 
via qRT-PCR. Unlike in chapter 3, qRT-PCR shown here was performed using 
primers specific for the E1 coding region of the genome. These were found to be 
more consistent than the primers for the AUD which were previously used. 
However, unlike the previous primers used, as these primers are specific for the 
E1 region of the genome, they will be detecting both genomic and subgenomic 
26s RNA.  
As shown by the dotted line in Figure 4.8, the levels of RNA detected for GAA is 





were above this level to some degree except G112A which reiterates the inability 
of this mutant to replicate. It is surprising however to observe that T111A and 
Y114A, which were both able to produce infectious virus as shown in Figure 4.6, 
exhibited genomic RNA levels not substantially above the GAA negative control. 
The mutant with the highest genomic RNA levels; V113A, was unable to produce 
detectable virus when electroporated into Huh7 cells. This may indicate an ability 
to replicate RNA but not form infectious virus.  
 
Figure 4.8 qRT-PCR of viral RNA from electroporated Huh7 cells. 
Corresponding cells from Figure 4.6 were TRIzol extracted at 24 hpt. 
Resulting RNA was adjusted to 50 ng/µL and 100 ng per RNA was used 
per qRT-PCR reaction using the MESA green qRT-PCR MasterMix 
(EuroGenTec) with primers specific for the E1 region of the CHIKV 
genome. Data normalised to cell only control (1.36x103 copy No/mL). 
Dotted line indicates input RNA levels as indicated from the GAA 
negative control.  
 
It was attempted to reverse transcribe the RNA from wt, T111A and Y114A 
samples in order to amplify the macro domain coding region for consensus 
sequencing. However, despite multiple attempts with various methods, it was 
only possible to successfully amplify a fragment by PCR from the wt cDNA, when 
using 30 cycles of the PCR program (Figure 4.9). Ideally, when screening PCR 
products for the presence of mutations, the cycle number should be kept to a 
minimum to reduce the possibility of introducing mutations, or selecting for 





work, a maximum of 25 cycles was used. Therefore, since it was not possible to 
amplify fragments for either the T111A or Y114A cDNA within 30 PCR cycles, 
this line of inquiry was abandoned.   
 
Figure 4.9 PCR amplification of a macro domain containing fragment from 
cDNA formed from total RNA of Huh7 cells transfected with macro 
domain mutant CHIKV RNA. Huh7 cells were transfected with wt and 
macro domain mutant CHIKV RNA. Total cell RNA was extracted at 
24 hpe using TRIzol. Resulting RNA was used to generate cDNA which 
was used as input for PCR to amplify a macro domain containing 
fragment for sequencing. Resulting PCR products from 25 cycles (A), 
and 30 cycles (B) were ran on agarose gels. The positive control (‘+’) 







4.2.2.3 C2C12 cells 
Due to the issues that occurred with the macro domain mutants in Huh7 cells 
another physiologically relevant cell line, C2C12 cells, were used to assess the 
replicative phenotypes of the CHIKV macro domain mutants .  
As for Huh7 cells, initially C2C12 cells were transfected with wt and mutant virus 
RNA, supernatant was collected at 24 and 48 hpt and titred via plaque assay. As 
shown by Figure 4.10, in contrast to the Huh7 cells, every mutant was able to 
produce some level of detectable, infectious virus by 48 hpt. Although none of 
the mutants, including the GAA negative control, were significantly different at 
the 48 h time point, presumably due to higher variation in the wt data caused by 
cytotoxicity at this later time point. Mutants G32A, T111A, and Y114A all 
resembled wt levels at 24 h however, unlike the wt, this was reduced at 48 h, 
possibly due to higher cytotoxicity for these particular mutants. Both D10A and 
V113A were reduced compared to wt. G112A which, although in both BHK and 
Huh7 cells was unable to produce any infectious virus, produced a low level of 
infectious virus in C2C12 cells by 48 hpe (4.7x102 PFU/mL). 
As the western blot indicates in Figure 4.10 B, nsP3 was detectable for wt, G32A, 
T111A, V113A and Y114A at both 24 and 48 hpt. By 48 h nsP3 was also 
detectable for D10A. Due to technical issues the 48 h samples for western blot 
were not equally loaded . Therefore the actin loading control must be taken into 









Figure 4.10 Macro domain mutants within the infectious CHIKV system in 
C2C12 cells. (A) C2C12 cells were transfected with wt or mutant CHIKV 
RNA. Cells were plated out into 12 well plates and supernatant 
harvested and titred by plaque assay on BHK cells at 24 and 48 hpt. 
(Data analysed by One-way ANOVA with Bonferroni correction 
compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01,).  (B) Western 
blot for nsP3 and actin loading control in corresponding transfected 
C2C12 cells at 24 and 48 hpt.  
 
IF was again performed on C2C12 cells that were transfected with wt or mutant 
CHIKV RNA to visualise nsP3. Transfected cells were fixed at 12 and 24 hpt and 
stained for nsP3, and nuclei using DAPI. As shown by Figure 4.11, at 12 hpt, the 
IF data is much in agreement to the viral titres produced (see Figure 4.10) with 
wt, G32A, T111A and Y114A all exhibiting similar, high levels of expression of 
nsP3 localised throughout the cytoplasm, with several perinuclear puncta. At 





resembled the wt. However, cells infected with T111A CHIKV had a very different 
appearance with many nsP3-positive cells containing abnormal nuclei that were 
smaller in size, and appeared to be hollow.  As shown by the inset image for 
T111A at 24 h, some nsP3 expressing cells did resemble those of wt, with intact 
nuclei, but these were a minority in the sample. For mutants D10A and V113A, 
no cells were found at 12 hpt that expressed nsP3, however, by 24 h both 
mutants exhibited nsP3 expression. Cells expressing D10A or V113A nsP3 at 
24 hpt contained fewer puncta of nsP3 that were less intense when compared to 
wt. In cells with G112A RNA, a small number of cells appeared to contain single 
puncta of nsP3 which did not increase by 24 hpt. In this experiment, no cells 
were detected for G112A that contained more than one puncta.  
 
Figure 4.11 Distribution of nsP3 in C2C12 cells transfected with mutant 
CHIKV RNA. IF was performed for nsP3 in C2C12 cells electroporated 
with macro domain mutant RNA, fixed at 12 and 24 hpt. Images taken 






Total cell RNA was extracted from transfected cells at 24 hpe by TRIzol 
extraction. Resulting RNA was then used for qRT-PCR. As shown in Figure 4.12, 
all mutants except G112A had copy numbers above the nsP4-GAA negative 
control. Mutants G32A, T111A and Y114A were all approximately wt levels, 
which reflects the virus titre data shown in Figure 4.10. Both D10A and V113A 
were drastically reduced from wt, indicating their poor ability to replicate RNA. At 
24 hpt, G112A is exhibiting no RNA replication as it is below GAA levels, again 
reflecting the data shown in Figure 4.10 however, this mutant was capable of 
producing virus at 48 hpt which would suggest it should be capable of some level 
of RNA replication.  
 
Figure 4.12 qRT-PCR of viral RNA from transfected C2C12 cells. 
Corresponding cells from Figure 4.6 were TRIzol extracted at 24 hpt. 
Resulting RNA was adjusted to 50 ng/µL and 100 ng per RNA was used 
per qRT-PCR reaction using the MESA green qRT-PCR MasterMix 
(EuroGenTec) using primers specific for the E1 region of the CHIKV 
genome. Data normalised to cell only control (1.31x103 copy No/mL). 
The dotted line indicates the level of input RNA which is that of the 
GAA polymerase negative control.  
 
To assess whether any replicative phenotype observed was due to reversion, 
corresponding RNA was reverse transcribed and a macro domain containing 
fragment was amplified via PCR for sequencing. As shown in Figure 4.13, it was 





and Y114A transfected cells. Therefore it was only possible to obtain the coding 
sequences for these mutants.  
As shown by the highlighted nucleotides in Figure 4.13 B, for all of the mutants 
that were successfully amplified by PCR, all original mutations were maintained.  
No additional mutations were detected, at least not within the macro domain 
coding region. Although it may have been interesting to determine whether 
mutants with lower titres were a result of reversion or compensatory mutations, 
it was not possible to amplify the macro domain PCR product from D10A or 







Figure 4.13 Consensus sequencing of cDNA generated from C2C12 cells 
24 h post transfection with macro domain mutant CHIKV RNA. TRIzol 
extracted RNA from Figure 4.12 was used to form cDNA and used as 
input for PCR to amplify the macro domain coding region. (A) PCR 
products were electrophoresed on a 1% agarose gel. (B) Successful 
PCR fragments (G32A, T111A and Y114A) were then sequenced via 
sanger consensus sequencing by GeneWiz. Resulting sequences 
were aligned with wt using Clustal omega with mutant nucleotides 





4.2.3 Phenotypic analysis of CHIKV macro domain mutants in 
mosquito cell lines 
As CHIKV is an arbovirus, it would be prudent to assess the role of the macro 
domain, not only in the human host but also in the mosquito vector. Therefore 
the phenotypes of the macro domain mutant viruses were assessed in the two 
Ae albopictus cell lines previously demonstrated to replicate CHIKV: C6/36 and 
U4.4 (chapter 3). However, as the optimisation in chapter 3 was performed by 
infection of cells with virus produced in BHK cells, further optimisation was 
required to determine both the transfection method and the appropriate time 
points to harvest virus.  
Transfection with lipofectamine was trialled as this had been used successfully 
with these cell lines with CHIKV replicon RNA (see section 3.2.2) and it had been 
reported that electroporation of mosquito cells was both inconsistent and 
requires specific reagents (Boylan et al., 2017, M Müller and A Merits personal 
communication). U4.4 and C6/36 cells were therefore transfected using 
lipofectamine with wt CHIKV RNA and supernatant collected over a three day 
period. Virus was then titred by plaque assay. As shown by Figure 4.14, C6/36 
cells produced low titres of infectious virus by 24 h, increasing to 107 PFU/mL at 
48 and 72 hpt . Conversely, U4.4 cells only produced detectable infectious virus 
at 72 hpt with the lower titres in the range of 105 PFU/mL, demonstrating the 
effect of an intact RNAi system on virus replication. It was therefore decided that 
the transfection protocol was successful and suitable for use in transfecting 








Figure 4.14 CHIKV titres from transfected mosquito cells over time. U4.4 
and C6/36 cells were transfected with wt CHIKV RNA, supernatant 
collected at 24, 48 and 72 hpt and resulting virus titred by plaque 
assay.  
 
U4.4 and C6/36 cells were then transfected with wt and mutant CHIKV RNA, 
incubated for 72 h prior to collection of supernatant and titration by plaque assay. 
As shown in Figure 4.15, there were some stark differences of the ability of the 
mutants to replicate in the two cell lines. For both cell lines, T111A resembled 
wt, with no significant different between T111A from wt titres. G32A resembled 
wt in C6/36 cells but demonstrated a significant increase in titre, compared to wt, 
in U4.4 cells. In both cell lines, G112A did not produce any detectable virus. In 
U4.4 cells, Y114A also resembled wt but in C6/36 cells, replication of this mutant 
was significantly reduced. For V1113A, there was no detectable virus in U4.4 
cells, yet this mutant produced titres of 2.1x106 PFU/mL in C6/36 cells, although 
this was still significantly reduced from wt. Similarly, D10A did not replicate at all 






Figure 4.15 Mutant virus titres from transfected mosquito cell lines. U4.4 
(A) and C6/36 cells (B) were transfected with wt or mutant CHIKV RNA 
as previously described (or mock transfected with no RNA present). 
Supernatant was collected at 72 hpt and titred by plaque assay on 
BHK cells. (Data analysed by One-way ANOVA with Bonferroni 
correction compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** 






In parallel, transfected mosquito  cells were TRIzol extracted and resulting RNA 
used for qRT-PCR. As shown in Figure 4.16, for the U4.4 cells, the qRT-PCR 
data is reflective of the virus titres shown in Figure 4.14. It is interesting that the 
three mutants that produced no detectable virus, D10A, G112A and V113A, were 
also below the level of the GAA polymerase negative control. This implies that 
these three mutants were completely unable to replicate RNA in U4.4 cells. In 
contrast, all mutants had copy number higher than the GAA control in C6/36 
cells. Again, the qRT-PCR data broadly reflected the virus titres produced in 
these cells. However, it is curious that both D10A, that produced low levels of 
virus, had a very similar copy number to that of G112A which was unable to 
produce virus in these cells. This could imply that the macro domain has an 







Figure 4.16 qRT-PCR in mosquito cells transfected with wt or mutant RNA 
(72 hpt). U4.4 and C6/36 cells were transfected with wt or mutant 
CHIKV RNA (or mock transfected with no RNA present). RNA was 
extracted via TRIzol at 72 hpt. Resulting RNA was adjusted to 50 ng/µL, 
and 100 ng per RNA was used per qRT-PCR reaction using the MESA 
green qRT-PCR MasterMix (EuroGenTec) using primers specific for 
the E1 region of the CHIKV genome. Data normalised to mock 
transfected control (4.78x103 and 8.27x103 copy No/mL respectively). 
The dotted line indicates the level of input RNA which is that of the 






To assess whether any of the replicative phenotypes observed in mosquito cells 
was due to reversion, corresponding RNA from the qRT-PCR experiments was 
reverse transcribed into cDNA and a macro domain containing fragment was 







Figure 4.17 Sequencing of the macro domain mutant genomes from 
infected U4.4 cells. Corresponding RNA to Figure 4.16 was reverse 
transcribed to form cDNA which was used the template to amplify a 
macro domain containing fragment via PCR. (A) Resulting PCR 
fragments were electrophoresed on a 1% agarose gel. (B) Samples 
containing the correct PCR fragment were sequenced via consensus 
Sanger sequencing by GeneWiz. Resulting sequences were aligned 





As seen previously in the C2C12 cells, all mutations present at time of 
transfection into the U4.4 cells, were retained by 72 h. Although the sequencing 
data received for the Y114A sample was of poor quality with several undefined 
bases present (termed ‘N’ in the sequence alignment), the original Y114A 
mutation (TAC>GCC) was clearly retained.  
This process was also performed for the C6/36 cells,. As shown by Figure 4.18 
A, it was only possible to amplify the macro domain DNA fragment from G32A, 
T111A, V113A and Y114A samples. Again, as seen in all other cells lines, for all 
the mutants that it was possible to obtain sequencing data, the original mutation 
present in the transfected RNA was retained for the 72 h, when the total cell RNA 






Figure 4.18 Sequencing of the macro domain mutant genomes from 
infected C6/36 cells. Corresponding RNA to Figure 4.16 was reverse 
transcribed to form cDNA and used as the template to amplify a macro 
domain containing DNA fragment via PCR. (A) Resulting PCR 
fragments were electrophoresed on a 1% agarose gel to ensure 
correct size and quality. (B) Samples containing the correct PCR 
fragment were sequenced via consensus Sanger sequencing by 
GeneWiz. Resulting sequences were aligned with wt using Clustal 






4.3.1 The macro domain is essential for CHIKV replication 
In this research, it has been demonstrated that the CHIKV nsP3 macro domain 
is essential for viral replication. In all cell lines, including both mammalian and 
mosquito, a single point mutation of G112A abrogated CHIKV replication, except 
in C2C12 cells at 48 h where it was capable of replicating to extremely low levels. 
Other mutants such as D10A and V113A exhibited low or no replication in all cell 
lines. This highlights that a functional macro domain is essential for efficient 
replication of CHIKV in both mammalian and mosquito cells.  
4.3.2 The different macro domain mutants produced a range of 
replicative phenotypes 
Here, the replicative phenotypes of a panel of mutations within the CHIKV nsP3 
macro domain were assessed in a range of cell lines. In the literature, several 
publications have made a similar panel of mutants and assessed the biochemical 
properties of these mutants. A summary of this data is shown in Table 4.1. 
Results from the infectious virus in Huh7 cells have been omitted from this table 
as, despite some replication from T111A and Y114A, all mutants were reduced 
at all time points to the same significance.   
It is of note that, regardless of cell line the mutant CHIKV RNA was transfected 
into, all virus samples were ultimately titred by plaque assay on BHK cells. 
Therefore these results may be affected by the ability of the mutant to replicate 
in BHK cells. However, in most cases, the qRT-PCR and western blot data 
largely corresponded with the virus titres indicating that the limitation of cell line 









wt D10A G32A T111A G112A V113A Y114A 
Replicon replication 
(Huh7) 




BHK wt <wt ~wt ~wt ND <wt ~wt 
C2C12 
wt <wt ~wt ~wt >wt <wt ~wt 
Replication in 
insect cells 
U4.4 wt ND ~wt ~wt ND ND ~wt 
C6/36 wt <wt ~wt ~wt ND <wt <wt 
 
Mutation maintained?* - NT Yes Yes NT Yes Yes 
 
ADPR binding (kD) 22.9 ND 21.0 71.4 ND+ 6.46^ 4.84 
Hydrolase activity (% wt)  100 16.1 75.3 64.1 3.7+ 15.0^ 40.6 
Phosphatase activity  wt <wt NT NT NT NT ND 
RNA binding wt ~wt NT NT NT NT <wt 
Table 4.1 Summary of the replicative phenotypes and known biochemical 
properties of the macro domain mutants. ND= none detected. NT = not 
tested / unable to test. ADPR binding and hydrolase activity data taken 
from McPherson et al., 2017. Phosphatase activity and RNA binding 
data taken from Malet et al., 2009, where, instead of G112A and V113A, 
mutations of +G112E and ^V113R were assessed.  
 
The D10A mutation in the CHIKV nsP3 macro domain was first assessed by 
Malet et al., 2009, where it was demonstrated that this mutation had a 
significantly reduced ability to bind ADP-ribose, though only a small reduction in 
phosphatase activity, and RNA binding capabilities similar to the wt macro 
domain. It has also been shown that the D10A mutation decreases the hydrolase 
capability of the CHIKV macro domain (McPherson et al., 2017). In this study, 
this mutant consistently replicated at a lower level than wt in replicon and virus 





U4.4 cells. This implies that RNA binding and phosphatase activity are less 
important for the role of the macro domain in virus replication than ADPR binding 
and hydrolase activity. It was not possible to sequence the RNA resulting from 
D10A-transfected cells to assess whether the production of infectious virus by 
D10A mutant was due to reversion, most likely due to low levels of virus RNA. 
However, the differences in replication in BHK cells between the ICA and the 24 
and 48 h titres indicates that it is probable that reversion or a compensatory 
mutation did occur. In addition, other studies have shown that virus produced 
with D10A mutant RNA had reverted to wt (McPherson et al., 2017).   
The G32 residue is highly conserved across the macro domains of many species. 
It was therefore unsurprising that, the replicon system, G32A exhibited poor RNA 
replication. However, in infectious virus, the G32A mutant was able to replicate 
at approximately wt levels in all cells except Huh7 cells. In C2C12, U4.4. and 
C6/36 cells, it was shown that this mutation was maintained in infection. This 
discord between the results from the replicon and infectious virus experiments 
indicates that the nsP3 macro domain may have roles required for virus 
production other than in RNA replication. Other studies have shown that the 
biochemical properties of the G32A mutant are not dissimilar to wt, with similar 
affinity for ADPR and only a slightly decreased level of hydrolase activity as 
shown in Table 4.1. As alanine and glycine are both hydrophobic residues with 
very little difference in structure, it is likely that this substitution mutation had very 
little effect on the structure or function of the macro domain. Other studies have 
shown that G32A and G32S were both able to replicate and maintain the 
mutation however, mutation of G32E reverted to wt, possibly due to the domain 
not tolerating the larger side chain of glutamate compared to the smaller residues 






Figure 4.19 Amino acid substitutions at position 32 of the CHIKV nsP3 
macro domain. Substitutions with small residues such as with alanine 
or serine are tolerated, able to produce virus and, in the case of G32A, 
are maintained, but larger residues such as glutamine are not 
tolerated.  
 
Both the T111A and Y114A mutations behaved similarly to wt across all cell lines. 
These were the only mutants capable of producing infectious virus in Huh7 cells, 
although both were significantly reduced from wt titres. Despite their similarities 
in virus production, other studies have shown the two mutants to possess very 
different biochemical properties. Y114A had reduced RNA binding to wt when 
assessed via slot blot, although this study did not assess the properties of the 
T111A mutant (Malet et al., 2009). It has been shown that T111A possesses 
weaker ADPR binding than wt, and hydrolase function of 64.1% of wt (see Table 
4.1). Conversely, Y114A was shown in this study to have a much higher affinity 
for ADPR compared to wt and a hydrolase activity of 40.6% of wt. It is surprisingly 
therefore that these two mutants have a similar replicative phenotype across a 
variety of cell lines given the differences in their biochemical properties. 
Particularly when it has been shown that these mutations are maintained in 
infected cells with no detected reversion or compensatory mutations within the 
macro domain. The T111A mutant became of particular interest from the IF data 





cytoplasmic puncta. In contrast, T111A nsP3 puncta were larger, less defined 
with some diffuse cytoplasmic nsP3. The nuclei of T111A-infected cells became 
highly distorted, appearing condensed and hollow. It has been shown that nuclei 
condense and become hollow due to apoptosis (Toné et al., 2007). This may 
indicate that, in this particular cell line, the T111A nsP3 is enhancing apoptosis, 
possibly due to an inability to inhibit a cellular process, as no other mutant or wt 
infected cells exhibited any indicators of apoptosis via IF at the 24 h time point.  
The glycine residue at position 112 was selected for mutagenesis as, similar to 
G32, it was highly conserved across the macro domains of many species. Both 
G32A and G112A behaved similarly in the replicon system, both replicating RNA 
to significantly reduced levels. However, in contrast to G32A, the G112A 
substitution had a detrimental effect on viral replication in the infectious system. 
The G112A mutant was unable to produce virus in any cell line with the exception 
of C2C12 cells where, at the 48 h time point, titres of approximately 
4.7x102 PFU/mL were detected. Unfortunately, it was not possible to determine 
through sequencing whether this was due to reversion. Other groups have 
shown that a mutation to glutamine at this position completely obliterated ADPR 
binding and had extremely low hydrolase activity (3.7% of wt, as shown in Table 
4.1) indicating that this residue is important for both ADPR binding and 
hydrolysis, and therefore unsurprising that this mutant consistently produced no, 
or very little virus in all cell lines assayed. The G112E mutant also readily 
reverted to wt (McPherson et al., 2017). It is interesting that a glutamine at this 
position allowed for enough initial replication to facilitate a reversion event, 
whereas in this study, a substitution for alanine prevented replication entirely in 
the majority of cell lines.  
Mutant V113A varied the most between cell lines implying that there are some 
cell-line specific roles of the nsP3 macro domain. In the replicon system in Huh7 
cells, V113A exhibited RNA replication that was significantly higher than wt. In 
the infectious system, V113A produced virus at both 24 and 48 h in BHK and 
C2C12 cells, although the titres produced by this mutant were much reduced 
from wt. In Huh7 cells, no virus was produced by the V113A mutant, despite 
having the highest level of genomic RNA detected via qRT-PCR of all the 





domain, separate to RNA replication, which is required to produce infectious 
virus. In mosquito cell lines, the V113A mutant is interesting as it did not produce 
any detectable virus in U4.4 cells but was only slightly reduced from wt in C6/36 
cells, again implying cell-line specific functions. This could again indicate that the 
macro domain may be involved in RNAi suppression as U4.4 cells, where this 
mutant was unable to replicate, have an intact RNAi pathway yet C6/36 cells do 
not.  
4.3.3 Elucidating the function of the macro domain in CHIKV 
replication 
4.3.3.1 ADP-ribose binding of the macro domain is required for efficient 
virus replication 
Comparing the replicative phenotypes of the macro domain mutants determined 
in this project to the biochemical data from the literature (summarised in Table 
4.1), implies that ADPR binding is the most important aspect of the CHIKV macro 
domain to facilitate virus replication. The two mutants with no detectable ADPR 
binding, D10A and G112A, were the two mutants that consistently produced 
either significantly reduced virus titres or no virus at all. It is unfortunate that it 
was not possible to determine whether the virus produced by these two mutants 
was a result of a reversion. Data from other groups implies that this may have 
been the case as McPherson et al., 2017 demonstrated that virus produced by 
D10A and G112E RNA was a result of reversion to the wt sequence.  
Hydrolase activity also appears important for the function of the macro domain 
as those with the lowest activity were again, poor at producing virus, including 
D10A, G112A and V113A. However, there appears to be less correlation 
between replication and hydrolase activity than there was for replication and 
ADPR affinity. V113A was able to replicate to wt levels in BHK cells, was reduced 
in C2C12 and C6/36 cells and was unable to produce any virus in U4.4 cells. 
This implies that either the hydrolase activity is less important for virus replication 
or it is required but in a cell-specific manner. However it is important to highlight 
that hydrolase activity was only assayed for a V113R mutant (McPherson et al., 
2017) , although it is likely that the V113A mutant also abrogates this enzymatic 





just over 40% of wt yet, in most cell lines used here, was shown to have 
replication comparable to wt, indicating that CHIKV can tolerate reduced 
hydrolase activity to produce infectious virus.  
It has been suggested in the literature that the ADPR 1”–phosphatase activity is 
unlikely to be the primary function of viral macro domains. Other viral macro 
domains such as the wt SARS-CoV and SFV macro domains possess no 
phosphatase activity indicating that this enzymatic activity is not required for viral 
replication (Egloff et al., 2006; Malet et al., 2009). The data shown here is in 
agreement with the literature as the Y114A mutant, which was shown to have 
poor ADPR 1”–phosphatase activity by Malet et al., 2009, replicated to wt levels 
in almost every cell line tested. Conversely, the D10A mutant, with only slightly 
decreased phosphatase activity from wt, consistently replicated to either 
significantly reduced levels or was unable to produce any virus.  
4.3.3.2 The macro domain does not affect cellular distribution of nsP3 
From the IF data, staining for nsP3 for all the macro domain mutants in both 
Huh7 and C2C12 cells, it would appear that none of the macro domain mutants 
induce any significant relocalisation of nsP3 as nsP3 remained cytoplasmic and 
punctate. This indicates that, for the replicative phenotypes observed, it is not 
the result of re-localisation of nsP3. This is in agreement with the literature where 
it has been shown that the HVD is responsible for nsP3 cellular localisation, not 
the macro domain or the AUD (Fros et al., 2012). However, for the majority of 
mutants that were unable to replicate, unlike wt nsP3, very few mutant puncta 
were observed in the perinuclear region of the cell. This may indicate that 
perinuclear nsP3 puncta only occur in established, or late-stage replication. 
4.3.3.3 Possible roles for the macro domain in countering cellular innate 
immunity  
Although the majority of the macro domain mutants exhibited consistent 
replication between the two different mosquito cells lines, both D10A and V113A 
differed, implying cell-specific functions of the CHIKV macro domain. Both the 
D10A and V113A mutants were able to produce virus, to a reduced level, in 
C6/36 cells but not in U4.4 cells. C6/36 cells have been shown to have an 





2010). Therefore, since D10A and V113A virus cannot replicate in U4.4 cells but 
can produce virus in C6/36 cells, this indicates that the nsP3 macro domain may 
play a role in RNAi inhibition to allow viral replication. It has been shown that the 
RNAi pathway is activated in mosquitos upon CHIKV infection (Morazzani et al., 
2012) and that an inhibition of the RNAi pathway in infected mosquito cells 
enhanced CHIKV replication and virus production (McFarlane et al., 2014). The 
expression of the nsP3 macro domain  was found to inhibit the RNAi pathway in 
Sf21 cells, a cell line derived from Spodoptera frugiperda (the fall armyworm), 
and that certain mutations (though none that correspond with the mutants shown 
here) can disrupt the ability of the nsP3 macro domain to exert this inhibition 
(Mathur et al., 2016). The specific mechanism of this function was not elucidated, 
however this study suggested that it is the RNA binding capability of the macro 
domain that facilitated this inhibition. However, no studies to date have confirmed 
this macro domain mediated inhibition in an infectious virus system or in a 
mosquito cell line. 
It has been shown previously that nsP3 macro domain mutants possessing wt 
ADPR affinity but reduced hydrolase activity were able to form replication 
complexes and support early stage virus replication in CHIKV-infected neuronal 
cells. However, host translational shut off occurred earlier than for wt CHIKV 
(Abraham et al., 2018). In this publication Y114A is used as an example mutant, 
and here our data is somewhat in agreement with this as in C2C12 cells, Y114A 
produces high titres, comparable to wt but is reduced at 48 h, possibly due to the 
early onset of apoptosis. However, Y114A exhibited very different levels of 
replication across time points in other cell lines, again highlighting that cell 
specific functions may be occurring. The early onset of host translational shutoff 
in cells transfected with Y114A CHIKV RNA may suggest a role for the macro 







4.3.4 Chapter summary 
In this study, six residues were selected for mutagenesis in the ADPR-binding 
pocket of the CHIKV nsP3 macro domain. These mutants were individually 
engineered into the infectious CHIKV system and their replicative phenotypes 
assessed in a range of mammalian and mosquito cell lines.  
From the six mutations assessed, a range of phenotypes were observed, some 
mutants were unable to produce virus, or able virus to levels significantly lower 
than wt, indicating the importance of the CHIKV nsP3 macro domain for efficient 
viral replication.  
Some mutations highlighted there may be cell-specific roles for the macro 
domain, such as V113A which replicated to a reduced level in BHK and C2C12 
cells but did not replicate in Huh7 cells. In addition, this mutant replicated to 
levels slightly reduced from wt in C6/36 cells, which have an inactive RNAi 
pathway, but was unable to produce virus in U4.4 cells. This, in agreement with 
the literature, highlights a possible role for the nsP3 macro domain in inhibition 
of the insect innate immunity RNAi pathway.  
When comparing the replicative phenotypes of the macro domain mutants to the 
biochemical analysis published by others, it appears that the ADPR-binding 
ability of the nsP3 macro domain is most important for replication. Mutants that 
had no detectable ADPR binding corresponded to low or undetectable levels of 
replication.  
In agreement with the literature, it appears that the ADPR 1”–phosphatase 
activity is not important for CHIKV replication as mutant Y114A, shown in the 
literature to have no detectable phosphatase activity consistently replicated to 












In response to viral infections, the first line of defence of cells are the innate 
immunity pathways. Many of these pathways have been shown to be crucial to 
limiting damage caused by viral infections and prevent spread of viruses to 
surrounding cells (Haller et al. 2006).  However, many viruses have developed 
strategies to combat and subvert these pathways in order to continue replicating 
in cells.  
In the case of CHIKV, it is known that infection of cells induces a robust interferon 
(IFN) response in humans, which has also been shown to be crucial to survival 
of mice infected with CHIKV (Schilte et al., 2010). However, little has been 
reported on other antiviral pathways in the context of CHIKV infection.  
Like most viruses, Alphaviruses have developed multiple strategies to counteract 
the innate immune response. CHIKV nsP2 has been shown to inhibit JAK-STAT 
signalling, an early stage in the exogenous IFN signalling pathway (Fros et al., 
2010). In addition, nsP2 has also been shown to induce host-translational shutoff 
in infected cells, shown to be a result of the degradation of Rpb1 – a catalytic 
subunit of the cellular RNA polymerase II (Akhrymuk et al., 2012; Fros et al., 
2013). In the case of VEEV, the 5’ UTR has been shown to be capable of altering 
the binding and function of IFIT-1 (interferon induced protein with 
tetratricopeptide repeats 1), a protein normally capable of binding viral capped 
RNAs and preventing their translation (Hyde et al., 2014). There is much 
evidence that the 5’ UTRs of other alphaviruses, including CHIKV, have similarly 
important antiviral activity (Hyde et al., 2015; Reynaud et al., 2015).   
The only anti-immune function reported to date for nsP3 is the interaction with 
G3BP. This interaction, as previous discussed in section 1.2.5.5 is thought to 
sequester G3BP and prevent it from forming functional cytoplasmic stress 
granules (Fros and Pijlman, 2016). When this interaction was lost through 
deletion of 30 aa of the HVD of nsP3 in SINV, virus replication was greatly 
reduced (Varjak et al., 2010). Though it is debateable whether this interaction is 
purely to prevent the formation of stress granules as it has been shown that the 
interaction with G3BP is critical for the formation of  replication complexes and 





exploit G3BP for replication, rather than the prevention of stress granule 
formation.  
From the results of the mutagenesis studies in chapter 4, many of the defective 
macro domain mutants seemed to exhibit their defective phenotype at or after 6 
hpt. This indicated that there may be some part played by the innate immune 
system, which can take up to 4 h for pathways to become fully activated in order 
to exhibit their effects (Janeway, 2001). Looking specifically at what role the 
macro domain may play in antagonising the innate immune response, attention 
was drawn to the NFкB pathway as it has recently been demonstrated that 
ADP-ribosylation plays a regulatory role in this pathway. It was therefore 
hypothesised that nsP3 may be able to interact with these ribosylated proteins 
and therefore interfere with the NFкB pathway.  
A mono-ribosyltransferase; ARTD10 (ADP-ribosyltransferase diphtheria toxin-
like 10, also known as PARP10) has been shown to be capable of regulating the 
NFкB pathway as over expression of ARTD10 prevented the nuclear 
translocation of NFкB, which is required in order for the expression of NFкB 
dependent genes (Verheugd et al., 2013). Further investigation demonstrated 
that this inhibition was a result of ARTD10 mono-ADP-ribosylating NEMO (NFкB 
essential modulator) also referred to as IKK-γ, a component of the IKK complex 
central to the NFкB pathway. 
The IKK complex is comprised of three proteins; IKKα, IKKβ, and IKKγ/NEMO. 
An active IKK complex is required for two key phosphorylation steps in the NFкB 
pathway. As indicated by Figure 5.1, the IKK complex phosphorylates IκB. IκB is 
normally bound to NFкB/p105 to keep it inactive in the cytoplasm. When 
phosphorylated by the IKK complex, it is removed and targeted for degradation, 
freeing NFкB in the cytoplasm (Solt and May, 2008).  The second, essential 
phosphorylation step is that of NFкB. The IKK complex phosphorylates the NFкB 
protein complex in the cytoplasm which is required for protein interactions to 
facilitate the nuclear translocation of NFкB (Dong et al., 2010).  
As summarised in Figure 5.2, ARTD10, prevents the formation of an active IKK 
complex by ADP-ribosylating NEMO, which prevents NEMO from being poly- 





required, the cellular protein MacroD2 (macro domain containing protein 2) 
antagonises ARTD10 by the removal of the ADPR from NEMO, allowing poly-
ubiquitination and the formation of an active IKK complex. This results in the 
downstream signalling of the NFкB pathway and activation of an antiviral state 
(Chen, 2012; Feijs et al., 2013). Mutations in both ARTD10 and MacroD2 results 
in dysregulation of inflammation and chronic diseases such as cancer and 
autoimmune related conditions (Khong et al., 2016; Sakthianandeswaren et al., 
2018).  
 
Figure 5.1 Overview of the NFкB pathway. There are multiple stimuli that 
trigger the NFкB pathway through various sensors and receptors. 
Regardless of activation, the pathway converges on the central IKK 
complex that is required to phosphorylate, and therefore remove, IкB 
from NFкB (p105), revealing the nuclear localisation signal of p105. 
The IKK complex also phosphorylates NFкB to allow translocation to 
the nucleus where it acts as a transcription factor for various 
inflammatory and antiviral genes. Original figure interpreted from 







Figure 5.2 Regulation of NEMO by ADP-ribosylation. (A) ARTD10 mono-
ribosylates NEMO, which prevents it being poly-k63 ubiquitinated. 
This prevents an active IKK complex from forming therefore the NFкB 
pathway does not continue. (B) When the pathway is triggered, the 
cellular protein MacroD2 is able to hydrolyse the ADP-ribose from 
NEMO, allowing poly-K63 ubiquinitination, allowing formation of an 
active IKK complex, allowing downstream effects of the NFкB pathway 
Original figure interpreted from Verheugd et al., 2013. 
 
More recently it has been shown that, in vitro, the CHIKV nsP3 macro domain 
can remove mono-ADP-ribose from ARTD10 and NEMO  as well as multiple 
other MARlysated substrates tested (Eckei et al., 2017). Though it is yet unclear 
whether nsP3 hydrolyses these proteins in vivo.  
To date, the only paper that investigates the NFкB pathway in CHIKV infection 
showed that CHIKV decreased NFкB activation through increased expression of 
miR-146a, though the precise mechanism of the upregulation of this particular 
miRNA by CHIKV is unknown (Selvamani et al.,  2014). MicroRNA-146a is 
known to inhibit the NFкB pathway though a negative feedback loop. This miRNA 
is associated with many autoimmune diseases, including rheumatoid arthritis 
where it has also been detected in the synovial fluid patients (Xu et al., 2012). 
Though it is unclear how miRNA-146a contributes to inflammation in these 
diseases.  
Studies have shown that CHIKV infection can be detected by toll-like receptor 3 





neutralising antibody response (Her et al., 2015). TLR3 is capable inducing both 
the NFкB and IFN pathways upon detection of dsRNA (Jiang et al., 2004; 
Uematsu and Akira, 2007). 
VEEV has been shown to activate the NFкB pathway, and that IKKβ, a 
component of the IKK complex, enhances the replication of the virus, though the 
precise mechanism of this is unknown (Amaya et al., 2014). In RVFV, the IKK 
complex has also been shown to enhance viral replication and it is thought that 
the complex is modified in order to phosphorylate the non-structural proteins of 





5.1.1 Aims  
This chapter address two main aims. Firstly, due to the limited information in the 
literature, to further investigate the role of the NFкB pathway in CHIKV infection. 
Following this, we aimed to investigate whether the CHIKV nsP3 was able to 
disrupt or affect the NFкB pathway. Additionally, to determine whether 
interactions between the nsP3 macro domain and ADP-ribosylated components 






5.2.1 Part 1 – CHIKV infection and the NFкB pathway 
5.2.1.1 Optimisation of the NFкB dual-luciferase reporter system 
Initially, it was sought to confirm previous findings by Selvamani et al., 2014 that 
CHIKV did not activate the NFкB pathway using our infectious system. Therefore 
a two-plasmid reporter system was utilised, similar to that used by Selvamani et 
al., As shown in Figure 5.1 A: firstly, a Firefly luciferase under control of a NFкB-
sensitive promoter (referred herein by NFкB-Fluc) and a Renilla luciferase 
(RLuc) under control of a herpesvirus TK promoter as a transfection control 
(referred herein as pRL-TK), as described by Abdul-Sada et al., 2017.  
Initially, optimisation was required of the dual reporter system. A range of cell 
lines were selected for their suitability with this system but also, ideally, these 
cells would be relevant to the study of CHIKV. From chapter 3, BHK, C2C12 and 
Huh7 cells have all been shown to be suitable for their use with CHIKV infectious 
and replicon systems. In addition, A549 cells were selected as they have been 
used in previous studies on virus interactions with the innate immune system and 
are known to have an intact and robust immune response (Hartman, Black and 
Amalfitano, 2007; Devhare et al., 2013). These four cell lines were transfected 
with the two reporter plasmids for 16 h prior to activation with TNFα treatment, a 
well-defined activator of the NFкB pathway (Schütze et al., 1995), or mock 
treated, for 6 h then lysed and luciferase quantified using a dual-luciferase 
system. The Firefly signal, induced by activation of the NFкB pathway, was 
normalised to the Renilla signal from pRL-TK, which is constitutively expressed 
upon successful transfection.  
As shown by Figure 5.3, only the human cell lines; A549 and Huh7, responded 
to TNFα treatment. The remaining two cell lines, BHK and C2C12 (hamster and 
mouse cells respectively), failed to respond to treatment, producing very little 
Fluc signal, at the detection limit of the assay. These cell lines were therefore not 
considered for further experiments investigating the NFкB pathway.  
Others have shown that A549 cells were refractory to CHIKV infection and these 





3 (Sourisseau et al., 2007; Roberts et al., 2017). Therefore these cells were not 
used for experiments involving infectious CHIKV. Huh7 cells which have 
previous been determined to facilitate productive infection (chapter 3, Roberts et 
al., 2017) and supported the NFкB dual-reporter system, as shown in Figure 5.3,  
were selected for use in experiments to determine the relationship between 
CHIKV and the NFкB pathway.  
 
 
Figure 5.3 Optimisation of the NFкB-Fluc and pRL-TK reporter system. (A) 
Schematic of the NFкB-Fluc and pRL-TK plasmids. NFкB-Fluc 
contains a Firefly luciferase under the control of a NFкB sensitive 
promoter. The pRL-TK plasmid contains a Renilla luciferase under the 
control of the constitutive human thymidine kinase promoter. (B) A 
range of cell lines were transfected with the NFкB-Fluc and pRL-TK 
plasmids at a ratio of 9:1, incubated for 16 h then treated with TNFα 
(50 ng/mL) or mock treated for 6 h. Cells were lysed and luciferase 
signal quantified by dual luciferase assay. Data is presented as the 
Fluc signal (indicating NFкB activation) normalised to the Rluc signal 





5.2.1.2 CHIKV infection does not activate the NFкB pathway 
To assess whether CHIKV infection activates the NFкB pathway, Huh7 cells 
were transfected with the NFкB dual reporter plasmids 16 h prior to infection with 
CHIKV at an MOI of 5 or mock infection. As positive and negative controls, 
separate populations of cells were TNFα or mock treated. Cells were then lysed 
over at different times over a 24 h period and luciferase levels assayed using the 
dual-luciferase system.  
As shown in Figure 5.4 B, CHIKV infected cells did not show any increase in the 
levels of Fluc when compared to mock infected or mock treated cells. TNFα 
infected cells however, induced high levels of Fluc expression that was 
detectable by 6 hpt and continued to increase over the 24 h period. To confirm 
that the CHIKV infected cells were indeed infected, the corresponding cell 
lysates were used to perform a western blot for nsP3. As shown by Figure 5.4 
part C, CHIKV infected cells express nsP3 detectable from 8 hpi, and strongest 







Figure 5.4 CHIKV infection does not activate the NFкB pathway in Huh7 
cells. (A) Huh7 cells were transfected with the reporter plasmids 16 h 
prior to infection (MOI=5), mock infection, TNFα treatment (50 ng/mL) 
or mock treatment. Cells were lysed at indicated time points and 
luciferase signal assayed. Fluc signal is normalised to Rluc signal 
(n=3).  (B) Western blot for nsP3 in indicated cells, showing that nsP3 
(~58 kDa) was only present in CHIKV infected cells.  
 
To further confirm these results in a more physiological system, the subcellular 
localisation of NFкB was assessed in infected cells. When the pathway is active, 
NFкB translocates to the nucleus, a phenomenon that is easily detectable by 
immunofluorescence. Huh7 cells were therefore infected with CHIKV at an MOI 
of 5, or mock infected or TNFα treated as a positive control. Cells were fixed at 
24 hpi and stained for nsP3 and the NFкB subunit; p65. As shown in Figure 5.5, 
in agreement with the previous data, CHIKV infected cells (confirmed by positive 





similar appearance to that of mock infected cells. In contrast, TNFα treated cells 
showed a marked difference with a clear increase in nuclear p65, more so than 
either the infected or mock infected cells.  
 
 
Figure 5.5  NFкB does not translocate to the nucleus in CHIKV infected 
cells. Huh7 cells were infected with CHIKV (MOI=5), mock infected or 
TNFα treated (50 ng/mL), fixed at 24 hpi and stained for the NFкB 
subunit; p65 (green), and nsP3 (red). Nuclear p65 indicates activation 
of the NFкB pathway.  
 
It is clear from Figure 5.4 and Figure 5.5 that nuclear translocation of NFкB, one 
of the final stages of the NFкB pathway, does not occur in CHIKV infected cells. 
It was therefore investigated whether the IKK complex was active in CHIKV 
infected cells, as the complex has been implicated in VEEV and RVFV 
replication. Huh7 cells were infected, mock infected or TNFα treated, and cells 
were lysed over a 6 h time course. IKK complex activation was assessed by 
western blotting for phosphorylated NFкB (p105), one of the targets of the kinase 
complex when activated. As shown by Figure 5.6, upon TNFα treatment, 
phosphorylated p105 appears between 0-15 min post treatment and persists for 





phosphorylated p105 throughout the entire 6 h time course, much resembling 
the mock infected cells. It could be argued that there are extremely faint bands 
in the CHIKV-infected cells around 30 min post infection. This shows that the IKK 
complex is either not active (or extremely weakly active) in CHIKV infected cells.  
 
 
Figure 5.6 The IKK Complex is not active in CHIKV infected cells. Cells were 
either infected, mock infected or TNFα treated, then lysed over a 6 h 
time course. Western blotting was then performed for  phospho-p105 
(~105 kDa, 30 µg lysate/well). The presence of phospho-p105 indicates 
an active IKK complex. 
 
5.2.1.3 CHIKV infection cannot suppress an activated NFкB pathway 
It has been clearly demonstrated that CHIKV does not activate the NFкB pathway 
but it was unclear to what extent the virus could inhibit the pathway. Therefore, 
similar experiments to those shown in section 5.2.1.2 were performed but using 
TNFα treatment and CHIKV infection in combination to assess the ability of 
CHIKV to inhibit or reduce activation of the NFкB pathway.  
Huh7 cells were transfected with the same reporter plasmids as described in 
Figure 5.4 A, then at 16 hpt were infected or mock infected with CHIKV for 1 h 
prior to replacing the media with either complete media or media containing 
TNFα. Cells were lysed over a time course and luciferase assayed using the dual 
luciferase system. As shown in Figure 5.7 A, there was no significant difference 
in NFкB activation between cells that were TNFα treated regardless of whether 





exhibited similar levels of NFкB activation regardless of infection. To confirm 
CHIKV infection, western blots for nsP3 were performed to demonstrate 
expression in infected cells and not in any other conditions, as shown in Figure 
5.7 B.  
 
 
Figure 5.7 CHIKV cannot inhibit TNFα-induced NFкB activation. (A) Cells 
were transfected with the NFкB-Fluc and pRL-TK plasmids, incubated 
for 16 h then either infected with CHIKV (MOI=5) or mock infected for 
1 h then either TNFα treated (50 ng/mL) or mock treated. Cells were 
lysed over a 24 h period and luciferase assayed. Data shown as Fluc 
signal normalised to Rluc (n=3). (B) Western blot for nsP3 on 
corresponding cell lysates.  
 
 
These findings were then further confirmed by immunofluorescence. Cells were 
infected or mock infected with CHIKV at an MOI of 5 for 1 h then media was 
replaced with either media containing TNFα or normal media, cells were 





As shown by Figure 5.8, for mock treated cells, both infected and mock infected 
show exclusion of p65 from the nucleus. In the TNFα treated cells, regardless of 
infection, p65 was shown to have translocated to the nucleus, indicating that 




Figure 5.8 CHIKV cannot inhibit TNFα-induced NFкB activation (IF). Cells 
were infected or mock infected with CHIKV MOI=5 for 1 h, then media 
replaced with TNFα (50 ng/µL) or normal media. Cells were fixed at 12 
hpi and stained for nsP3 (green) and p65 (red). Nuclear localisation of 






5.2.1.4 NFкB activation reduces production of CHIKV in infected cells 
As it has been shown that CHIKV does not induce the NFкB pathway upon 
infection and that infection is not able to suppress the pathway if exogenously 
activated, we sought to determine the effects of an activated NFкB pathway upon 
production of CHIKV in infected cells. It was hypothesised that, if CHIKV is 
actively inhibiting the NFкB pathway it must be advantageous to do so, therefore 
activating the pathway in CHIKV infected cells may reduce virus production.  
To determine whether activation of NFкB would affect production of infectious 
CHIKV, cells were treated with TNFα at either 6 h prior to infection, at the time 
of infection, or 1 h post infection (as shown in the schematic Figure 5.9 A). 
Infections were performed at an MOI of 5. Supernatant was harvested at 24 hpi 
and titred by plaque assay.  
As shown in Figure 5.9, TNFα treatment of cells, regardless of time of application, 
reduced CHIKV titres at 24 hpi. However, this reduction was only significant 
when TNFα was applied at time of infection, or 1 h post infection. This indicates 
that CHIKV suppression of the NFкB pathway is required for efficient viral 
replication. It was confirmed that the pathway was activated at indicated times 
via IF of p65 on cells treated with TNFα parallel to the infection experiment. 
Activation of the NFкB pathway was identified via nuclear translocation of p65 as 






Figure 5.9 Activating the NFкB pathway reduces CHIKV titres. (A) A 
schematic representing the time scale of the experiment: Huh7 Cells 
were treated with TNFα either 6 h prior to infection, at the time of 
infection, or at 1 h post-infection. (B) Cells were infected with CHIKV 
at MOI=5. Supernatant was harvested at 1 h and 24 h for each sample 
and titred by plaque assay. Titres for 24 h were normalised to that of 
the 1 h samples. Data is presented as % of untreated cells (two 
separate experiments combined, each at n=2 data analysed by One-
way ANOVA with Bonferroni correction compared to wt, ns = P > 0.05, 
* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). (C) Cells were TNFα treated 
in parallel, fixed at 6 hpt and stained for p65 to confirm activation of 





5.2.2 Part 2 – CHIKV nsP3 inhibits the NFкB pathway  
5.2.2.1 Optimisation of nsP3 expression 
Now it has been confirmed that CHIKV infection does not activate the NFкB 
pathway, it was investigated whether nsP3 was specifically involved in inhibition 
of the pathway. To determine this, an expression construct of nsP3 was 
generated. As shown in Figure 5.10 part A, wt, untagged nsP3 was cloned into 
pcDNA3.1+. This was achieved by generating the coding sequence for nsP3 
flanked by a start and stop codons, and BamHI and NotI restriction sites via 
amplification by PCR. Resulting PCR fragments were then purified via ethanol 
precipitation and, along with the empty pcDNA3.1+ vector, subjected to 
restriction digest. Resulting DNA was then separated by agarose gel 
electrophoresis, the relevant bands extracted and ligated together.  
 
Figure 5.10 Optimisation of nsP3 expression in mammalian cells. (A) A 
schematic of the nsP3 expression vector with wt, untagged nsP3 in 
pcDNA3.1+, under the control of a CMV promoter. Herein referred to 
as pcDNA3.1+ nsP3 (B) A549 and Huh7 Cells were transfected with 
1 µg of pcDNA3.1+ nsP3 and cells were lysed at 16, 24 and 48 hpt and 
western blot performed for detection of nsP3.  
 
To assess the optimal cell line and transfection protocol to use for experiments 





plasmids as shown in Figure 5.3 in section 5.2.1.1, A549 and Huh7 cells were 
assessed for their expression levels of nsP3 when transfected with pcDNA3.1+ 
nsP3. Whilst both cell lines exhibited similar levels of nsP3 expression, as shown 
by the western blot in 
Figure 5.10 B, Huh7 cells appeared to have significant degradation of nsP3 
whereas A549 cells had very little degradation. Therefore, for the following 
experiments assessing the effects of nsP3 expression on the NFкB pathway, 
A549 cells were used.  For A549 cells, the optimal time for nsP3 expression was 
at 16 hpt, therefore for following experiments, cells were transfected and 
incubated for 16 h prior to downstream applications.  
5.2.2.2 nsP3 expression inhibits NFкB activation  
To assess whether nsP3 could inhibit the NFкB pathway, A549 cells were 
transfected with the NFкB reporter plasmids and co-transfected with an 
expression vector with either wt or D10A mutant nsP3 (a construct generated 
using the same protocol as wt as described in 5.2.2.1) or empty vector as a 
negative control. At 16 hpt, cells were treated with TNFα or mock treated. Cells 
were lysed at 6 h post-TNFα treatment and luciferase assayed via the dual 
luciferase system. As shown by Figure 5.11 A, expression of wt nsP3 significantly 
reduced NFкB activation in activated cells. Reduction was also seen at a basal 
level (in mock treated cells) though this was not statistically significant. In 
contrast, mutant D10A nsP3 behaved similarly to the empty vector control with 
no significant difference in NFкB activation between the two. 
Despite this assay providing highly reproducible results (Figure 5.11 A is a result 
of three separate experiments), detection of protein expression in these 
experiments was difficult and inconsistent. As shown by Figure 5.11 B, when 
attempting to confirm nsP3 expression in these cell lysates by western blotting, 
often none, or very little could be detected when compared to a positive nsP3 
control (in this case, an infected cell lysate). It has been previously shown that 
nsP3 is an unstable protein with high turnover, possibly the extended time of the 
experiment or the presence of additional plasmids was limiting expression or 
increasing degradation of nsP3. It was therefore decided to tag nsP3 to increase 






Figure 5.11 wt nsP3 reduces NFкB activation but expression is unstable. 
(A) A549 cells were transfected with the NFкB-Fluc and pRL-TK 
plasmids and co-transfected with either pcDNA3.1+ nsP3 wt or D10A 
or empty pcDNA3.1+ vector. Cells were then TNFα treated (50 ng/mL, 
activated) or mock treated, prior to lysis at 6 hpt and luciferase levels 
assayed (two separate repeats combined, each repeat n=3, data 
analysed by One-way ANOVA with Kruskal-Wallis test and Dunns’ 
correction compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01). (B) 
Western blot for nsP3 in transfected cells (30 µg/well). In these 
experiments, it was challenging to demonstrate consistent nsP3 





The first tag used in an attempt to stabilise and better detect nsP3 was ZsGreen. 
This tag has been used previously in both the CHIKV replicon, and infectious 
virus with ZsGreen cloned into the engineered SpeI site within the HVD of nsP3 
(Pohjala et al., 2011) and is well tolerated in both replicon and virus as shown by 
Remenyi et al., 2018. An expression construct was generated using the same 
method as described in 5.2.2.1 but with the nsP3-ZsGreen virus template in order 
to generate a coding sequence of nsP3-ZsGreen that was digested and ligated 
into the pcDNA3.1+ vector, a schematic of which is shown in Figure 5.12 A. 
Previous work demonstrated that the presence of the ZsGreen tag within nsP3 
had little effect on virus replication (Remenyi et al., 2018). To ensure that the 
ZsGreen tag did not exhibit any significant differences in the behaviour of nsP3 
when expressed in isolation, the newly formed nsP3-ZsGreen construct was 
transfected into cells, alongside expression constructs of ZsGreen alone and the 
empty vector as controls and  the subcellular localisation assessed by confocal 
microscopy. As shown by Figure 5.12 B, the cellular localisation of the nsP3-
ZsGreen resembled the defined, cytoplasmic punctate appearance of the nsP3 
shown previously in both replicon and virus (chapter 3). It was therefore 
concluded that the addition of the ZsGreen tag in nsP3 did not significantly alter 






Figure 5.12 An addition of the ZsGreen tag does not affect the cellular 
localisation of nsP3. (A) A schematic of the ZsGreen tagged nsP3, 
where ZsGreen is present within the C-terminal HVD of nsP3. (B) 
Confocal images of A549 cells transfected with an expression vector 
of either nsP3-ZsGreen, ZsGreen alone or empty vector, cells were 
fixed and DAPI-stained 16 hpt and imaged via the LSM700 confocal 
microscope.  
 
This construct was therefore used in further experiments. As shown in Figure 
5.13 A and C, successful expression of the nsP3-ZsGreen constructs was easily 
detectable by wide field fluorescence microscopy and western blot. However, 
when used in the NFкB reporter plasmid system, the levels of activation had 
changed from the previous experiment using the untagged nsP3 expression 
constructs in Figure 5.11. As shown by Figure 5.13 B, the mutant D10A nsP3 
exhibited some reduction in NFкB activation in activated cells, and significant 
reduction of activation at the basal level in mock treated cells.  
When performing IF to assess the sub-cellular localisation of p65 it became 
apparent why the results for the ZsGreen tagged nsP3 constructs (shown in 
Figure 5.13) differed from those seen previously. As shown in Figure 5.14, when 
activating cells with TNFα, in the ZsGreen-transfected cells (which should be 
acting as the negative control), p65 remains cytoplasmic when it should 





Indicating that ZsGreen alone is capable of inhibiting p65 nuclear translocation 







Figure 5.13 Tagging of nsP3 with ZsGreen improved stability, and the 
detection of the protein. (A) Wide-field fluorescence microscopy of 
A549 cells transfected with pcDNA3.1+ nsP3 wt, D10A or empty 
vector, alongside the NFкB reporter plasmids, imaged 16 hpt, prior to 
activation. (B) Cells were then TNFα treated (50 ng/mL, activated) or 
mock treated, prior to lysis at 6 hpt and luciferase levels assayed 
(2 separate repeats combined, each repeat n=3, data analysed by One-
way ANOVA with Kruskal-Wallis test and Dunns’ correction compared 
to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01). (C) Western blot for 







Figure 5.14 Immunofluorescence of p65 with ZsGreen-tagged constructs. 
Cells were transfected with pcDNA3.1+ either empty vector, nsP3-
ZsGreen or ZsGreen alone. At 16 hpt, cells were TNFα treated (A) or 
mock treated (B) for 6 h prior to fixation and immunofluorescence for 







Due to the unsuitability of the ZsGreen tag, it was then considered to use a Flag 
tag at the C terminal end of nsP3. A Flag tag was suggested due to its short size 
(8 aa and  ~1 kDa) so would be unlikely to affect the function of nsP3 or interfere 
with cellular pathways.  
Prior to using the nsP3-Flag (referred to herein as nsP3-F) construct in 
experiments, firstly it was important to check that the properties of nsP3-F did 
not differ to untagged, wt nsP3. Therefore, the nsP3-F and untagged nsP3 
expression constructs were transfected into cells alongside the NFкB reporter 
plasmids, and cells were activated or mock activated as before. As shown in 
Figure 5.15 A, the behaviour of the Flag-tagged nsP3 protein was similar to that 
of the untagged nsP3 (when compared to cells transfected with empty vector) 
and there was no significant difference between nsP3 and nsP3-F. It was also 
confirmed that the nsP3-F was detectable via western blotting. Figure 5.15 B 
demonstrates that cells transfected with nsP3-F expressed the protein which was 







Figure 5.15 Optimisation of the nsP3-F construct for use in NFкB 
experiments. (A) Cells were transfected with the NFкB-Fluc and 
pRL-TK plasmids and co-transfected with either empty pcDNA3.1+ 
vector or the vector expressing nsP3 (untagged) or nsP3-F. Cells were 
then TNFα or mock treated for 6 h prior to lysis and luciferase 
quantified. (n=3, data analysed by One-way ANOVA with Kruskal-
Wallis test and Dunns’ correction compared to wt, ns = P > 0.05, * = P 
≤ 0.05, ** = P ≤ 0.01). (B) Western blot for nsP3-F (59 kDa) using both 






Now that a suitable tagged expression construct had been generated and 
validated, it was then put into the experimental system. Additionally, two controls, 
alongside the empty vector control, were used as indicated in Figure 5.16 A. 
Firstly, a pcDNA3.1+ GFP construct as a negative control to ensure that excess 
protein expression was not inducing the observed results. GFP expression has 
been successfully used as a negative control in experiments assessing inhibition 
of the NFкB in the literature (Ember et al., 2012). Secondly, a pcDNA4 construct 
expressing B14, a vaccina virus protein that is a well characterised inhibitor of 
the NFкB pathway where it has been shown to bind to IKKβ and inhibit the 
formation of a functional IKK complex (Chen et al., 2008). In this expression 
construct, B14 was tagged at the N-terminus with a Flag tag (herein referred to 
as F-B14) and was used as a positive control.  
As in the previous experiments, empty vector, nsP3-F, GFP and F-B14 
expression constructs were transfected into cells, alongside the NFкB dual 
reporter plasmids. Cells were incubated for 16h then treated or mock treated with 
TNFα and lysed at 6 h post treatment. As shown in Figure 5.16 B, when cells are 
activated by TNFα, nsP3-F inhibits the NFкB pathway to the same extent as the 
known inhibitor F-B14. For the inhibition of basal levels, (as indicated by the 
mock treated cells), nsP3-F  does significantly reduce activation when compared 
to empty vector but not quite to the same level of inhibition that F-B14 is capable 
of. The expression of GFP did not induce any significant differences in NFкB 
activation, when compared to empty vector, for the treated or mock treated cells. 
Protein expression for nsP3-F and F-B14 were confirmed by western blotting as 
shown in Figure 5.16. Unfortunately, it was not possible to detect GFP on a 
western blot so wide-field fluorescent images were taken to confirm GFP 
expression (Figure 5.16 D). 
IF was then utilised to determine the sub-cellular localisation of p65 in nsP3-F 
expressing cells. Cells were again transfected with the relevant constructs, 
incubated for 16 h prior to treatment with TNFα or mock treated. Cells were fixed 
at 6 hpt and stained for p65. Additionally, all cells, except GFP-expressing cells, 
were additionally stained for nsP3. As is expected, Figure 5.17 B shows that, for 
all cells, when mock treated, p65 is predominantly cytoplasmic. When treated 





vector or GFP-expressing cells, p65 becomes nuclear indicating an active NFкB 
pathway. In cells that are clearly expressing nsP3-F, p65 is restricted from the 
nucleus, remaining mostly cytoplasmic. This indicates that the expression of 
nsP3-F in cells prevents nuclear translocation of NFкB therefore inhibiting the 






Figure 5.16 nsP3-F inhibits the NFкB pathway. (A) A schematic of the 
expression constructs used in this experiment. (B) Cells were 
transfected with the NFкB-Fluc and pRL-TK plasmids and 
co-transfected with expression constructs for GFP, nsP3-F, F-B14 or 
empty vector. At 16 hpt cells were TNFα or mock treated for 6 h prior 
to lysis and luciferase quantified. (Two experiments combined, each 
n=3, data analysed by One-way ANOVA with Bonferroni correction 
compared to wt, ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
**** = P ≤ 0.0001). (C) Western blot for nsP3-F (59 kDa) and F-B14 (15 
kDa). (D) Wide field fluorescent microscopy images of GFP-






Figure 5.17 The expression of nsP3-F inhibits nuclear translocation of p65. 
A549 cells were transfected with either nsP3-F, GFP or empty vector 
expression constructs. At 16 hpt, cells were TNFα (A) or mock treated 
(B) for 6 h prior to fixation and staining for p65 (red). Cells were co-
stained for nsP3 (shown in green/488), except GFP expressing cells.  
 
Quantification was performed on the TNFα samples shown in Figure 5.17 by 
imaging via tile scans (see Figure 5.18 A) and manually counting nsP3 or GFP 
positive and negative cells with nuclear p65. As shown by Figure 5.18 B, of the 
cells expressing GFP, approximately 75% had nuclear p65, only a slight 





approximately 20% of the nsP3 expressing cells contained nuclear p65, a 
reduction of approximately 50% from the nsP3-negative cells.  
 
Figure 5.18 Quantification of nuclear p65 in TNFα treated, nsP3-F and GFP 
expressing cells. (A) An example tile scan of cells stained for nsP3 
and p65. (B) The number of cells with nuclear p65 was quantified 
manually for both cells that were positively expressing nsP3/GFP, or 
that were negative for protein expression from the same sample. Data 
shown is percentage of cells with nuclear p65 from total cells counted 
for each condition. Cells counted for each conditions were 51, 55, 26 





5.2.2.3 The macro domain is partly responsible for the anti-NFкB 
activity of nsP3 
To determine whether inhibition of the NFкB pathway by nsP3 involved the macro 
domain, initially it was attempted to generate an expression construct for the 
macro domain and a Flag-tagged macro domain. As shown in Figure 5.19, 
neither the macro domain or Flag tagged macro domain expression constructs 
produced detectable expression of the macro domain.  
 
Figure 5.19 Western blot to test macro domain expression. A549 cells were 
transfected with either empty vector, or expression constructs of 
F-B14, nsP3-F, macro domain or macro domain-Flag (both approx. 
15 kDa) for 16 h prior to lysis and western blot performed in order to 
detect macro domain expression. Both anti-Flag and anti-nsP3 
primary antibodies were used.  
 
As it was not feasible to express the macro domain to determine whether it was 
capable of inhibiting the NFкB pathway, the macro domain mutants (as defined 
in chapter 4), were employed instead. Flag-tagged nsP3 constructs with each 
individual mutation were generated as described previously in 5.2.2.1, and used, 
alongside the wt nsP3-F construct, with  the NFкB reporter plasmid system as 
before. As shown in Figure 5.20, all the mutants were successfully expressed in 
transfected cells and produced a range of NFкB inhibition phenotypes. Upon 





significantly reduced NFкB activation when compared to the empty vector 
negative control. In the mock transfected cells, representing basal levels of NFкB 
activation (Figure 5.20 B), all mutants were capable of significantly reducing the 
activation levels except D10A, G112A and Y114A. These results indicate that 






Figure 5.20 nsP3 macro domain mutants exhibit a wide range of inhibitory 
effects on the NFкB pathway. A549 cells were transfected with the 
nsP3-F wt and mutant expression constructs alongside F-B14, GFP 
and empty vector controls. At 16 hpt, cells were TNFα activated (A) or 
mock treated (B) then lysed at 6 h post treatment and luciferase 
assayed. (n=3, data analysed by One-way ANOVA with Bonferroni 
correction compared to empty vector, ns = P > 0.05, * = P ≤ 0.05, ** = P 
≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001 ) (C) Confirmation of protein 
expression by western blotting for nsP3 and Flag tag (for F-B14) on 





When comparing this data to the known biochemical properties of the CHIKV 
nsP3 macro domain (McPherson et al., 2017), as shown in Table 5.1, there is a 
correlation between the ability of the mutant nsP3s to inhibit the NFкB pathway 
and the ability to bind ADPR. Specifically, D10A, T111A and G112A exhibited 
the least inhibition of the pathway and are the three mutants with the lowest 
affinity for ADPR, with D10A and G112A having no detectable binding and T111A 
demonstrating far less affinity to ADPR than the wt or any other mutant. There is 
little correlation between NFкB inhibition and the hydrolase activity of the 
mutants. For example, V113A, the only mutant able to significantly inhibit the 
NFкB pathway when activated, has stronger ADPR binding than wt but only 15% 
hydrolase activity of wt. This data indicates that ADPR affinity, and not hydrolase 
activity, may be crucial for the role of the nsP3 macro domain in its ability to 
inhibit the NFкB pathway.  
Table 5.1 Comparison of the macro domain mutants inhibition of the NFкB 
pathway to their biochemical properties. *Data from McPherson et al. 
2017, **V113R was used in this study instead of V113A. Colours 
denote comparison to wt. (Light green = approximately wt, dark green 
= above wt, yellow = below wt, and red = less than 30% wt).  
 
Again, IF was performed to corroborate the luciferase data. The wt and mutant 
nsP3-F expression constructs and the empty vector control were transfected into 
cells, incubated 16 h then treated with TNFα. After 6 h, cells were fixed and 
stained for p65 and nsP3. The IF data (Figure 5.21) generally agrees with the 
luciferase data. Both wt and V113A nsP3 are shown to exclude p65 from the 
nucleus of cells. For T111A and Y114A nsP3 the distribution of p65 resembles 
the highly nuclear distribution shown by the empty vector control. For all other 
mutants; D10A, G32A and G112A, there is some reduction in p65 in the nucleus 
 nsP3 mutants Controls 




Inhibition of NFкB 
pathway (%) 
49.2 6.3 24.7 -24.7 0.4 34.1 26.8 40.6 0 3 
ADPR k
D 
(µM)* 22.9 NDB 21.0 71.4 NDB 6.46** 4.84 N/A N/A N/A 
Hydrolase activity 
(% wt)* 





when comparing to the empty vector control, though it is not as distinct as the 
nuclear exclusion exhibited in the wt nsP3-expressing cells. Interestingly for 
many of these three mutants, there appears to be a concentration of p65 in the 
perinuclear region which may indicate translocation is being inhibited at, or near 






Figure 5.21 IF of p65 in nsP3 wt and mutant expressing cells. A549 cells 
were transfected with nsP3-F expression vector for wt or mutant nsP3 
or empty vector as a negative control. At 16 hpt, cells were TNFα 
treated for 6 h prior to fixation and staining for p65 (shown in green) 





5.2.2.4 Elucidating the stage of nsP3-mediated inhibition of the NFкB 
pathway 
Here, it has been shown that the macro domain of nsP3 is capable of inhibiting 
the NFкB pathway and that nsP3 expression prevents the nuclear translocation 
of NFкB to the nucleus. However, it is still unclear at which stage of the NFкB 
pathway CHIKV nsP3 functions. Therefore it was investigated whether the IKK 
complex, central to the NFкB pathway, was active in nsP3 expressing cells. This 
would determine whether the inhibition was occurring before/at or after the IKK 
complex in the pathway. Again, cells were transfected with the nsP3-F, F-B14 
and GFP expressing constructs as well as empty vector. Cells were then 
activated with TNFα and lysed over a short time course. Western blots were then 
performed to detect phosphorylated p105, the presence of which indicates that 
the IKK complex is active. Once the IKK complex is active, the phosphorylation 
of p105 occurs rapidly but is short lived as p105 then translocates to the nucleus 
to act as a transcription factor. As shown in Figure 5.22, cells transfected with 
empty vector, once activated, exhibit phospho-p105 at 5 min-post activation 
which persists for 25-30 min. This is mirrored by the GFP negative control. In the 
presence of B14 however, there is a delay in the phosphorylation of p105, with 
first detection being at 15 min post-treatment, and with weaker signal than either 
the empty vector or GFP negative controls. This is as expected as B14 directly 
inhibits the IKK complex through an interaction with IKKβ (Chen et al., 2008). 
Cells expressing nsP3 appeared to exhibit similar levels of expression with 
phospho-p105 appearing at similar time points and both the GFP and empty 
vector controls. This implies that nsP3 inhibition of the NFкB pathway occurs 











Figure 5.22 The IKK complex is active in nsP3-F expressing cells. A549 
cells were transfected with an expression construct for nsP3-F, F-B14, 
GFP or empty vector. Cells were incubated for 16 h then activated with 
TNFα. Cells were lysed at 5 minute intervals over a 30 min period and 
western blotting was performed for the detection of phosphor-p105. 
The presence of phospho-p105 indicates an active IKK complex.  
 
It was also investigated whether CHIKV nsP3 co-localised with either NEMO or 
ARTD10. Unfortunately, through various different methods and attempts at 
optimisation, it was not possible to visualise NEMO through 
immunofluorescence. However it was possible to detect ARTD10 though this 
method. Cells were therefore infected with CHIKV and fixed over a 24 h time 
course and stained for both nsP3 and ARTD10. As shown by Figure 5.23, nsP3 
was only detected after 8 hpi. At this point, and at the later time of 24 hpi, co-
localisation of nsP3 with ARTD10 was observed. Though many cells within the 
sample exhibited co-localisation, it must be noted that it was not observed in all 
infected cells. Also, in cells that did exhibit co-localisation of ARTD10 with nsP3, 






Figure 5.23 Immunofluorescence for ARTD10 and nsP3. Huh7 cells were 
infected with CHIKV at MOI=10. Cells were fixed over a 24 h period and 
stained for ARTD10 (green) and nsP3 (red). Detectable levels of nsP3 










5.3.1 The NFкB pathway in CHIKV infection  
CHIKV is known to induce a highly inflammatory environment in infected cells. In 
particular, it has been well defined that CHIKV infected cells produce a robust 
IFN response and that this response is critical for survival from infection (Her et 
al., 2010; Priya et al., 2014; Nair et al., 2017). Inhibition of the IFN pathway can 
enhance CHIKV replication. CHIKV is capable of inhibition of the IFN pathway, 
to some extent, via nsP2 which is able to promoting the nuclear export of STAT1, 
therefore reducing JAK-STAT signalling (Wichit et al., 2017; Göertz et al., 2018).  
Only one publication to date has examined the role of NFкB in CHIKV infection. 
Selvamani et al. demonstrated that CHIKV did not activate the NFкB pathway 
and linked this lack of activation with overexpression of microRNA-146a. 
However, the mechanism of how CHIKV induced upregulation of this miRNA was 
not elucidated. This chapter therefore aimed to reiterate these findings and 
investigate whether the nsP3 macro domain played a role in the disruption of the 
NFкB pathway.  
5.3.1.1 CHIKV infection does not activate the NFкB pathway 
Prior to investigating any potential roles nsP3 may have in subverting the NFкB 
pathway, firstly the relationship between the NFкB pathway and CHIKV was 
investigated. In agreement with Selvamani et al, here it was demonstrated that 
CHIKV does not induce an NFкB response in infected cells. This was confirmed 
by both luciferase assay, using NFкB reporter plasmids, and by IF of the NFкB 
subunit p65 in infected cells. In both these data, it was shown that CHIKV 
infection does not induce the activation of the NFкB pathway.  
It was further sought to determine whether the IKK complex, the central 
component of the NFкB pathway, was active in CHIKV infected cells. This was 
assessed by western blot of phosphorylated-p105. The IKK complex 
phosphorylates NFкB (p105) rapidly after activation. Here, the CHIKV infected 
cells resembled the mock-infected cells with little phospho-p105 being detected. 
This indicates that the NFкB pathway is either not being activated, or, potentially, 





5.3.1.2 CHIKV cannot inhibit an exogenously activated NFкB pathway 
As it had been established that CHIKV does not activate the NFкB pathway, it 
was sought to determine whether CHIKV could inhibit an activated NFкB 
pathway. Through luciferase assay with the NFкB reporter plasmids, it was 
shown that CHIKV infection could not inhibit the NFкB pathway once activated 
exogenously via TNFα. This was further confirmed by IF of p65 where CHIKV 
infected, TNFα treated cells contained nuclear p65, much like the TNFα-treated, 
mock-infected cells. This indicates that whilst CHIKV does not induce an NFкB 
response in infected cells, its potentially inhibitory activity is not sufficient enough 
to overcome the NFкB pathway once activated by external stimuli.  
5.3.1.2.1 CHIKV production is reduced when cells are TNFα treated 
Since CHIKV infection does not induce the NFкB pathway, nor is the virus 
capable of inhibiting an activated pathway, what effect an active pathway would 
have on CHIKV replication was investigated. A time of addition study using TNFα 
showed that, regardless of time of stimulation, CHIKV titres were reduced when 
titred at 24 hpi. However, this reduction was only significant with cells treated 
either at the time of infection, or 1 h post infection. It is not immediately obvious 
why treatment with TNFα significantly reduced CHIKV production when cells 
were treated at or 1 h post infection, but not at 6 h prior to infection. This could 
suggest that CHIKV is better able to disrupt the pathway once later stages of the 
pathway have been reached, but is not able to establish infection during the early 
stages of the pathway being stimulated. Alternatively, presence of CHIKV 
proteins or RNA at the time of TNFα treatment could be inducing an innate 
response better tailed to counter CHIKV infection. As shown in the schematic of 
the NFкB pathway (Figure 5.1), TNFα is detected via a cell surface receptor, 
whereas RNA viruses, such as CHIKV are mostly detected through dsRNA 
sensing in endosomes and the cytoplasm (Jensen and Thomsen, 2012). These 
different mechanisms of detection result in the triggering of different pathways to 
ultimately activate the IKK complex and trigger the NFкB pathway. Due to a 
complex variety of interactions with other pathways, the different routes of the 
pathway induced by different stimuli produce altered inflammatory responses 





2010). It therefore may be that, the TNFα stimulus in combination with the 
presence of the virus in early stages of replication may alter the pathway and 
therefore tailor the response to be more effective against CHIKV. In contrast, 
when cells are pre-treated, by the time of CHIKV infection they have only been 
exposed to TNFα for a substantial amount of time. Therefore these cells have a 
fully activated NFкB pathway, though, since this inflammatory state was formed 
in the absence of any virus, may be less specifically anti-viral and therefore allow 
more replication once infected than the cells treated with TNFα in combination 
with early stages of replication.  
5.3.2 nsP3 inhibits the NFкB pathway  
Once it had been established that CHIKV does not activate the NFкB pathway 
and that an activated pathway reduces viral replication, the potential role of nsP3 
as an inhibitor of the NFкB pathway was investigated. It was therefore necessary 
to engineer an appropriate expression construct for nsP3. Initially, wt, untagged 
nsP3 was engineered into a mammalian expression vector. Despite producing 
encouraging results where it was shown that cells transfected with the wt nsP3 
expression construct had consistently reduced NFкB activation in the luciferase 
assay system, it was challenging to consistently detect expression of nsP3, both 
wt and mutant, in these cells via western blot. In the literature, it has been shown 
that nsP3, and in particular, full length nsP3 is particularly unstable and is quickly 
degraded in cells (Varjak et al., 2010). It was therefore decided that using a 
tagged nsP3 may increase stability and detection of the protein.  
There is a variety of different protein tags in the literature each with their 
advantages and disadvantages. There are a wide range of fluorescent tags 
which are advantageous as they allow easy detection of the tagged protein via 
fluorescence microscopy. However these tags do tend to be quite large and 
therefore may affect protein folding or function, so care must be taken over 
selecting an appropriate tag and ensuring the resulting expressed protein is not 
affected by the tag (Thorn, 2017).  
Initially, a ZsGreen tag was adopted and placed in the HVD of the nsP3 
expression construct. The use of ZsGreen, a 26 kDa protein isolated from 





be more stable and less toxic to cells than the conventional EGFP (Matz et al., 
1999). This tag was chosen as it has been used in replicon and infectious CHIKV 
systems with no apparent adverse effects on CHIKV replication (Remenyi et al., 
2018). It also allowed for checking successful transfection before proceeding 
with the experiments, as cells could be quickly checked under a fluorescent 
microscope to observe nsP3-ZsGreen expression. Additionally, it improved 
detection of nsP3 via western blot. It may be that the addition of a large, stable 
tag was able to limit degradation of the protein.  However, when repeating the 
luciferase assay with the tagged versions of nsP3, both wt and mutant, different 
results were produced. Unlike in experiments using untagged nsP3, 
ZsGreen-tagged D10A nsP3 exhibited some inhibition of the NFкB pathway, 
though this was not as strong an inhibition as wt nsP3. When using the ZsGreen 
constructs to analyse the sub-cellular localisation of p65, it became apparent that 
the expression of ZsGreen alone was able to block nuclear translocation of p65. 
Therefore the expression of ZsGreen in cells results in inhibition the NFкB 
pathway, and explains the difference seen in the luciferase data between the 
untagged and ZsGreen-tagged nsP3 expression. ZsGreen was therefore 
considered an unsuitable control for these experiments and a different tagging 
strategy was required. 
The next attempt at tagging nsP3 was using a Flag tag. A Flag tag is an artificial 
protein tag, specifically designed to be as small as possible whilst being large 
enough to be a specific epitope for a monoclonal antibody (Hopp et al., 1988). A 
Flag tag is the protein sequence DYKDDDDK, which is recognised by a highly 
specific monoclonal antibody termed M1. It is a hydrophilic tag that has shown 
to be less likely to denature the protein it is fused to. Use of a Flag tag to tag 
nsP3 would also be consistent with the B14 positive control which is Flag tagged 
at the N terminus. The Flag tag was therefore engineered at the C terminal end 
of nsP3. Prior to conducting any further experiments, it was firstly assessed 
whether the Flag tag helped stabilise and detect nsP3 by western blot and, more 
importantly, whether the tagged nsP3 behaved in a similar way to untagged 
nsP3. Therefore, the nsP3-F expression construct was compared to the nsP3-
untagged construct in the context of the NFкB reporter plasmid system. 





flag-tagged nsP3 in terms of their effects of the NFкB pathway. The addition of 
the Flag tag to the C-terminus of nsP3 enhanced stability and detection of the 
protein as nsP3 could be clearly be detected via western blot, using the anti-
nsP3 antibody. The tagged protein could also be detected using the anti-Flag 
antibody but to a lesser extent. This reduction could potentially be due to the anti-
Flag antibody being monoclonal and, since nsP3-F only contains a single flag 
tag at the C terminus, it would have fewer epitopes to detect per nsP3-F 
molecule. The stronger signal produced by the nsP3 antibody is likely to be due 
to it being polyclonal and therefore able to bind multiple epitopes per protein 
molecule. Therefore the anti-nsP3 antibody was used to detect nsP3-F for further 
experiments.  
5.3.2.1 Expression of nsP3-F inhibits the NFкB pathway 
The nsP3-F construct was then used in experiments to determine nsP3 inhibition 
of the NFкB pathway. By this point in the project, a positive control had been 
acquired – a Flag-tagged B14 expression construct (F-B14, kindly provided by 
Geoffrey Smith, as described in Chen et al., 2008). B14 is a vaccinia protein that 
is a well characterised inhibitor of the NFкB pathway. B14 is able to bind to, and 
inhibit, IKKβ; a key component of the IKK complex. In addition, another negative 
control was also engineered; pcDNA3.1+ GFP to ensure that excessive protein 
expression was not the cause of the inhibitory effect on the NFкB pathway 
observed for nsP3 expression. The nsP3-F alongside the empty vector, GFP and 
F-B14 controls were used in the NFкB reporter system as before. The GFP 
negative control behaved in a similar manner as the empty vector, showing its 
suitability as a negative control, unlike with ZsGreen. The F-B14 positive control 
exhibited an inhibitory effect for both conditions as expected. The expression of 
nsP3-F also inhibited the NFкB pathway under both stimulated and basal 
conditions. The nsP3-F construct was able to inhibit the NFкB pathway to similar 
levels as F-B14. Protein expression of F-B14 and nsP3-F were confirmed by 
western blot. Unfortunately it was not possible to detect GFP via western blot 
with the reagents available, therefore GFP expression was confirmed by 
fluorescence microscopy instead. This data shows, for the first time, that nsP3 is 
significantly inhibiting the NFкB pathway, and the expression of nsP3 was 





Similarly to previously experiments, immunofluorescence of p65 in 
protein-expressing cells was performed to confirm the findings of the luciferase 
assay. In agreement with the luciferase data and previous experiments, in cells 
expressing nsP3, when stimulated, p65 remained cytoplasmic. This indicates 
that the presence of  nsP3 in cells is able to prevent the translocation of NFкB to 
the nucleus and therefore inhibit activation of the NFкB pathway. This was further 
confirmed by imaging the samples via tile scan and performing quantification. In 
nsP3 expressing cells, approximately 20% exhibited nuclear p65 whereas for 
GFP expressing cells, nuclear p65 was observed in over 70% of cells. This 
further clarifies that the restriction of nuclear translocation of p65 by nsP3 is not 
an uncommon occurrence.   
5.3.2.2 The macro domain of nsP3 contributes to NFкB inhibition 
It was then sought to determine whether the macro domain of nsP3 had a role in 
the inhibition of the NFкB pathway. The initial untagged-nsP3 expression 
experiment indicated that wt nsP3 could prevent activation of the NFкB pathway 
whereas the mutant D10A could not. This indicated that the macro domain may 
be important in this inhibition. Though many attempts were made, it was not 
possible to express either the macro domain by itself or a Flag-tagged macro 
domain. This may be due to degradation as macro domains are often parts of 
much larger, multi-domain proteins (Li et al., 2013). In the case of CHIKV nsP3, 
the macro domain is the N-terminal domain, with two further domains 
downstream which are likely to improve stability. Therefore, expression of the 
macro domain was abandoned and a different approach used. The six macro 
domain mutants as described in chapter 4 were engineered in the nsP3-Flag 
expression construct and similarly to previous experiment, the NFкB luciferase 
reporter assay was performed. Reassuringly, in this experiment, the flag tagged 
D10A mutant behaved in a similar manner to the previous experiments that used 
untagged nsP3 expression constructs. Again confirming the that the Flag tag was 
not disrupting nsP3 functions. When activated by TNFα, two mutants significantly 
reduced activation: V113A and Y114A. In contrast, in the mock treated cells 
(indicating basal levels of NFкB activation) all mutants except D10A, G112A and 
Y114A demonstrated a significant reduction in activation of the pathway. This 





when activated, though when not activated, most mutants were able to induce 
some reduction of the pathway. This indicates that a TNFα-activated pathway is 
effective in overcoming the actions of mutated nsP3 in terms of its inhibition of 
the innate immune system. Though when the pathway is inactive, even mutated 
nsP3 can exert some effects. This may indicate that the interaction required for 
inhibition is weaker for the nsP3 mutants compared to wt and is therefore easier 
for the innate immune system of the cells to overcome when the pathway is 
activated by external stimuli. It is surprising that Y114A significantly reduced the 
pathway when externally activated, but not at basal levels. However, given the 
large error bars for the Y114A samples at basal levels, this implies there may 
have been an outlier in the data. Due to time constraints, this experiment was 
only performed once at n=3. Ideally more repeats of this experiment would have 
been performed to confirm the outcomes.  
When comparing the biochemical properties of the macro domain mutants, 
(previously published by McPherson et al., 2017) to their ability to inhibit the 
NFкB pathway, there is some indication of what may be responsible for the 
inhibitory effect. The hydrolase activity of the mutants, has little correlation with 
NFкB inhibition. There is, however, some correlation with the macro domain 
mutants ability to bind ADPR. Mutants D10A, T111A and G112A were the least 
inhibitory of the NFкB pathway when activated and were the three mutants with 
no, or extremely low affinity for ADPR. This implies that, in agreement with the 
original hypothesis, ADPR binding is responsible for the macro domain mediated 
inhibition of the NFKB pathway, possibly via binding an ADP-ribosylated 
component of the pathway. However, not all the mutants correlated so well. Both 
G32A, which had similar ADPR affinity to wt, and Y114A, which had a much 
higher affinity than wt, only mildly inhibited the NFкB pathway, with the inhibition 
by Y114A not being significant. This may indicate that ADPR binding is only one 
aspect of the method of inhibition.  
5.3.2.3 Investigating the stage of the NFкB pathway where nsP3 is 
enacting its inhibitory function 
Now it has been well established that nsP3 is able to inhibit the NFкB pathway 





responsible for, it was sought to determine at what stage in the pathway nsP3 
exerted its inhibitory affects. It was originally hypothesised that nsP3 could 
interact with the NFкB pathway through either ARTD10 or NEMO – both of which 
are ADP-ribosylated, and are involved in the central IKK step of the pathway. It 
therefore seemed logical to investigate whether the active complex could form in 
nsP3–expressing cells. This was assessed by western blotting for phosphor-
p105 where the IKK complex appears as active in nsP3-expressing cells as it is 
in the GFP-expressing and empty vector-transfected cells. In contrast, F-B14 
expressing cells have a delayed, muted response which was expected due to its 
direct inhibitory effect on the complex. This demonstrated that nsP3 is inhibiting 
the pathway at some point after IKK activation but before nuclear translocation 
of p65. Though this narrows down the part of the pathway of which nsP3 is 
causing inhibition, it does not necessarily confirm a lack of interaction with either 
ARTD10 or NEMO. Unfortunately, it was not possible using available reagents 
to visualise NEMO through IF.  However, it was possible to perform IF for nsP3 
and ARTD10 which demonstrated co-localisation between the two proteins. 
Though co-localisation between two proteins via IF does not confirm a definite 
interaction, it does indicate that, at the very least, ARTD10 is interacting with the 
virus machinery, in areas where nsP3 is present.  
Originally, it was postulated that if nsP3 was capable of hydrolysing the ADPR 
moiety from ARTD10 or NEMO in vivo, it would lead to activation of the NFкB 
pathway. However, since it has been shown repeatedly, that CHIKV does not 
activate the NFкB pathway, this now seems an unlikely hypothesis. It could be 
that nsP3 is capable of interacting with either of these proteins through the ADPR 
but without hydrolysis. Also, the interaction between nsP3 and ARTD10 could be 
unrelated to the NFкB pathway. ARTD10 is a highly multifunctional protein that 
is involved in many cellular pathways. In addition to innate immunity, ARTD10 
has been implicated in apoptosis, DNA repair, and cell cycle regulation 
(Kaufmann et al., 2014). It is a highly dynamic protein within cells and has been 
shown to form discrete bodies within the cytoplasm. The function of these 
ARTD10 bodies is unknown but they are not associated with either p-bodies or 
stress granules (Kleine et al., 2012). As a result, Kleine et al. hypothesised that 





has also been shown to interact with p62 which has a role in autophagy 
(Johansen and Lamark, 2011; Kleine et al., 2012). Both of these roles of ARTD10 
may be advantageous for an RNA virus to exploit, as CHIKV is known to induce 
autophagy to delay apoptosis (Joubert et al., 2012). It may be that the CHIKV 
nsP3 macro domain interacts with ARTD10, independent of the role of nsP3 in 
NFкB inhibition, in order to disrupt other pathways or hijack the RNA shuttling 
function of ARTD10 in order to promote virus replication. More research is 
required to confirm an interaction between nsP3 and ARTD10 and to determine 
the function of this interaction.  
In this work, it was necessary to produce many expression constructs of nsP3 
and the macro domain as none were available at the time. These constructs were 
generated with a variety of tags and mutants which may prove useful for further 






5.3.3 Chapter summary 
Looking specifically of what cellular functions the nsP3 macro domain may 
possess, it was hypothesised that this N-terminal domain may be capable of 
interacting with the ribosylated proteins involved in the NFкB pathway in order to 
interfere with inflammation. More specifically, the nsP3 macro domain could 
potentially interact with NEMO, a component of the IKK complex and ARTD10, 
which is auto-ribosylated and regulates NEMO through ADP-ribosylation.  
Here, an agreement with the literature, it has been demonstrated that CHIKV 
infection does not activate the NFкB pathway. Looking more specifically at nsP3, 
it has been shown that expression of the protein inhibits the NFкB pathway to 
similar levels of B14, a vaccinia virus protein, well characterised as an NFкB 
inhibitor. Immunofluorescence revealed that p65, a subunit of NFкB, was unable 
to translocate to the nucleus of activated cells expressing nsP3. When using a 
panel of macro domain mutants to assess their ability to inhibit the pathway, it 
revealed that the nsP3 macro domain is at least partly responsible for NFкB 
inhibition. The mutants produced a range of inhibitory phenotypes with some 
mutants exhibiting inhibition similar to wt levels, and others having no inhibitory 
effects at all. When comparing these inhibitory phenotypes to the known 
biochemical properties of the macro domain mutants, it suggested that the 
ADPR-binding capability may be responsible for the macro domain’s inhibitory 
effects.  
When attempting to determine the stage at which nsP3 exerts its inhibition of the 
NFкB pathway, it was shown that this effect occurs after IKK complex activation 
but prior to NFкB nuclear translocation. Due to time constraints it was not 
possible to further determine the step of inhibition.  
Due to the original hypothesis, it was investigated whether nsP3 interacted with 
ARTD10. IF showed co-localisation between the two proteins across different 
stages of infection, indicating that an interaction does indeed occur between 
ARTD10 and the virus machinery. Unfortunately, due to time constraints, it was 
not possible to determine the nature or purpose of this interaction. Although this 










Macro domains are found in the proteins of all species including many positive 
sense single stranded viruses. In CHIKV, as with all alphaviruses, there is a 
macro domain at the N-terminus of nsP3. At the start of this project, it was known 
that nsP3 is required for CHIKV replication, but the function of nsP3, and 
specifically of the macro domain was unclear.  
Recent studies by others have assessed the biochemical properties of the 
CHIKV macro domain which has been shown to possess both ADP-ribose 
hydrolase and ADP-ribose 1”–phosphatase activities as well as affinity for ADR-
ribose and RNA. However, it was unclear which processes these properties 
relate to in the context of infected cells. The macro domain had also been shown 
to be a virulence factor as certain mutations within the domain exhibited a less 
severe morbidity in mice.  
In order to facilitate study of the nsP3 macro domain in this project, optimisation 
was required to determine suitable cell lines for use for CHIKV research and 
optimal methods for us of the replicon and the infectious virus systems available 
to us. Prior to this study, very little work had been conducted on establishing 
suitable cell lines for CHIKV research. In humans, is has been established that 
CHIKV replicates to high titres within the lymphoid tissues, muscles, liver, joints 
and brain in infected individuals. Other studies have aimed to define specific cell 
types in the body that become infected with CHIKV, in order to determine spread 
of the virus through the lymphatic and cardiovascular systems. However, in 
practise, many studies examining the molecular biology of CHIKV have utilised 
cells that are not physiologically relevant to the in vivo  infection such as Vero 
cells, BHK cells and HeLa cells. Being an arbovirus, it is also important to study 
CHIKV in the mosquito vectors; Aedes aegypti and Aedes albopictus. In both 
vector species, it has been shown that CHIKV replicates in most tissues, 
producing high titres in the midgut and salivary glands in particular. In this study, 
we aimed to determine a set of physiologically-relevant cell lines that supported 
the replication of CHIKV in order to study the molecular and cellular biology of 
the virus.  
From a large panel of cell lines, including those that were physiologically relevant 





mosquito cell lines were shown here to support both replicon and virus 
replication, and allowed expression of nsP3 to detectable levels via western 
blotting and IF.  
Now that a range of appropriate and useful cell lines had been established, and 
replicon and virus system had been optimised, the project could then focus on 
the aim of determining the function of the macro domain in CHIKV replication.  
At the start of this project, little work had been conducted specifically on the 
CHIKV nsP3 macro domain, however the three-dimensional structure of the 
domain had been previously solved by x-ray crystallography (Malet et al., 2009). 
This structure revealed the binding pocket of the domain, and, in the same study, 
revealed some of the properties of the domain. It was shown that the CHIKV 
nsP3 macro domain binds ADP-ribose (both monomeric and polymeric forms) 
and RNA. In addition, it possessed ADP-ribose 1″-phosphate phosphatase 
enzymatic activity.  
Informed by the available structures, sequence homology between various 
macro domains, and limited mutagenesis work from the literature (Malet et al., 
2009), here, a panel of mutants were generated in the binding pocket of the nsP3 
macro domain and their replicative phenotypes assessed in both replicon and 
infectious virus. These mutants exhibited a range of replicative phenotypes, 
some of which varied greatly between cell lines. This indicated that the macro 
domain may have some cell-specific functions. In addition, for certain mutants, 
the difference in phenotypes between the two mosquito cell lines used here 
indicated a potential role for the macro domain in inhibiting the RNAi pathway, in 
agreement with the literature (Mathur et al., 2016). 
Over the course of this study, several publications that studied the CHIKV nsP3 
macro domain became available (McPherson et al., 2017; Abraham et al., 2018). 
Of note, it was shown that the macro domain possessed hydrolase activity, 
similar to that previously demonstrated for the hepatitis E macro domain. In 
addition, other groups had generated a similar set of mutations within the macro 
domain binding pocket and assessed each mutant for ADP-ribose affinity and 





Combining the phenotypic data from this study with those in the literature 
revealed a strong correlation between ADP-ribose affinity and virus replication. 
Mutants with undetectable ADP-ribose affinity were those less able to produce 
infectious virus in most cell lines.  
McPherson et al. suggested that hydrolase activity is also important for CHIKV 
replication, although the data presented here suggests it is not as essential as 
several macro domain mutants with low hydrolase activity were tolerated, 
producing virus whilst maintaining the mutation. These data are summarised in 
Figure 6.1. 
.  
Figure 6.1 Summary of macro domain mutants biochemical and resulting 
replicative phenotypes. Mutants that possess poor or no ADP-ribose 
affinity either did not produce virus or were capable to low levels. The 
literature indicates this is probably through reversion. Mutants with 
poor hydrolase activity were able to produce virus in most cell types 
and, where possible to assess the sequence of resulting virus RNA, 





However, as several mutants possessed poor ADP-ribose binding and poor 
hydrolase activity in combination, it is difficult to draw conclusive conclusions 
from this work alone. Further mutagenesis experiments, using specific mutations 
that affect either hydrolase activity or ADP-ribose binding would be useful in 
determining the importance of these properties. Though this may prove difficult 
as it is likely that hydrolase activity is reliant on ADP-ribose binding.  
Much like with other studies examining the roles of viral macro domains, the data 
produced here indicated that the ADP-ribose 1″-phosphate phosphatase activity 
is not required for replication. Other groups have demonstrated viral macro 
domains such as that of SARS-coronavirus and SFV possess no detectable 
phosphatase activity (Egloff et al., 2006; Malet et al., 2009). The CHIKV macro 
domain mutant Y114A was shown here to replicate broadly to wt levels, yet in 
the literature it was shown to have no detectable phosphatase activity. This 
provides further evidence to the theory that ADP-ribose 1″-phosphate 
phosphatase activity is not the primary function of viral macro domains.  
The data produced by the mutagenesis experiments, and by others in the 
literature, suggested a role for the CHIKV nsP3 macro domain in antagonising 
the innate immunity of infected cells. Recently, it had been shown that ADP-
ribosylation is important in many signalling pathways, including the NFкB 
pathway. Mono-ribosylation of NEMO, a key IKK component, by ARTD10 (which 
is auto-ribosylated), results in suppression of the NFкB pathway as ribosylation 
prevents NEMO from forming an active IKK complex (Verheugd et al., 2013). It 
was therefore investigated whether the CHIKV nsP3 macro domain was able to 
interfere with this pathway potentially through binding and/or hydrolysis of ADP-
ribosylated proteins in this pathway.  
Prior to focussing on nsP3, it was investigated whether the NFкB pathway is 
activated upon CHIKV infection. In agreement with the literature, it was 
demonstrated in the studies described here that the NFкB pathway is not 
activated at any point during CHIKV infection. It was further shown that CHIKV 
cannot suppress an exogenously activated pathway and that, when the pathway 





A major finding of this project is that nsP3 is capable of inhibiting the NFкB 
pathway. Using expression constructs, tagged nsP3 was expressed in cells that 
were co-transfected with NFкB reporter plasmids. When these cells were 
exogenously activated, those expressing nsP3 demonstrated significantly lower 
levels of  NFкB activation. This was reiterated via IF where, in the presence of 
nsP3, the NFкB subunit p65 remained in the cytoplasm, unable to translocate to 
the nucleus.  
In this project, it was not possible to confirm expression of the macro domain 
(both untagged or flag-tagged) in cells. Therefore, to confirm involvement of the 
macro domain in NFкB inhibition, the macro domain mutants described in 
chapter 4 were engineered into the flag-tagged nsP3 expression construct and 
used alongside the NFкB reporter plasmid system. This luciferase assay 
revealed that the different mutants produced a range of inhibitory phenotypes – 
when the pathway was activated, some nsP3 mutants were completely unable 
to inhibit the pathway, with only one mutant capable of significant inhibition. 
However, the majority of mutants were able to suppress the basal levels of NFкB 
activation.  
When comparing the biochemical data available in the literature as described 
previously to the levels of inhibition exerted by the macro domain mutants, there 
is a strong correlation between ADP-ribose binding and inhibition of the NFкB 
pathway. The three mutants with the lowest affinity for ADP-ribose were also the 
three mutants least capable of NFкB inhibition. The V113A mutant which was 
the only macro domain mutant able to significantly inhibit the NFкB pathway has 
poor hydrolase activity (15% wt) indicating that ADP-ribose hydrolysis is not 
required for this inhibitory affect.  
Further investigation into at what stage in the pathway this inhibition was being 
enacted by the nsP3 macro domain revealed that, contrary to the initial 
hypothesis, the IKK complex was active in nsP3-expressing cells. This indicates 
that inhibition of the NFкB pathway by nsP3 occurs after the formation of an 
active IKK complex but prior to the nuclear translocation of NFкB as summarised 
Figure 6.2. Further work would be required to determine at which stage in the 






Figure 6.2 Summary of the effect of nsP3 on the NFкB pathway. It has been 
shown that in nsP3 expressing cells, the IKK complex is active and 
the phosphorylated form of p105 can be detected. It is also known that 
NFкB is not able to translocate to the nucleus in the presence of nsP3. 
This indicates that the stage of inhibition enacted by nsP3 is after p105 
phosphorylation but prior to, or at the stage of nuclear translocation.  
 
It was demonstrated in this work that at no point in CHIKV infection is the NFкB 
pathway activated, nor was an active IKK complex detected in infected cells. This 
implies that CHIKV may have other mechanisms to inhibit or evade detection by 
the NFкB pathway other than via the nsP3 macro domain. Most viruses activate 
the pathway through TLR detection in endosomes, an early stage in CHIKV 





examining other CHIKV proteins, such as the structural proteins, may reveal 
other inhibitors of innate immune pathway, other +ssRNA viruses express 
structural proteins that have been shown to inhibit the NFкB pathway (see Table 
6.1). 
Though it has been clearly demonstrated here that the CHIKV nsP3 macro 
domain is capable of NFкB inhibition, the precise mechanism of action is yet to 
be determined. Many viruses express proteins that are capable of inhibiting the 
NFкB pathway. Multiple DNA viruses express specific proteins that inhibit the 
NFкB pathway. For example, the vaccinia protein B14, used in this study, is 
capable of binding IKKβ and inhibits the IKK complex, is one of seven proteins 
expressed by Vaccinia virus that inhibit the NFкB pathway by various methods. 
Of the +ssRNA viruses, hepatitis C virus, West Nile Virus, Poliovirus, and SARS 
coronavirus all express proteins that inhibit the NFкB pathway, as detailed in 
Table 6.1. For all these proteins, they block the pathway at, or prior to the 
formation of an active IKK complex.  
Virus Protein Mechanism of inhibition 
Hepatitis C virus 
NS5A Inhibits TRAF2 signalling (Park et al., 2003) 
NS5B Inhibits IKKα (Choi et al., 2006) 
Core Inhibits IKKβ (Joo et al., 2005) 
West Nile virus NS1 
Blocks TLR3 activation of NFкB pathway (Wilson 
et al., 2008) 
Poliovirus 3C protease Cleaves p65 (Neznanov et al., 2005) 
SARS-coronavirus M Binds IKKβ (Fang et al., 2007) 
Table 6.1 Proteins expressed by +ssRNA viruses that inhibit the NFкB 
pathway. Reviewed in Rahman and McFadden, 2011. 
 
There are very few examples in the literature of virus proteins that inhibit the 
NFκB pathway past the IKK complex/IκB degradation stage. One example is the 
N protein of Hantaan virus (HTNV), a segmented, negative sense RNA virus. 
This protein has been shown to block nuclear translocation of the NFкB p65 





2009). Though this protein has little in common with nsP3, and with a distinctly 
different cellular localisation to that of nsP3, this mechanism of inhibition 
highlights that not all inhibitory effects of viral proteins are due to direct 
interactions of components of specific pathways.  
With viruses such as varicella-zoster virus (VZV), it has been observed that NFкB 
transiently translocates to the nucleus and is then sequestered back into the 
cytoplasm through an unknown mechanism (Jones and Arvin, 2006). A more 
detailed time course observing the localisation of p65 could reveal whether this 
occurs with CHIKV. However, it is unlikely that the NFкB inhibition exerted by 
nsP3 is by this mechanism as nsP3 has never exhibited nuclear localisation.  
Many bacterial toxins are ADP-ribosyltransferases, which MARylate various 
cellular proteins to enhance infection and interact with cellular innate immune 
pathways (Cohen and Chang, 2018). This highlights the likelihood of ADP-
ribosylation being a common occurrence in cellular innate immunity pathways. It 
is therefore possible that there are other, currently undiscovered, ribosylation 
events that regulate NFкB pathway. As shown in Figure 6.2, depending on the 
mechanism of activation the p50 subunit of NFкB can be K63-ubiquitinated, 
which signals for proteasome processing of p50 to produce p52 for nuclear 
translocation. There are many instances where ADP-ribose and ubiquitination 
counteract each other, much like with the regulation of NEMO, described in 
chapter 5. It may be possible that the CHIKV nsP3 macro domain interacts with, 
and inhibits the pathway another ADPR-dependent stage.   
Though other viral macro domains have been implicated in antagonising cellular 
innate immunity, none have been implicated in the NFкB pathway. The hepatitis 
E virus macro domain has been shown to inhibit the IFN pathway by blocking 
IRF-3 phosphorylation (Nan et al., 2014). The SARS-coronavirus macro domain 
has also been implicated in the inhibition of the IFN response though the precise 
mechanism is unknown (Kuri et al., 2011). Though CHIKV is known to induce a 
robust IFN response in infected cells, it was not investigated in this project 
whether the nsP3 macro domain interfered with the IFN response, though this 
may be an interesting line of inquiry. No other viral macro domains to date have 





similar experiments performed here, to determine whether other viral macro 
domains have similar inhibitory functions to those demonstrated by the nsP3. 
This work highlights the potential for therapeutics to be developed that target the 
nsP3 macro domain. If a therapeutic were capable of inhibiting the macro domain 
from exerting its effects on the NFкB pathway, infected cells may be able to 
successfully eliminate the virus. Alternatively, as it was shown that an activated 
NFкB pathway reduces CHIKV titres, modulation of the immune response could 
potentially be used to treat CHIKV infection. 
Currently, ongoing work within the Harris group and with collaborators is being 
conducted to design small molecular inhibitors for the CHIKV nsP3 macro 
domain. As it is an essential domain required for CHIKV replication that 
possesses a small binding pocket, it was identified as a potential drug target. 
There are, however, some concerns over the potential toxicity, or off-target 
effects of any macro domain inhibitor, as many cellular proteins also possess 
macro domains required for essential functions. However, the macro domains of 
alphaviruses are highly conserved and, although there is some sequence 
homology between the alphavirus macro domains and those found in human 
proteins, it is probable that, via high throughput screening for small molecule 
inhibitors, some will be identified that are specific to the CHIKV macro domain. 
In addition, any compounds found to have potential inhibitory effects can be 
further chemical modification can be performed to enhance effectivity and 
specificity. 
It is important to acknowledge that nsP3 is likely to be a highly multifunctional 
protein. Having investigated the role of the macro domain of nsP3 in isolation, 
future work would be useful to assess the function of the macro domain in 
combination with the other domains; the AUD and HVD as all alphavirus nsP3s 
have evolved to contain these three domains, suggesting shared functions. 
However, several +ssRNA viruses, other than alphaviruses, contain macro 
domains within multi-domained proteins with very little resemblance to nsP3. 
This suggests some shared function of the macro domain across species of 





here for the CHIKV macro domain, are shared by the macro domains of other 
viral species.  
In conclusion, work here has not only increased the general knowledge of the 
cellular and molecular biology of CHIKV, but also that of viral macro domains 
across different virus families. The macro domain of nsP3 has been shown to be 
a virulence factor, capable of inhibiting the NFкB pathway. This highlights the 
potential of the nsP3 macro domain as a drug target. Alternatively, immune 
modulation via therapeutics that activate the NFкB pathway may be another 





Chapter 7 Appendix 
7.1.1 Primers 
 
Primer name Template DNA Destination 
vector 












CHIKV ICRES wt 
pcDNA3.1+ CCG TAC GGA TCC ACC 
ATG GCA CCG TCG TAC 
CGG GTA AAA CGC ATG 
 









CHIKV ICRES wt 
pcDNA3.1+ CAC TAG CTC GAG TTA 
CCC ACC TGC CCT GTC 
TAG TCT TAA C 
 
66 1:40 (nsP3) 
2:10 (nsP3-ZsG) 
P58 nsP3 FWD 
BamHI 
 
CHIKV  ICRES 
(wt/mutant) 
pcDNA3.1+ CCG TAC GGA TCC ACC 




P59 nsP3 stop 
Flag NotI 
 
CHIKV  ICRES 
(wt/mutant) 
pcDNA3.1+ AGC TCA CTG CGG CCG 
CTT ACT TGT CGT CAT 
CGT CTT TGT AGT CCC 






















nsP3 macro D10A 
FWD 
WT CHIKV ICRES  AAA ACG CAT GGC CAT 




nsP3 macro D10A 
FWD 











P31 G32A Q5 REV WT CHIKV ICRES  ACC GGG TGG CGC AGT 






P32 nsP3 macro 
T111A FWD 
 
WT CHIKV ICRES  TCT CCT CTC CGC AGG 
TGT ATA CT 
 
58 14:30 
P33 nsP3 macro 
T111A FWD 
 
WT CHIKV ICRES  GGT ATA GCT ACA CTA 






P34 nsP3 macro 
G112A FWD 
 
WT CHIKV ICRES  CCT CTC CAC AGC TGT 
ATA CTC AG 
 
57 14:30 
P35 nsP3 macro 
G112A FWD 
 
WT CHIKV ICRES  AGA GGT ATA GCT ACA 






P36 nsP3 macro 
V113A FWD 
 
WT CHIKV ICRES  CTC CAC AGG TGC ATA 
CTC AGG AG 
 
62 14:30 
P37 nsP3 macro 
V113A FWD 
 







P38 nsP3 macro 
Y114A FWD 
 
WT CHIKV ICRES  CAC AGG TGT AGC CTC 
AGG AGG GAA AG 
 
62 14:30 
P39 nsP3 macro 
Y114A FWD 
 




nsP4 GAA P43 nsP4 GAA Q5 
FWD 
 
WT CHIKV ICRES  CGC CAA CAT AAT ACA 




P44 nsP4 GAA Q5 
REV 
 
WT CHIKV ICRES GCG CCG ATG AAG GCC 
GCG CAC GC  
 
68 14:30 























(Chiam et al., 
2013) 
Table 7.3 Primers used for qRT-PCR.  
 





Macro PCR Prod for 
seq FWD 
 
cDNA from RNA 
TRIzol extracted 
from infected cells 





Macro PCR Prod for 
seq REV 
 
cDNA from RNA 
TRIzol extracted 
from infected cells 




Table 7.4 Primers used for amplification of macro-domain coding 
sequence containing fragment from cDNA for sequencing. 
 
Primer name Used to sequence Primer sequence 




T7 FWD seq  pcDNA3.1+ constructs TAATACGACTCACTATAGGG 
P62  
Macro PCR Prod for seq FWD 
 









7.1.2 Plasmid maps 
 
Figure 7.1 Plasmid map of pcDNA3.1+. Enzyme set shown are unique 






Figure 7.2 Dual luciferase (dLuc) CHIKV replicon plasmid map. Enzyme 
set shown are unique and double cutters. Plasmid map created 






Figure 7.3 CHIKV wt ICRES virus construct plasmid map. Enzyme set 







7.1.3 Supplementary figures 
 
Figure 7.4 Nucleotide and amino acid sequences of wt macro domain and 
mutations generated. (A) wt macro domain sequence with codons 
and corresponding residues selected for mutagenesis highlighted in 
green. (B) Mutations (generated into the infectious CHIKV construct 
individually) in the nucleotide sequence are highlighted in blue, 
alongside resulting residue changes; D10A, G32A, T111A, G112A, 
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